Document And Entity Information
Document And Entity Information | 6 Months Ended |
Jun. 30, 2018 | |
Document Information [Line Items] | |
Entity Registrant Name | Precision Therapeutics Inc. |
Entity Central Index Key | 1,446,159 |
Trading Symbol | aipt |
Current Fiscal Year End Date | --12-31 |
Entity Filer Category | Non-accelerated Filer |
Entity Current Reporting Status | Yes |
Entity Emerging Growth Company | false |
Entity Small Business | true |
Document Type | S4 |
Document Period End Date | Jun. 30, 2018 |
Document Fiscal Year Focus | 2,018 |
Document Fiscal Period Focus | Q2 |
Amendment Flag | false |
Condensed Consolidated Balance
Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) | Jun. 30, 2018 | Dec. 31, 2017 |
Current Assets: | ||
Cash & cash equivalents | $ 1,004,269 | $ 766,189 |
Certificates of deposit | 244,971 | |
Accounts Receivable | 315,327 | 137,499 |
Notes Receivable | 167,512 | 667,512 |
Inventories | 244,660 | 265,045 |
Prepaid Expense and other assets | 275,476 | 289,966 |
Total Current Assets | 2,007,244 | 2,371,182 |
Notes Receivable | 1,112,524 | 1,070,000 |
Equity Method Investment (Note 2) | 581,742 | |
Fixed Assets, net | 184,385 | 87,716 |
Intangibles, net | 115,139 | 95,356 |
Total Assets | 4,001,034 | 3,624,254 |
LIABILITIES AND STOCKHOLDERS' EQUITY | ||
Accounts Payable | 165,588 | 140,462 |
Accrued Expenses | 455,326 | 785,215 |
Deferred Revenue | 18,342 | 6,663 |
Total Liabilities | 639,256 | 932,340 |
Commitments and Contingencies | ||
Stockholders’ Equity: | ||
Common Stock, $.01 par value, 50,000,000 authorized, 6,943,283 and 4,564,428 outstanding | 120,893 | 69,432 |
Additional paid-in capital | (62,138,569) | (57,380,256) |
Accumulated deficit | 58,898,476 | 54,765,045 |
Total Stockholders' Equity | 3,361,778 | 2,691,914 |
Total Liabilities and Stockholders' Equity | 4,001,034 | 3,624,254 |
Series B Convertible Preferred Stock [Member] | ||
Stockholders’ Equity: | ||
Preferred stock | 792 | 792 |
Series C Convertible Preferred Stock [Member] | ||
Stockholders’ Equity: | ||
Preferred stock | $ 6,479 |
Condensed Consolidated Balanc_2
Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares | Jun. 30, 2018 | Feb. 21, 2018 | Dec. 31, 2017 | Dec. 28, 2017 | Apr. 19, 2017 | Jan. 29, 2017 | Dec. 31, 2016 | Oct. 27, 2016 | Oct. 04, 2016 | Sep. 15, 2016 | Sep. 14, 2016 |
Common stock, par value (in dollars per share) | $ 0.01 | $ 0.01 | $ 0.01 | $ 0.01 | $ 0.01 | $ 0.01 | $ 0.01 | ||||
Common stock, shares authorized (in shares) | 50,000,000 | 50,000,000 | 50,000,000 | 24,000,000 | 50,000,000 | 8,000,000 | 200,000,000 | 100,000,000 | |||
Common stock, shares outstanding (in shares) | 12,089,446 | 6,943,283 | 4,564,428 | ||||||||
Series B Convertible Preferred Stock [Member] | |||||||||||
Preferred stock, par value (in dollars per share) | $ 0.01 | $ 0.01 | $ 0.01 | ||||||||
Preferred stock, shares authorized (in shares) | 20,000,000 | 20,000,000 | 20,000,000 | ||||||||
Preferred stock, shares outstanding (in shares) | 79,246 | 79,246 | 79,246 | ||||||||
Series C Convertible Preferred Stock [Member] | |||||||||||
Preferred stock, par value (in dollars per share) | $ 0.01 | $ 0.01 | $ 0.01 | ||||||||
Preferred stock, shares authorized (in shares) | 20,000,000 | 20,000,000 | 20,000,000 | ||||||||
Preferred stock, shares outstanding (in shares) | 0 | 647,819 | 0 |
Condensed Consolidated Statemen
Condensed Consolidated Statements of Operations and Other Comprehensive Loss (Unaudited) - USD ($) | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||
Jun. 30, 2018 | Jun. 30, 2017 | Jun. 30, 2018 | Jun. 30, 2017 | Dec. 31, 2017 | Dec. 31, 2016 | |
Revenue | $ 770,179 | $ 281,988 | $ 654,836 | $ 456,495 | ||
Cost of goods sold | 226,314 | 59,003 | 148,045 | 181,620 | ||
Gross margin | 543,865 | 222,985 | 506,791 | 274,875 | ||
General and administrative expense | 1,945,670 | 3,346,777 | 6,041,485 | 5,174,799 | ||
Operations expense | 666,496 | 383,001 | 1,207,724 | 1,158,117 | ||
Sales and marketing expense | 1,104,623 | 378,724 | 1,004,175 | 467,970 | ||
Total Expense | 3,716,789 | 4,108,502 | 8,253,384 | 6,800,889 | ||
Loss on equity method investment | (960,508) | |||||
Net loss available to common shareholders | $ (2,373,410) | $ (2,543,670) | (4,133,432) | (3,885,517) | (7,746,593) | (6,526,014) |
Comprehensive loss | $ (2,373,410) | $ (2,543,670) | $ (4,133,432) | $ (3,885,517) | $ (7,746,593) | $ (6,524,513) |
Loss per common share - basic and diluted (in dollars per share) | $ (0.20) | $ (0.41) | $ (0.36) | $ (0.62) | $ (1.22) | $ (2.31) |
Weighted average shares used in computation - basic and diluted (in shares) | 11,632,221 | 6,308,554 | 6,362,989 | 2,823,345 |
Condensed Consolidated Statem_2
Condensed Consolidated Statement of Stockholders' Equity (Unaudited) - USD ($) | Over-Allotment Option [Member]Preferred Stock [Member]Series C Preferred Stock [Member] | Over-Allotment Option [Member]Preferred Stock [Member]Series B Preferred Stock [Member] | Over-Allotment Option [Member]Preferred Stock [Member] | Over-Allotment Option [Member]Common Stock [Member] | Over-Allotment Option [Member]Additional Paid-in Capital [Member] | Over-Allotment Option [Member]Retained Earnings [Member] | Over-Allotment Option [Member]AOCI Attributable to Parent [Member] | Over-Allotment Option [Member] | Consulting Agreement One [Member]Preferred Stock [Member]Series C Preferred Stock [Member] | Consulting Agreement One [Member]Preferred Stock [Member]Series B Preferred Stock [Member] | Consulting Agreement One [Member]Preferred Stock [Member] | Consulting Agreement One [Member]Common Stock [Member] | Consulting Agreement One [Member]Additional Paid-in Capital [Member] | Consulting Agreement One [Member]Retained Earnings [Member] | Consulting Agreement One [Member]AOCI Attributable to Parent [Member] | Consulting Agreement One [Member] | Consulting Agreement Two [Member]Preferred Stock [Member] | Consulting Agreement Two [Member]Common Stock [Member] | Consulting Agreement Two [Member]Additional Paid-in Capital [Member] | Consulting Agreement Two [Member]Retained Earnings [Member] | Consulting Agreement Two [Member]AOCI Attributable to Parent [Member] | Consulting Agreement Two [Member] | Helomics Holding Corp. [Member]Preferred Stock [Member]Series C Preferred Stock [Member] | Helomics Holding Corp. [Member]Preferred Stock [Member]Series B Preferred Stock [Member] | Helomics Holding Corp. [Member]Preferred Stock [Member] | Helomics Holding Corp. [Member]Common Stock [Member] | Helomics Holding Corp. [Member]Additional Paid-in Capital [Member] | Helomics Holding Corp. [Member]Retained Earnings [Member] | Helomics Holding Corp. [Member]AOCI Attributable to Parent [Member] | Helomics Holding Corp. [Member] | Investor Relations Consultant [Member]Preferred Stock [Member]Series C Preferred Stock [Member] | Investor Relations Consultant [Member]Preferred Stock [Member]Series B Preferred Stock [Member] | Investor Relations Consultant [Member]Preferred Stock [Member] | Investor Relations Consultant [Member]Common Stock [Member] | Investor Relations Consultant [Member]Additional Paid-in Capital [Member] | Investor Relations Consultant [Member]Retained Earnings [Member] | Investor Relations Consultant [Member]AOCI Attributable to Parent [Member] | Investor Relations Consultant [Member] | Series E Warrants [Member]Preferred Stock [Member]Series C Preferred Stock [Member] | Series E Warrants [Member]Preferred Stock [Member]Series B Preferred Stock [Member] | Series E Warrants [Member]Preferred Stock [Member] | Series E Warrants [Member]Common Stock [Member] | Series E Warrants [Member]Additional Paid-in Capital [Member] | Series E Warrants [Member]Retained Earnings [Member] | Series E Warrants [Member]AOCI Attributable to Parent [Member] | Series E Warrants [Member] | Re-priced Warrants [Member]Preferred Stock [Member]Series C Preferred Stock [Member] | Re-priced Warrants [Member]Preferred Stock [Member]Series B Preferred Stock [Member] | Re-priced Warrants [Member]Preferred Stock [Member] | Re-priced Warrants [Member]Common Stock [Member] | Re-priced Warrants [Member]Additional Paid-in Capital [Member] | Re-priced Warrants [Member]Retained Earnings [Member] | Re-priced Warrants [Member]AOCI Attributable to Parent [Member] | Re-priced Warrants [Member] | Preferred Stock [Member]Series C Preferred Stock [Member] | Preferred Stock [Member]Series B Preferred Stock [Member] | Preferred Stock [Member] | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | AOCI Attributable to Parent [Member] | Total |
Balance at Dec. 31, 2015 | $ 18,950 | $ 2,080 | $ 44,584,118 | $ (40,492,437) | $ 4,112,711 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance (in shares) at Dec. 31, 2015 | 208,259 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued pursuant to the public offering | $ 260 | $ 116,740 | $ 117,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued pursuant to the public offering (in shares) | 26,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting Expense | 165,271 | 165,271 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Unrealized (loss) from marketable securities | $ 1,501 | 1,501 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Net loss | (6,526,014) | (6,526,014) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance at Dec. 31, 2016 | 792 | $ 45,644 | 47,894,196 | (47,018,451) | 1,501 | 923,682 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance (in shares) at Dec. 31, 2016 | 79,246 | 4,564,428 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued pursuant to the public offering | $ 1,750 | $ 392,000 | $ 393,750 | $ 17,500 | 3,403,688 | 3,421,188 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued pursuant to the public offering (in shares) | 175,000 | 1,750,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting Expense | 2,131,821 | 2,131,821 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reverse shares issued for escrow with GLG Pharma pursuant to the termination agreement | $ (4,000) | (4,000) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reverse shares issued for escrow with GLG Pharma pursuant to the termination agreement (in shares) | (400,000) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued for services | $ 1,000 | $ 219,000 | $ 220,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued for services (in shares) | 100,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Unrealized (loss) from marketable securities | (1,501) | (1,501) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Net loss | $ (3,885,517) | $ (3,885,517) | (3,885,517) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance at Jun. 30, 2017 | $ 792 | $ 61,894 | $ 54,040,705 | $ (50,903,968) | $ 3,199,423 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance (in shares) at Jun. 30, 2017 | 79,246 | 6,189,428 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance at Dec. 31, 2016 | 792 | $ 45,644 | 47,894,196 | (47,018,451) | 1,501 | 923,682 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance (in shares) at Dec. 31, 2016 | 79,246 | 4,564,428 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued pursuant to the public offering | $ 1,750 | 392,000 | 393,750 | $ 17,500 | 3,403,688 | 3,421,188 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued pursuant to the public offering (in shares) | 175,000 | 1,750,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting Expense | 4,042,256 | 4,042,256 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reverse shares issued for escrow with GLG Pharma pursuant to the termination agreement | $ (4,000) | (4,000) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reverse shares issued for escrow with GLG Pharma pursuant to the termination agreement (in shares) | (400,000) | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued for services | $ 1,000 | $ 219,000 | $ 220,000 | $ 433 | $ 63,699 | $ 64,132 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued for services (in shares) | 100,000 | 43,333 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Unrealized (loss) from marketable securities | (1) | (1,501) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Net loss | (7,746,593) | (7,746,593) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred conversion to common shares pursuant to private placement agreement | (5,659) | $ 6,604 | 85,236 | 86,182 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred conversion to common shares pursuant to private placement agreement (in shares) | 660,522 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance at Dec. 31, 2017 | 7,271 | $ 69,432 | 57,380,256 | (54,765,045) | 2,691,914 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance (in shares) at Dec. 31, 2017 | 647,819 | 79,246 | 6,943,283 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued pursuant to the public offering | $ 2,153 | $ 202,268 | $ 1 | $ 204,422 | $ 29,000 | 2,726,087 | 2,755,087 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued pursuant to the public offering (in shares) | 215,247 | 2,900,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Vesting Expense | 460,368 | 460,368 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Net loss | (4,133,432) | (4,133,432) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred conversion to common shares pursuant to private placement agreement | (6,479) | $ 5,897 | 582 | 0 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred conversion to common shares pursuant to private placement agreement (in shares) | (647,819) | 589,747 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Investment pursuant to Helomics 20% acquisition | $ 11,000 | $ 1,031,250 | $ 1,042,250 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Investment pursuant to Helomics 20% acquisition (in shares) | 1,100,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant exercises | $ 888 | $ 87,948 | $ 88,836 | $ 2,523 | $ 249,810 | $ 252,333 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant exercises (in shares) | 88,836 | 252,333 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance at Jun. 30, 2018 | $ 792 | $ 120,893 | $ 62,138,569 | $ (58,898,476) | $ 3,361,778 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance (in shares) at Jun. 30, 2018 | 79,246 | 12,089,446 |
Condensed Consolidated Statem_3
Condensed Consolidated Statement of Stockholders' Equity (Unaudited) (Parentheticals) - $ / shares | Jun. 30, 2018 | Feb. 21, 2018 | Aug. 31, 2015 |
Series E Warrants [Member] | Common Stock [Member] | |||
Warrant exercises, exercise price per share (in dollars per share) | $ 1 | ||
Common Stock [Member] | Over-Allotment Option [Member] | |||
Price of shares issued (in dollars per share) | $ 0.9497 | ||
Over-Allotment Option [Member] | |||
Price of shares issued (in dollars per share) | $ 0.9497 | ||
Price of shares issued (in dollars per share) | $ 9 |
Condensed Consolidated Statem_4
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) | 6 Months Ended | |
Jun. 30, 2018 | Jun. 30, 2017 | |
Cash flow from operating activities: | ||
Net loss | $ (4,133,432) | $ (3,885,517) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Loss on equity method investment | 960,508 | |
Depreciation and amortization | 41,062 | 35,995 |
Vested stock options and warrants | 460,368 | 2,131,821 |
Equity instruments issued for management and consulting | 216,000 | |
Gain (loss) from sale of marketable securities | (1,837) | |
Changes in assets and liabilities: | ||
Accounts receivable | (177,828) | (6,085) |
Inventories | 20,385 | 30,004 |
Prepaid expense and other assets | 14,490 | (39,892) |
Accounts payable | 25,126 | (162,685) |
Accrued expenses | (329,889) | (394,767) |
Deferred revenue | 11,679 | 6,159 |
Net cash used in operating activities | (3,107,531) | (2,070,804) |
Cash flow from investing activities: | ||
Proceeds from sale of marketable securities | 284,665 | |
Purchase of certificates of deposit | (2,593,174) | |
Redemption of certificates of deposit | 244,971 | |
Advance on notes receivable | (42,524) | |
Purchase of fixed assets | (129,990) | (38,637) |
Purchase of intangibles | (27,524) | (1,229) |
Net cash provided by (used in) investing activities: | 44,933 | (2,348,375) |
Cash flow from financing activities: | ||
Proceeds from exercise of warrants into common stock | 341,169 | |
Issuance of common stock | 2,959,509 | 3,814,938 |
Net cash provided by financing activities | 3,300,678 | 3,814,938 |
Net increase (decrease) in cash and cash equivalents | 238,080 | (604,241) |
Cash at beginning of period | 766,189 | 1,764,090 |
Cash at end of period | 1,004,269 | 1,159,849 |
Non-cash transactions: | ||
Conversion of Preferred Stock to Common Stock | 6,479 | |
Equity method investment - Helomics | $ 1,542,250 |
Consolidated Balance Sheets
Consolidated Balance Sheets - USD ($) | Jun. 30, 2018 | Dec. 31, 2017 | Dec. 31, 2016 |
Current Assets: | |||
Cash & cash equivalents | $ 1,004,269 | $ 766,189 | $ 1,764,090 |
Certificates of deposit | 244,971 | 100,000 | |
Marketable securities | 284,329 | ||
Accounts Receivable | 315,327 | 137,499 | 38,919 |
Notes Receivable | 167,512 | 667,512 | |
Inventories | 244,660 | 265,045 | 272,208 |
Prepaid Expense and other assets | 275,476 | 289,966 | 148,637 |
Total Current Assets | 2,007,244 | 2,371,182 | 2,608,183 |
Notes Receivable | 1,112,524 | 1,070,000 | |
Fixed Assets, net | 184,385 | 87,716 | 101,496 |
Intangibles, net | 115,139 | 95,356 | 97,867 |
Total Assets | 4,001,034 | 3,624,254 | 2,807,546 |
LIABILITIES AND STOCKHOLDERS' EQUITY | |||
Accounts Payable | 165,588 | 140,462 | 220,112 |
Accrued Expenses | 455,326 | 785,215 | 1,346,105 |
Deferred Revenue | 18,342 | 6,663 | 7,998 |
Total Current Liabilities | 932,340 | 1,574,215 | |
Accrued Expenses | 309,649 | ||
Total Liabilities | 639,256 | 932,340 | 1,883,864 |
Commitments and Contingencies | |||
Stockholders’ Equity: | |||
Common Stock, $.01 par value, 50,000,000 authorized, 6,943,283 and 4,564,428 outstanding | 120,893 | 69,432 | 45,644 |
Additional paid-in capital | (62,138,569) | (57,380,256) | (47,894,196) |
Accumulated deficit | 58,898,476 | 54,765,045 | 47,018,451 |
Accumulated Other Comprehensive Income | 1,501 | ||
Total Stockholders' Equity | 3,361,778 | 2,691,914 | 923,682 |
Total Liabilities and Stockholders' Equity | 4,001,034 | 3,624,254 | 2,807,546 |
Series B Convertible Preferred Stock [Member] | |||
Stockholders’ Equity: | |||
Preferred stock | 792 | 792 | 792 |
Series C Convertible Preferred Stock [Member] | |||
Stockholders’ Equity: | |||
Preferred stock | $ 6,479 |
Consolidated Balance Sheets (Pa
Consolidated Balance Sheets (Parentheticals) - $ / shares | Jun. 30, 2018 | Feb. 21, 2018 | Dec. 31, 2017 | Dec. 28, 2017 | Apr. 19, 2017 | Jan. 29, 2017 | Dec. 31, 2016 | Oct. 27, 2016 | Oct. 04, 2016 | Sep. 15, 2016 | Sep. 14, 2016 |
Common stock, par value (in dollars per share) | $ 0.01 | $ 0.01 | $ 0.01 | $ 0.01 | $ 0.01 | $ 0.01 | $ 0.01 | ||||
Common stock, shares authorized (in shares) | 50,000,000 | 50,000,000 | 50,000,000 | 24,000,000 | 50,000,000 | 8,000,000 | 200,000,000 | 100,000,000 | |||
Common stock, shares outstanding (in shares) | 12,089,446 | 6,943,283 | 4,564,428 | ||||||||
Series B Convertible Preferred Stock [Member] | |||||||||||
Preferred stock, par value (in dollars per share) | $ 0.01 | $ 0.01 | $ 0.01 | ||||||||
Preferred stock, shares authorized (in shares) | 20,000,000 | 20,000,000 | 20,000,000 | ||||||||
Preferred stock, shares outstanding (in shares) | 79,246 | 79,246 | 79,246 | ||||||||
Series C Convertible Preferred Stock [Member] | |||||||||||
Preferred stock, par value (in dollars per share) | $ 0.01 | $ 0.01 | $ 0.01 | ||||||||
Preferred stock, shares authorized (in shares) | 20,000,000 | 20,000,000 | 20,000,000 | ||||||||
Preferred stock, shares outstanding (in shares) | 0 | 647,819 | 0 |
Consolidated Statements of Comp
Consolidated Statements of Comprehensive Income (Loss) - USD ($) | 12 Months Ended | |
Dec. 31, 2017 | Dec. 31, 2016 | |
Revenue | $ 654,836 | $ 456,495 |
Cost of goods sold | 148,045 | 181,620 |
Gross margin | 506,791 | 274,875 |
General and administrative expense | 6,041,485 | 5,174,799 |
Operations expense | 1,207,724 | 1,158,117 |
Sales and marketing expense | 1,004,175 | 467,970 |
Interest expense | 3 | |
Total Expense | 8,253,384 | 6,800,889 |
Net loss available to common shareholders | (7,746,593) | (6,526,014) |
Other comprehensive income | ||
Unrealized (loss) from marketable securities | 1,501 | |
Comprehensive loss | $ (7,746,593) | $ (6,524,513) |
Loss per common share - basic and diluted (in dollars per share) | $ (1.22) | $ (2.31) |
Weighted average shares used in computation - basic and diluted (in shares) | 6,362,989 | 2,823,345 |
Consolidated Statements of Stoc
Consolidated Statements of Stockholders' Equity - USD ($) | Series A Warrants [Member]Common Stock [Member] | Series A Warrants [Member]Additional Paid-in Capital [Member] | Series A Warrants [Member] | Series B Warrants [Member]Common Stock [Member] | Series B Warrants [Member]Additional Paid-in Capital [Member] | Series B Warrants [Member] | Investment Banker [Member]Common Stock [Member] | Investment Banker [Member]Additional Paid-in Capital [Member] | Investment Banker [Member] | Investor Relations Consultant [Member]Preferred Stock [Member] | Investor Relations Consultant [Member]Common Stock [Member] | Investor Relations Consultant [Member]Additional Paid-in Capital [Member] | Investor Relations Consultant [Member]Retained Earnings [Member] | Investor Relations Consultant [Member]AOCI Attributable to Parent [Member] | Investor Relations Consultant [Member] | GLG Pharma, LLC. [Member]Common Stock [Member] | GLG Pharma, LLC. [Member] | Former CEO [Member]Common Stock [Member] | Former CEO [Member]Additional Paid-in Capital [Member] | Former CEO [Member] | The 2016 Registered Direct Offering [Member]Common Stock [Member] | The 2016 Registered Direct Offering [Member]Additional Paid-in Capital [Member] | The 2016 Registered Direct Offering [Member] | Over-Allotment Option [Member]Preferred Stock [Member] | Over-Allotment Option [Member]Common Stock [Member] | Over-Allotment Option [Member]Additional Paid-in Capital [Member] | Over-Allotment Option [Member]Retained Earnings [Member] | Over-Allotment Option [Member]AOCI Attributable to Parent [Member] | Over-Allotment Option [Member] | Consulting Agreement One [Member]Preferred Stock [Member] | Consulting Agreement One [Member]Common Stock [Member] | Consulting Agreement One [Member]Additional Paid-in Capital [Member] | Consulting Agreement One [Member]Retained Earnings [Member] | Consulting Agreement One [Member]AOCI Attributable to Parent [Member] | Consulting Agreement One [Member] | Consulting Agreement Two [Member]Preferred Stock [Member] | Consulting Agreement Two [Member]Common Stock [Member] | Consulting Agreement Two [Member]Additional Paid-in Capital [Member] | Consulting Agreement Two [Member]Retained Earnings [Member] | Consulting Agreement Two [Member]AOCI Attributable to Parent [Member] | Consulting Agreement Two [Member] | Investor Relations Consultant [Member]Common Stock [Member] | Investor Relations Consultant [Member]Additional Paid-in Capital [Member] | Investor Relations Consultant [Member] | Private Placement [Member]Preferred Stock [Member] | Private Placement [Member]Additional Paid-in Capital [Member] | Private Placement [Member] | Preferred Stock [Member] | Common Stock [Member] | Additional Paid-in Capital [Member] | Retained Earnings [Member] | AOCI Attributable to Parent [Member] | Total |
Balance at Dec. 31, 2015 | $ 18,950 | $ 2,080 | $ 44,584,118 | $ (40,492,437) | $ 4,112,711 | ||||||||||||||||||||||||||||||||||||||||||||||||
Balance (in shares) at Dec. 31, 2015 | 208,259 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued for two options exercised at $65.75 per share (in shares) | 1,312 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued for two options exercised at $65.75 per share | $ 13 | 86,240 | 86,253 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued for preferred stock conversion into common stock per the break-up of the Unit from the 2015 public offering | (18,158) | $ 664 | 17,494 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued for preferred stock conversion into common stock per the break-up of the Unit from the 2015 public offering (in shares) | 66,396 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant exercises (in shares) | 2,318,663 | 628,237 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Warrant exercises | $ 23,187 | $ 556,479 | $ 579,666 | $ 6,282 | $ 150,777 | $ 157,059 | |||||||||||||||||||||||||||||||||||||||||||||||
Shares issued for services (in shares) | 135,995 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued for services | $ 1,360 | $ 508,620 | $ 509,980 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued pursuant to the public offering (in shares) | 26,000 | 400,000 | 20,000 | 756,999 | |||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued pursuant to the public offering | $ 260 | $ 116,740 | $ 117,000 | $ 4,000 | $ 4,000 | $ 200 | $ 90,151 | $ 90,351 | $ 7,570 | $ 1,618,335 | $ 1,625,905 | ||||||||||||||||||||||||||||||||||||||||||
Vesting Expense | 165,271 | 165,271 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Unrealized (loss) from marketable securities | $ 1,501 | 1,501 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Corrections due to rounding for reverse split and DTCC increase (in shares) | 2,567 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Corrections due to rounding for reverse split and DTCC increase | $ 28 | (29) | (1) | ||||||||||||||||||||||||||||||||||||||||||||||||||
Net loss | (6,526,014) | (6,526,014) | |||||||||||||||||||||||||||||||||||||||||||||||||||
Balance at Dec. 31, 2016 | 792 | $ 45,644 | 47,894,196 | (47,018,451) | 1,501 | 923,682 | |||||||||||||||||||||||||||||||||||||||||||||||
Balance (in shares) at Dec. 31, 2016 | 4,564,428 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued for services (in shares) | 100,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued for services | $ 1,000 | $ 219,000 | $ 220,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued pursuant to the public offering (in shares) | 175,000 | 1,750,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued pursuant to the public offering | $ 1,750 | $ 392,000 | $ 393,750 | $ 17,500 | 3,403,688 | 3,421,188 | |||||||||||||||||||||||||||||||||||||||||||||||
Vesting Expense | 2,131,821 | 2,131,821 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Unrealized (loss) from marketable securities | (1,501) | (1,501) | |||||||||||||||||||||||||||||||||||||||||||||||||||
Net loss | $ (3,885,517) | $ (3,885,517) | (3,885,517) | ||||||||||||||||||||||||||||||||||||||||||||||||||
Reverse shares issued for escrow with GLG Pharma pursuant to the termination agreement (in shares) | (400,000) | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Reverse shares issued for escrow with GLG Pharma pursuant to the termination agreement | $ (4,000) | (4,000) | |||||||||||||||||||||||||||||||||||||||||||||||||||
Balance at Jun. 30, 2017 | $ 792 | $ 61,894 | $ 54,040,705 | $ (50,903,968) | $ 3,199,423 | ||||||||||||||||||||||||||||||||||||||||||||||||
Balance (in shares) at Jun. 30, 2017 | 6,189,428 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance at Dec. 31, 2016 | 792 | $ 45,644 | 47,894,196 | (47,018,451) | 1,501 | 923,682 | |||||||||||||||||||||||||||||||||||||||||||||||
Balance (in shares) at Dec. 31, 2016 | 4,564,428 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued for services (in shares) | 100,000 | 43,333 | 50,000 | ||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued for services | $ 1,000 | $ 219,000 | $ 220,000 | $ 433 | $ 63,699 | $ 64,132 | $ 500 | $ 78,500 | $ 79,000 | ||||||||||||||||||||||||||||||||||||||||||||
Shares issued pursuant to the public offering (in shares) | 175,000 | 1,750,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued pursuant to the public offering | $ 1,750 | 392,000 | 393,750 | $ 12,138 | $ 1,201,681 | $ 1,213,819 | $ 17,500 | 3,403,688 | 3,421,188 | ||||||||||||||||||||||||||||||||||||||||||||
Vesting Expense | 4,042,256 | 4,042,256 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Unrealized (loss) from marketable securities | (1) | (1,501) | |||||||||||||||||||||||||||||||||||||||||||||||||||
Net loss | (7,746,593) | (7,746,593) | |||||||||||||||||||||||||||||||||||||||||||||||||||
Reverse shares issued for escrow with GLG Pharma pursuant to the termination agreement (in shares) | (400,000) | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Reverse shares issued for escrow with GLG Pharma pursuant to the termination agreement | $ (4,000) | (4,000) | |||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred conversion to common shares pursuant to private placement agreement | (5,659) | $ 6,604 | 85,236 | 86,182 | |||||||||||||||||||||||||||||||||||||||||||||||||
Preferred conversion to common shares pursuant to private placement agreement (in shares) | 660,522 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance at Dec. 31, 2017 | 7,271 | $ 69,432 | 57,380,256 | (54,765,045) | 2,691,914 | ||||||||||||||||||||||||||||||||||||||||||||||||
Balance (in shares) at Dec. 31, 2017 | 6,943,283 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued pursuant to the public offering (in shares) | 215,247 | 2,900,000 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Shares issued pursuant to the public offering | $ 2,153 | $ 202,268 | $ 1 | $ 204,422 | $ 29,000 | 2,726,087 | 2,755,087 | ||||||||||||||||||||||||||||||||||||||||||||||
Vesting Expense | 460,368 | 460,368 | |||||||||||||||||||||||||||||||||||||||||||||||||||
Net loss | (4,133,432) | (4,133,432) | |||||||||||||||||||||||||||||||||||||||||||||||||||
Preferred conversion to common shares pursuant to private placement agreement | (6,479) | $ 5,897 | 582 | 0 | |||||||||||||||||||||||||||||||||||||||||||||||||
Preferred conversion to common shares pursuant to private placement agreement (in shares) | 589,747 | ||||||||||||||||||||||||||||||||||||||||||||||||||||
Balance at Jun. 30, 2018 | $ 792 | $ 120,893 | $ 62,138,569 | $ (58,898,476) | $ 3,361,778 | ||||||||||||||||||||||||||||||||||||||||||||||||
Balance (in shares) at Jun. 30, 2018 | 12,089,446 |
Consolidated Statements of St_2
Consolidated Statements of Stockholders' Equity (Parentheticals) | Dec. 31, 2017$ / shares |
Investor Relations Consultant [Member] | |
Price of shares issued (in dollars per share) | $ 1.58 |
Consolidated Statements of Cash
Consolidated Statements of Cash Flows - USD ($) | 12 Months Ended | |
Dec. 31, 2017 | Dec. 31, 2016 | |
Cash flow from operating activities: | ||
Net loss | $ (7,746,593) | $ (6,526,014) |
Adjustments to reconcile net loss to net cash used in operating activities: | ||
Depreciation and amortization | 71,562 | 82,356 |
Vested stock options and warrants | 4,042,256 | 165,271 |
Equity instruments issued for management and consulting | 359,133 | 721,330 |
Issuance of common stock in cashless warrant exchange | 736,725 | |
(Gain) loss on Sales of Equipment | (2,387) | |
Gain (loss) from sale of marketable securities | (1,837) | (4,716) |
Changes in assets and liabilities: | ||
Accounts receivable | (98,580) | (636) |
Inventories | 7,163 | (40,468) |
Prepaid expense and other assets | (141,329) | 122,943 |
Accounts payable | (79,650) | (430,301) |
Accrued expenses | (870,540) | 791,459 |
Deferred revenue | (1,335) | 2,998 |
Net cash used in operating activities | (4,459,750) | (4,381,440) |
Cash flow from investing activities: | ||
Purchase of marketable securities | (850,000) | |
Proceeds from sale of marketable securities | 284,665 | 571,887 |
Purchase of certificates of deposit | (3,084,971) | (1,100,000) |
Redemption of certificates of deposit | 2,940,000 | 1,000,000 |
Advance on notes receivable | (1,737,512) | |
Purchase of fixed assets | (45,093) | (32,760) |
Purchase of intangibles | (10,179) | (11,987) |
Net cash provided by (used in) investing activities: | (1,653,090) | (422,860) |
Cash flow from financing activities: | ||
Net proceeds from issuance of preferred stock | 1,300,001 | |
Net proceeds from issuance of common stock | 3,814,938 | 1,712,158 |
Net cash provided by financing activities | 5,114,939 | 1,712,158 |
Net increase (decrease) in cash and cash equivalents | (997,901) | (3,092,142) |
Cash at beginning of period | 1,764,090 | 4,856,232 |
Cash at end of period | $ 766,189 | $ 1,764,090 |
Note 1 - Summary of Significant
Note 1 - Summary of Significant Accounting Policies | 6 Months Ended | 12 Months Ended |
Jun. 30, 2018 | Dec. 31, 2017 | |
Notes to Financial Statements | ||
Significant Accounting Policies [Text Block] | NOTE 1 Nature of Operations and Continuance of Operations Precision Therapeutics Inc., (the “Company”) was originally incorporated on April 23, 2002 August 6, 2013, December 16, 2013, August 31, 2015, February 1, 2018, February 1, 2018. February 2, 2018. As of June 30, 2018, 12,089,446 $.01 two 1 2 April 2009, 510 The Company acquired 25% first 2018, April 2018 June 2018, 4. 149,000 first The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company has incurred recurring losses from operations and has an accumulated deficit of $58,898,476. not $1,004,269 June 30, 2018 one not Since inception to June 30, 2018, $35,840,380 1 $2,055,000 2 $13,555,003 3 $1,739,770 4 $3,937,500 $358,312 5 $1,300,000 6 $2,755,000 7 $5,685,000 Interim Financial Statements The Company has prepared the unaudited interim financial statements and related unaudited financial information in the footnotes in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. These interim financial statements reflect all adjustments consisting of normal recurring accruals, which in the opinion of management, are necessary to present fairly the Company’s position, the results of its operations and its cash flows for the interim periods. These interim financial statements reflect all intercompany eliminations. These interim financial statements should be read in conjunction with the annual financial statements and the notes thereto contained in the Form 10 April 2, 2018. may not Recent Accounting Developments In May 2014, No. 2014 09, Revenue from Contracts with Customers (Topic 606 January 1, 2018 not December 31, 2017. January 1, 2018 606, not 605, Revenue Recognition not December 31, 2017, not January 1, 2018, no 3 In January 2016, No. 2016 01, Financial Instruments-Overall (Subtopic 825 10 2016 01” not not January 1, 2018. June 30, 2018, no In February 2016, No. 2016 02, Leases (Topic 842 2016 02” December 15, 2018. Valuation of Intangible Assets The Company reviews identifiable intangible assets for impairment annually, or whenever events or changes in circumstances indicate the carrying amount may not may not not Accounting Policies and Estimates The presentation of financial statements is in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Cash Equivalents The Company considers all highly liquid debt instruments with a maturity of three Certificates of Deposit Short-term interest-bearing investments are those with maturities of less than one three one Fair Value Measurements Under generally accepted accounting principles as outlined in the FASB’s Accounting Standards Codification (ASC) 820, 820 three Level 1 Level 2 Level 3 no The Company uses observable market data, when available, in making fair value measurements. Fair value measurements are classified according to the lowest level input that is significant to the valuation. The fair value of the Company’s investment securities was determined based on Level 1 Inventories Inventories are stated at the lower of cost and net realizable value, with cost determined on a first first June 30, 2018 December 31, 2017 Finished goods $ 31,782 $ 62,932 Raw materials 168,735 141,028 Work-In-Process 44,143 61,085 Total $ 244,660 $ 265,045 Property and Equipment Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the respective assets. Estimated useful asset life by classification is as follows: Years Computers and office equipment 3 - 7 Leasehold improvements 3 Manufacturing tooling 3 - 7 Demo equipment 3 The Company’s fixed assets consist of the following: June 30, 2018 December 31, 2017 Computers and office equipment $ 201,123 $ 183,528 Leasehold improvements 122,188 25,635 Manufacturing tooling 108,955 108,955 Demo equipment 59,210 43,368 Total 491,476 361,486 Less: Accumulated depreciation 307,091 273,770 Total Fixed Assets, Net $ 184,385 $ 87,716 Upon retirement or sale, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred. Depreciation expense was $18,825 $33,321 three six June 30, 2018 $14,519 $30,204 three six June 30, 2017. Intangible Assets Intangible assets consist of trademarks and patent costs. Amortization expense was $4,070 $7,741 three six June 30, 2018 $2,902 $5,790 three six June 30, 2017. Income Taxes The Company accounts for income taxes in accordance with ASC 740 Income Taxes 740” 740, There is no 100% The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not no Tax years subsequent to 2014 Offering Costs Costs incurred which are direct and incremental to an offering of the Company’s securities are deferred and charged against the proceeds of the offering, unless such costs are deemed to be insignificant in which case they are expensed as incurred. Patents and Intellectual Property On January 25, 2014, No. PCT/US2014/013081 61756763 one January 25, 2013. 148 The Company’s PCT patent application is for the new model of the surgical fluid waste management system. The Company obtained a favorable International Search Report from the PCT searching authority indicating that the claims in its PCT application are patentable (i.e., novel and non-obvious) over the cited prior art. A feature claimed in the PCT application is the ability to maintain continuous suction to the surgical field while measuring, recording and evacuating fluid to the facility’s sewer drainage system. This provides for continuous operation of the STREAMWAY System unit in suctioning waste fluids, which means that suction is not The Company holds the following granted patents in the United States and a pending application in the United States on its earlier models: US7469727, US8123731 No. US20090216205 August 8, 2023. In July 2015, The United States Patent Office has assigned application #14/763,459 As of November 22, 2017, #14743665.3 1651 Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high credit quality financial institutions and, by policy, generally limits the amount of credit exposure to any one $794,125 Segments The Company operates in two three six June 30, 2018 2017 $3,178 $0 three 2018 2017, $5,866 $26,662 first six 2018 2017, Risks and Uncertainties The Company is subject to risks common to companies in the medical device industry, including, but not | NOTE 1 Nature of Operations and Continuance of Operations The Company was originally incorporated on April 23, 2002 August 6, 2013, December 16, 2013, August 31, 2015, February 1, 2018, February 1, 2018. February 2, 2018. As of December 31, 2017, 6,943,283 $.01 1 25 October 27, 2016. April 2009, 510 The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company has suffered recurring losses from operations and had a stockholders’ deficit until August 31, 2015 not Since inception to December 31, 2017, $29,065,934 $2,055,000 $13,555,003 $1,739,770 $3,937,500 $358,312 $1,300,000 $5,685,000 Recent Accounting Developments In May 2014, 2014 09, Revenue from Contracts with Customers 606, 2015 14, “Revenue from Contracts with Customers: Deferral of the Effective Date,” 2016 08, “Revenue from Contracts with Customers: Principal versus Agent Considerations (Reporting Revenue Gross versus Net),” 2016 10, “Revenue from Contracts with Customers: Identifying Performance Obligations and Licensing,” 2016 12, “Revenue from Contracts with Customers: Narrow-Scope Improvements and Practical Expedients.” 2017 13. December 15, 2017, not two 606. January 1, 2018 January 1, 2018, not In August 2014, 2014 15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern December 15, 2016, first 2017. In July 2015, No. 2015 11 , Inventory (Topic 330 December 15, 2016, first 2017. In November 2015, 2015 17, “Income Taxes (Topic 740 December 15, 2016 first 2017. In January 2016, No. 2016 01, Financial Instruments-Overall (Subtopic 825 10 2016 01” not not December 15, 2017, not In February 2016, No. 2016 02, (Topic 842” 2016 02” December 15, 2018. In March 2016, No. 2016 09, “Compensation (Topic 718 “ASU2016 09” 2016 09 December 15, 2016. first 2017. In August 2016, No. 2016 15, Statement of Cash Flows (Topic 230 December 15, 2017, not 2016 15 On December 22, 2017, 2017 34% 21%. We reviewed all other significant newly issued accounting pronouncements and determined they are either not no Valuation of Intangible Assets We review identifiable intangible assets for impairment in accordance with ASC 350 may not may not not Accounting Policies and Estimate The presentation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Presentation of Taxes Collected from Customers Sales taxes are imposed on the Company’s sales to nonexempt customers. The Company collects the taxes from customers and remits the entire amounts to the governmental authorities. The Company’s accounting policy is to exclude the taxes collected and remitted from revenues and expenses. Shipping and Handling Shipping and handling charges billed to customers are recorded as revenue. Shipping and handling costs are recorded within cost of goods sold on the statement of operations. Advertising Advertising costs are expensed as incurred. Advertising expenses were $37,060 2017, $71,212 2016. Research and Development Research and development costs are charged to operations as incurred. Research and development costs were approximately $289,000 $406,000 2017 2016, Revenue Recognition The Company recognizes revenue in accordance with the SEC’s Staff Accounting Bulletin Revenue Recognition and ASC 606 We recognize revenue when the following criteria are met: persuasive evidence of an arrangement exists – we receive both a signed purchase order and contract of terms and conditions confirming the sale from the customer; delivery has occurred – the goods are shipped from our warehouse and delivered and accepted by the customer; the selling price is fixed or determinable – confirmed on the customer purchase order and then invoiced immediately upon shipment of the goods; and collectability is reasonably assured – our customers are long standing hospitals, ambulatory surgical centers and others that pass credit checks. The terms of our agreements with our customers are specified in written agreements. These written agreements, the purchase order and the matching invoice, constitute the persuasive evidence of the arrangements with our customers that are a precondition to the recognition of revenue. We undertake an evaluation of the creditworthiness of both new and, on a periodic basis, existing customers. Based on these reviews we determine whether collection of our prospective revenue is probable. We have adopted the provisions of Accounting Standards Update, or “ASU” 2014 09, 606 606 January 1, 2018 While we continue to assess all potential impacts of the standard, it is currently anticipated that the standard will not Cash Equivalents The Company considers all highly liquid debt instruments with a maturity of three Certificates of Deposit Short-term interest-bearing investments are those with maturities of less than one three one Investment Securities Readily marketable investments in debt and equity services are classified as available-for-sale and are reported at fair value with unrealized gains losses recorded in other comprehensive income. Unrealized gains are charged to earnings when an incline in fair value above the cost basis is determined to be other-than-temporary. Realized gains and losses on dispositions are based on the net proceeds and the adjusted book value of the securities sold, using the specific identification method. Fair Value Measurements Under generally accepted accounting principles as outlined in the Financial Accounting Standards Board’s Accounting Standards Certification 820, 820 three Level 1 Level 2 Level 3 no The Company uses observable market data, when available, in making fair value measurements. Fair value measurements are classified according to the lowest level input that is significant to the valuation. The fair value of the Company’s investment securities were determined based on Level 1 Receivables Receivables are reported at the amount the Company expects to collect on balances outstanding. The Company provides for probable uncollectible amounts through charges to earnings and credits to the valuation based on management’s assessment of the current status of individual accounts, changes to the valuation allowance have not Inventories Inventories are stated at the lower of cost or market, with cost determined on a first first December 31, 2017 December 31, 2016 Finished goods $ 62,932 $ 38,201 Raw materials 141,028 165,812 Work-In-Process 61,085 68,195 Total $ 265,045 $ 272,208 Property and Equipment Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the respective assets. Estimated useful asset life by classification is as follows: Years Computers and office equipment 3 - 7 Leasehold improvements 5 Manufacturing Tooling 3 - 7 Demo Equipment 3 The Company’s investment in Fixed Assets consists of the following: December 31, 2017 December 31, 2016 Computers and office equipment $ 183,528 $ 164,318 Leasehold Improvements 25,635 25,635 Manufacturing Tooling 108,955 103,204 Demo Equipment 43,368 23,236 Total 361,486 316,393 Less: Accumulated Depreciation 273,770 214,897 Total Fixed Assets, Net $ 87,716 $ 101,496 Upon retirement or sale, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred. Depreciation expense was $58,872 2017 $73,249 2016. Intangible Assets Intangible assets consist of trademarks and patent costs. Amortization expense was $12,689 2017 $9,107 2016. Income Taxes The Company accounts for income taxes in accordance with ASC 740 Income Taxes (“ASC 740” 740, The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not no Tax years subsequent to 2014 Patents and Intellectual Property On January 25th, 2014, No. PCT/US2014/013081 61756763 one January 25th, 2013. 148 Our PCT patent application is for the new model of the surgical fluid waste management system. We obtained a favorable International Search Report from the PCT searching authority indicating that the claims in our PCT application are patentable (i.e., novel and non-obvious) over the cited prior art. A feature claimed in the PCT application is the ability to maintain continuous suction to the surgical field while measuring, recording and evacuating fluid to the facilities sewer drainage system. This provides for continuous operation of the STREAMWAY System unit in suctioning waste fluids, which means that suction is not The Company holds the following granted patents in the United States and a pending application in the United States on its earlier models: US7469727, US8123731 No. US20090216205 August 8, 2023. In July 2015, The United States Patent Office has assigned application #14/763,459 As of November 22, 2017, #14743665.3 1651, Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high credit quality financial institutions and, by policy, generally limits the amount of credit exposure to any one $563,000 Product Warranty Costs In 2017 2016, $6,209 $34,665 Segments The Company operates in two 2017 2016 $26,662 2017. Risks and Uncertainties The Company is subject to risks common to companies in the medical device industry, including, but not |
Note 2 - Equity Method Investme
Note 2 - Equity Method Investment | 6 Months Ended |
Jun. 30, 2018 | |
Notes to Financial Statements | |
Equity Method Investments and Joint Ventures Disclosure [Text Block] | NOTE 2 The Company has an equity method investment in Helomics. The unaudited six Helomics Holdings Corporation For the Six Months Ended June 30, 2018 Revenue $ 215,055 Gross margin $ (71,625 ) Net loss from continuing operations $ (4,529,380 ) Net loss to investee $ (4,331,380 )1 1 80% January 11, 2018 – February 27, 2018, 75% six Helomics’ first six not |
Note 3 - Revenue Recognition
Note 3 - Revenue Recognition | 6 Months Ended |
Jun. 30, 2018 | |
Notes to Financial Statements | |
Revenue from Contract with Customer [Text Block] | NOTE 3 Revenue from Product Sales The Company’s revenue consists primarily of sales of the STREAMWAY System, as well as sales of the proprietary cleaning fluid and filters for use with the STREAMWAY System. The Company sells its products directly to hospitals and other medical facilities using employed sales representatives and independent contractors. Purchase orders, which are governed by sales agreements in all cases, state the final terms for unit price, quantity, shipping and payment terms. The unit price is considered the observable stand-alone selling price for the arrangements. The Company sales agreement, Terms and Conditions, is a dually executed contract providing explicit criteria supporting the sale of the STREAMWAY System. The Company considers the combination of a purchase order and the Terms and Conditions to be a customer’s contract in all cases. The Company recognizes revenue when it satisfies a performance obligation by transferring control of the promised goods or services to its customers, in an amount that reflects the consideration the Company expects to be entitled to in exchange for those goods or services. Sales taxes are imposed on the Company’s sales to nonexempt customers. The Company collects the taxes from the customers and remits the entire amounts to the governmental authorities. The Company has elected the accounting policy to exclude sales taxes from revenue and expenses. Product sales consist of a single performance obligation that the Company satisfies at a point in time. The Company recognizes product revenue when the following events have occurred: (a) the Company has transferred physical possession of the products, (b) the Company has a present right to payment, (c) the customer has legal title to the products, and (d) the customer bears significant risks and rewards of ownership of the products. Based on the shipping terms specified in the sales agreements and purchase orders, these criteria are generally met when the products are shipped from the Company’s facilities (“FOB origin”, which is the Company’s standard shipping terms). As a result, the Company determined that the customer is able to direct the use of, and obtain substantially all of the benefits from, the products at the time the products are shipped. The Company may, may 30 60 Customers may one one one All amounts billed to a customer in a sales transaction related to shipping and handling, if any, represent revenues earned for the goods provided, and these amounts have been included in revenue. Costs related to such shipping and handling billing are classified as cost of goods sold. Variable Consideration The Company records revenue from distributors and direct end customers in an amount that reflects the transaction price it expects to be entitled to after transferring control of those goods or services. The Company’s current contracts do not Warranty The Company generally provides one no not Contract Balances The Company records a receivable when it has an unconditional right to receive consideration after the performance obligations are satisfied. As of June 30, 2018, December 31, 2017, $315,327 $137,499, three six June 30, 2018, not The Company deferred revenues related primarily to maintenance plans of $18,342 $6,663 June 30, 2018 December 31, 2017, Practical Expedients The Company has elected the practical expedient not |
Note 4 - Stockholders' Equity,
Note 4 - Stockholders' Equity, Stock Options and Warrants | 6 Months Ended | 12 Months Ended |
Jun. 30, 2018 | Dec. 31, 2017 | |
Notes to Financial Statements | ||
Stockholders' Equity Note Disclosure [Text Block] | NOTE 4 2018 In January 2018, 2,900,000 $0.95 one 0.3 one $1.00 $2,755,000, 45 290,000 87,000 $0.001 February 21, 2018, 215,247 $0.01, $0.9497 $188,066 $16,354 8% Share Exchange Agreement With Helomics On January 11, 2018, 2,500,000 1,100,000 March 2018 $500,000 5% 25% $500,000 1,100,000 12 $8,000,000. 20% may Merger Agreement with Helomics On October 26, 2018, not 4.0 3.5 1.1 20% 860,000 18 $8.8 23.7 $1.00 5.0 $1.00 75% $8.8 0.6 $1.00 23.7 14.2 $1.00 995,000 $0.01 597,000 $0.01 Completion of the Merger is subject to customary closing conditions including the approval of the Merger by the stockholders of both companies and other conditions. The Merger Agreement likewise contains customary representations, warranties and covenants, including covenants obligating each of the Company and Helomics to continue to conduct their respective businesses in the ordinary course, and to provide reasonable access to each other’s information. Finally, the Merger Agreement contains certain termination rights in favor of each of the Company and Helomics. Increases in Authorized Shares At a special meeting of the stockholders on January 29, 2017, 8,000,000 24,000,000 At the annual meeting on December 28, 2017, 24,000,000 50,000,000 $0.01 January 2, 2018. Equity Incentive Plan The Company has an equity incentive plan, which allows issuance of incentive and non-qualified stock options to employees, directors and consultants of the Company, where permitted under the plan. The exercise price for each stock option is determined by the Board of Directors. Vesting requirements are determined by the Board of Directors when granted and currently range from immediate to three three ten Accounting for share-based payment The Company uses the Black-Scholes option valuation model which requires the input of significant assumptions including an estimate of the average period of time employees will retain vested stock options before exercising them, the estimated volatility of the Company's common stock price over the expected term, the expected dividend rate, the risk-free interest rate, and forfeiture taken at occurrence. Changes in the assumptions can materially affect the estimate of fair value of stock-based compensation and, consequently, the related expense recognized. The assumptions the Company uses in calculating the fair value of stock-based payment awards represent the Company's best estimates, which involve inherent uncertainties and the application of management's judgment. As a result, if factors change and the Company uses different assumptions, the Company's equity-based compensation expense could be materially different in the future. Since the Company's common stock has no no 2 7 15 10 When an option or warrant is granted in place of cash compensation for services, the Company deems the value of the service rendered to be the value of the option or warrant. In most cases, however, an option or warrant is granted in addition to other forms of compensation and its separate value is difficult to determine without utilizing an option pricing model. For that reason the Company also uses the Black-Scholes option-pricing model to value options and warrants granted to non-employees, which requires the input of significant assumptions including an estimate of the average period the investors or consultants will retain vested stock options and warrants before exercising them, the estimated volatility of the Company's common stock price over the expected term, the number of options and warrants that will ultimately be forfeited before completing vesting requirements, the expected dividend rate and the risk-free interest rate. Changes in the assumptions can materially affect the estimate of fair value of stock-based consulting and/or compensation and, consequently, the related expense recognized. Since the Company has limited trading history in its stock and no first Valuation and accounting for options and warrants The Company determines the grant date fair value of options and warrants using a Black-Scholes option valuation model based upon assumptions regarding risk-free interest rate, expected dividend rate, volatility and estimated term. On January 15, 2018, 50,000 $0.01 $0.97 four third fourth On March 12, 2018, 111,112 $0.01 $1.35 four third fourth For grants of stock option and warrants in 2018 2.33% 3.00% 0% 59% 66% 5 10 $0.4816 $1.0044 The following summarizes transactions for stock options and warrants for the periods indicated: Stock Options Warrants Number of Average Number of Average Exercise Outstanding at December 31, 2016 165,643 $ 11.22 871,101 $ 52.22 Issued 2,612,070 1.45 1,082,946 1.49 Expired (12,730 ) 10.39 (2,790 ) 281.46 Exercised - - - - Outstanding at December 31, 2017 2,764,983 $ 2.00 1,951,257 $ 23.74 Issued 482,402 1.11 957,000 1.00 Expired (127,130 ) 2.22 (10,706 ) 199.55 Exercised - - (341,169 ) 1.00 Outstanding at June 30, 2018 3,120,255 $ 1.85 2,556,382 $ 5.97 At June 30, 2018, 2,154,442 $2.05 9.40 2,556,382 six June 2018 June 2017 $460,368 18,276 $997,772 16 The following summarizes the status of options and warrants outstanding at June 30, 2018: Range of Prices Shares Weighted Remaining Life Options $ 0.91 10,000 9.80 $ 0.965 3,000 9.88 $ 0.97 191,753 9.52 $ 1.01 124,358 9.51 $ 1.10 22,730 9.76 $ 1.13 143,807 10.00 $ 1.35 111,112 9.71 $ 1.454 17,200 9.26 $ 1.47 2,373,226 8.99 $ 2.10 14,286 8.76 $ 2.25 293 8.16 $ 2.42 20,640 8.14 $ 2.80 57,145 8.51 $ 3.75 3,998 8.01 $ 4.125 3,636 8.26 $ 4.1975 7,147 8.22 $ 4.25 3,529 7.76 $ 5.125 3,902 8.19 $ 65.75 190 7.32 $ 73.50 1,157 7.51 $ 77.50 2,323 7.01 $ 80.25 187 7.26 $ 86.25 232 6.76 $ 131.25 81 4.19 $ 148.125 928 4.72 $ 150.00 1,760 4.13 $ 162.50 123 6.51 $ 206.25 121 6.26 $ 248.4375 121 5.04 $ 262.50 130 5.04 $ 281.25 529 4.55 $ 318.75 3 4.86 $ 346.875 72 5.76 $ 431.25 306 5.69 $ 506.25 188 5.51 $ 596.25 42 5.25 3,120,255 Warrants $ 1.00 1,372,828 4.36 $ 1.07 697,946 4.35 $ 2.25 385,000 3.57 $ 123.75 94,084 2.17 $ 243.75 2,529 1.10 $ 309.375 2,850 1.11 $ 309.50 222 1.36 $ 506.25 59 0.63 $ 609.375 862 0.60 2,556,382 At the annual meeting on December 28, 2017, 2012 5,000,000, December 4, 2017, 2012 2016 July 28, 2016 not 2.5 2016 not 2012 2017 December 28, 2017. $1.9 fourth 2017. Stock Options and Warrants Granted by the Company The following table is the listing of stock options and warrants as of June 30, 2018 Stock Options: Year Shares Price 2011 173 $281.25 2012 1,841 131.25 – 150.00 2013 1,553 148.13 – 596.25 2014 836 162.50 – 431.25 2015 4,088 65.75 – 86.25 2016 100,292 2.25 – 5.13 2017 2,529,070 1.01 - 2.10 2018 482,402 0.91 - 1.35 Total 3,120,255 $0.91 – 596.25 Warrants: Year Shares Price 2014 6,455 $243.75 – $609.38 2015 94,151 0.00 – 243.75 2016 504,666 1.00 2017 1,082,946 1.07 - 2.25 2018 868,164 1.00 Total 2,556,382 $0.00 – $609.38 | NOTE 3 2015 On August 31, 2015 ( 1,666,667 $9.00 $8.28 $0.72 8.00% $13.8 45 250,000 not 1% $70,000. On August 31, 2015, 228,343 1,895,010 75,801 1,895,010 7,580,040 Each Unit consisted of one $0.01 one four February 29, 2016. For a description of the terms of the Series B Convertible Preferred Stock included within the Units, see “Certificate of Designation for Series B Preferred Stock” below. For a description of the terms of the Series A Warrants included within the Units, see “Series A Warrants” below. Series A Warrants August 31, 2020. one $123.75 Holders may Total Shares = (A x Where: ☐ Total Shares is the number of shares of Common Stock to be issued upon a Cashless Exercise. ☐ A is the total number of shares with respect to which the Series A Warrant is then being exercised. ☐ B is the Black Scholes Value (as defined below). ☐ C is the closing bid price of the Common Stock as of two no may $0.43 The Black Scholes Value (as defined above) as of September 30, 2016 $4.319, September 30, 2016, $4.125. .40 6,141,115 September 30, 2016, 2,318,663 35,084 August 31, 2015 two $0.43 $4.319 September 30, 2016), 564 The Series A Warrants will not 4.99% 13 1934, In addition to (but not three 1 2 Unit Purchase Option The Company, in connection with the Offering, entered into a Unit Purchase Option Agreement, dated as of August 31, 2015 ( 5% 83,333 125% $11.25 May 2016 135,995 Series B Preferred Stock Each share of Series B Preferred Stock is convertible into one six not 4.99% no No Unit Exchange On February 4, 2014, $2,055,000 20,550 $0.01, $100 February 4, 2014. August 31, 2015, 228,343 3,391 3 9 August 31, 2015, no Redemption of Convertible Notes In connection with the closing of the Offering, $933,074 40% $1,548,792. 4. $167,031 Registered Exchange Offer for Warrants On March 25, 2016, $0.01 3,157,186 March 31, 2016, 10.05 may one 10.2 one April 21, 2016. 1,770,556 18,059,671 March 31, 2016 July 6, 2016 1,251,510 20,122 2016 On November 29, 2016, $1,983,337. 756,999 $2.62 five 756,999 six $4.46 $1,739,770. 2017 On January 19, 2017 1,750,000 $2.25 one 0.2 one $2.25 $3,937,500. 175,000 35,000 $0.01 $358,312. 2017 On November 30, 2017, 1,213,819 $1.071 606,910 $1.26 five one six $1,300,000 1.167 1,250,269 142,466 $189,285. Equity Incentive Plan The Company has an equity incentive plan, which allows issuance of incentive and non-qualified stock options to employees, directors and consultants of the Company, where permitted under the plan. The exercise price for each stock option is determined by the Board of Directors. Vesting requirements are determined by the Board of Directors when granted and currently range from immediate to three three ten Accounting for share-based payment The Company has adopted ASC 718 Compensation-Stock Compensation 718" 718 January 1, 2006 January 1, 2006. January 1, 2006, not ASC 718 Since the Company's common stock has no no 2 7 15 10 When an option or warrant is granted in place of cash compensation for services, the Company deems the value of the service rendered to be the value of the option or warrant. In most cases, however, an option or warrant is granted in addition to other forms of compensation and its separate value is difficult to determine without utilizing an option pricing model. For that reason the Company also uses the Black-Scholes option-pricing model to value options and warrants granted to non-employees, which requires the input of significant assumptions including an estimate of the average period the investors or consultants will retain vested stock options and warrants before exercising them, the estimated volatility of the Company's common stock price over the expected term, the number of options and warrants that will ultimately be forfeited before completing vesting requirements, the expected dividend rate and the risk-free interest rate. Changes in the assumptions can materially affect the estimate of fair value of stock-based consulting and/or compensation and, consequently, the related expense recognized. Since the Company has limited trading history in its stock and no first Valuation and accounting for options and warrants The Company determines the grant date fair value of options and warrants using a Black-Scholes option valuation model based upon assumptions regarding risk-free interest rate, expected dividend rate, volatility and estimated term. On July 1, 2016, 40,000 $0.01 $3.75 six fifth sixth On October 4, 2016, 400,000 $0.01, For grants of stock options and warrants in 2016 1.46% 2.45% 0% 59% 66% 5 10 $1.6329 $3.7195 On April 19, 2017, 400,000 $0.01, For grants of stock options and warrants in 2017 1.92% 2.40% 0% 59% 66% 5 10 $0.6541 $1.5489 The following summarizes transactions for stock options and warrants for the periods indicated: Stock Options Warrants Number of Average Number of Average Outstanding at December 31, 2015 31,350 $ 133.23 323,099 $ 128.40 Issued 157,982 3.14 1,487,881 0.71 Expired (22,377 ) 122.13 - - Exercised (1,312 ) 65.75 (939,879 ) - Outstanding at December 31, 2016 165,643 $ 11.22 871,101 $ 52.22 Issued 2,612,070 1.45 1,082,946 1.49 Expired (12,730 ) 10.39 (2,790 ) 281.46 Exercised - - - - Outstanding at December 31, 2017 2,764,983 $ 2.00 1,951,257 $ 23.74 At December 31, 2017, 1,728,264 $2.29 9.45 1,253,311 2017 2016 $1,892,159 $165,271, $1,139,172 24 The following summarizes the status of options and warrants outstanding at December 31, 2017: Range of Exercise Prices Shares Weighted Options: $ 1.01 124,358 10.00 $ 1.454 17,200 9.75 $ 1.47 2,456,226 9.48 $ 2.10 14,286 9.25 $ 2.25 293 8.65 $ 2.42 24,768 8.38 $ 2.80 57,145 9.01 $ 3.75 44,000 8.50 $ 4.125 3,636 8.75 $ 4.1975 7,147 8.72 $ 4.25 3,529 8.25 $ 5.125 3,902 8.69 $ 65.75 190 7.40 $ 73.50 1,157 8.01 $ 77.50 2,323 7.50 $ 80.25 187 7.75 $ 86.25 232 7.25 $ 131.25 81 4.69 $ 148.125 928 5.21 $ 150.00 1,760 4.63 $ 162.50 123 7.01 $ 206.25 121 6.75 $ 248.4375 121 5.54 $ 262.50 130 5.54 $ 281.25 529 5.04 $ 318.75 3 5.35 $ 346.875 72 6.25 $ 431.25 306 6.19 $ 506.25 188 6.00 $ 596.25 42 5.75 Total 2,764,983 Warrants $ 1.07 697,946 4.85 $ 2.25 385,000 4.06 $ 4.46 756,999 3.92 $ 93.75 2,255 0.19 $ 123.75 94,084 2.67 $ 150.00 4,114 0.20 $ 225.00 107 0.07 $ 243.75 2,529 1.59 $ 281.25 3,107 0.14 $ 309.375 2,850 1.61 $ 309.50 222 1.85 $ 337.50 178 0.46 $ 371.25 944 0.41 $ 506.25 59 1.12 $ 609.375 862 1.09 Total 1,951,257 Stock options and warrants expire on various dates from January 2018 December 2027. At a special meeting of stockholders held on September 15, 2016, 100,000,000 200,000,000 September 16, 2016, October 26, 2016, one twenty-five 1:25 200,000,000 8,000,000 5:00 October 27, 2016, October 28, 2016. may January 29, 2017. 8,000,000 24,000,000 December 28, 2017, January 2, 2018, 24,000,000 50,000,000 $0.01 2012 5,000,000, December 4, 2017, 2012 2016 not 2.5 2016 not 2012 2017 December 28, 2017. $1.9 fourth 2017. Stock Options and Warrants Granted by the Company The following table is the listing of stock options and warrants as of December 31, 2017 Stock Options: Year Shares Price 2011 173 281.25 2012 1,841 131.25 – 150.00 2013 1,553 148.13 – 596.25 2014 835 162.50 – 431.25 2015 4,088 65.75 – 86.25 2016 144,423 2.25 – 5.13 2017 2,612,070 1.01 – 2.10 Total 2,764,983 $ 1.01 – 596.25 Warrants: Year Shares Price 2013 10,705 93.75 – 371.25 2014 6,455 243.75 – 609.38 2015 94,152 0.00 – 243.75 2016 756,999 4.46 2017 1,082,946 1.07 – 2.25 Total 1,951,257 $ 0.00 – 609.38 |
Note 5 - Notes Receivable
Note 5 - Notes Receivable | 6 Months Ended | 12 Months Ended |
Jun. 30, 2018 | Dec. 31, 2017 | |
Notes to Financial Statements | ||
Financing Receivables [Text Block] | NOTE 5 In July 2017, 8% December 31, 2017. $1,070,000 December 31, 2017. March 2018, $1,112,524, 8% two February 28, 2020. In October 2017, $600,000 December 2017, $67,512 fifty 50% March 2018, $500,000 833,333 5% 25%. $167,512 | NOTE 4– In July 2017, 8% December 31, 2017. $1,070,000 December 31, 2017. March 2018, $1,112,524, eight 8% two February 28, 2020. The Company advanced $600,000 8% April 30, 2018. December 2017, $67,512.10 fifty 50% March 2018, $500,000 833,333 5% 25%. $167,512.10 |
Note 6 - Loss Per Share
Note 6 - Loss Per Share | 6 Months Ended | 12 Months Ended |
Jun. 30, 2018 | Dec. 31, 2017 | |
Notes to Financial Statements | ||
Earnings Per Share [Text Block] | NOTE 6 The following table presents the shares used in the basic and diluted loss per common share computations: Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Numerator Net loss available in basic and diluted calculation $ (2,373,410 ) $ (2,543,670 ) $ (4,133,432 ) $ (3,885,517 ) Comprehensive loss (2,373,410 ) (2,543,670 ) (4,133,432 ) (3,885,517 ) Denominator: Weighted average common shares outstanding-basic 11,878,490 6,167,689 11,632,221 6,308,554 Effect of diluted stock options, warrants and preferred stock (1) - - - - Weighted average common shares outstanding-basic 11,878,490 6,167,689 11,632,221 6,308,554 Loss per common share-basic and diluted $ (0.20 ) $ (0.41 ) $ (0.36 ) $ (0.62 ) ( 1 June 30, 2018 June 30, 2017 5,676,637 3,850,878, June 30, 2018 79,246. | NOTE 5 The following table presents the shares used in the basic and diluted loss per common share computations: Year Ended December 31, 2017 2016 Numerator: Net loss available in basic and diluted calculation $ (7,746,593 ) $ (6,526,014 ) Other comprehensive income: Unrealized gain (loss) from marketable securities - 1,501 Comprehensive (loss) (7,746,593 ) (6,524,513 ) Denominator: Weighted average common shares outstanding-basic 6,362,989 2,823,345 Effect of dilutive stock options, warrants and preferred stock (1) - - Weighted average common shares outstanding-basic 6,362,989 2,823,345 Loss per common share-basic and diluted $ (1.22 ) $ (2.31 ) ( 1 December 31, 2017 December 31, 2016 4,716,240 1,036,744, December 31, 2017 79,246 647,819 |
Note 7 - Related Party Transact
Note 7 - Related Party Transactions | 6 Months Ended | 12 Months Ended |
Jun. 30, 2018 | Dec. 31, 2017 | |
Notes to Financial Statements | ||
Related Party Transactions Disclosure [Text Block] | NOTE 7 The Audit Committee has the responsibility to review and approve all transactions to which a related party and the Company may In April 2018, one six $12,000 240,000 2012 | NOTE 8 The Audit Committee has the responsibility to review and approve all transactions to which a related party and the Company may One of the Company’s directors, Richard L. Gabriel, is the Chief Operating Officer and serves as a director of GLG Pharma (“GLG”). Another Company director, Tim Krochuk, is on the supervisory board for GLG. In September 20, 2016, 400,000 four 100,000 November 1, 2016, November 2, 2016, April 2017, |
Note 8 - Subsequent Events
Note 8 - Subsequent Events | 6 Months Ended | 12 Months Ended |
Jun. 30, 2018 | Dec. 31, 2017 | |
Notes to Financial Statements | ||
Subsequent Events [Text Block] | NOTE 8 On July 13, 2017, 2012 2016 July 28, 2016, not December 2017, July 2018, no | NOTE 11 In January 2018, 2,900,000 $0.95 one 0.3 one $1.00 $2,755,000, 45 290,000 87,000 $0.001 February 21, 2018, 215,247 $0.01, $0.9497 $188,066 $16,354 8% On January 11, 2018, 2,500,000 1,100,000 $500,000 5% 25% $500,000 12 $8,000,000. 20% may On February 22, 2018, $667,512.50. $500,000 833,333 2,500,000 10,000,000 3,333,333 25% 13,333,333 $167,512.50 On February 27, 2018, may 25% 48Hour |
Note 1 - Summary of Significa_2
Note 1 - Summary of Significant Accounting Policies -2 | 6 Months Ended | 12 Months Ended |
Jun. 30, 2018 | Dec. 31, 2017 | |
Notes to Financial Statements | ||
Significant Accounting Policies [Text Block] | NOTE 1 Nature of Operations and Continuance of Operations Precision Therapeutics Inc., (the “Company”) was originally incorporated on April 23, 2002 August 6, 2013, December 16, 2013, August 31, 2015, February 1, 2018, February 1, 2018. February 2, 2018. As of June 30, 2018, 12,089,446 $.01 two 1 2 April 2009, 510 The Company acquired 25% first 2018, April 2018 June 2018, 4. 149,000 first The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company has incurred recurring losses from operations and has an accumulated deficit of $58,898,476. not $1,004,269 June 30, 2018 one not Since inception to June 30, 2018, $35,840,380 1 $2,055,000 2 $13,555,003 3 $1,739,770 4 $3,937,500 $358,312 5 $1,300,000 6 $2,755,000 7 $5,685,000 Interim Financial Statements The Company has prepared the unaudited interim financial statements and related unaudited financial information in the footnotes in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. These interim financial statements reflect all adjustments consisting of normal recurring accruals, which in the opinion of management, are necessary to present fairly the Company’s position, the results of its operations and its cash flows for the interim periods. These interim financial statements reflect all intercompany eliminations. These interim financial statements should be read in conjunction with the annual financial statements and the notes thereto contained in the Form 10 April 2, 2018. may not Recent Accounting Developments In May 2014, No. 2014 09, Revenue from Contracts with Customers (Topic 606 January 1, 2018 not December 31, 2017. January 1, 2018 606, not 605, Revenue Recognition not December 31, 2017, not January 1, 2018, no 3 In January 2016, No. 2016 01, Financial Instruments-Overall (Subtopic 825 10 2016 01” not not January 1, 2018. June 30, 2018, no In February 2016, No. 2016 02, Leases (Topic 842 2016 02” December 15, 2018. Valuation of Intangible Assets The Company reviews identifiable intangible assets for impairment annually, or whenever events or changes in circumstances indicate the carrying amount may not may not not Accounting Policies and Estimates The presentation of financial statements is in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Cash Equivalents The Company considers all highly liquid debt instruments with a maturity of three Certificates of Deposit Short-term interest-bearing investments are those with maturities of less than one three one Fair Value Measurements Under generally accepted accounting principles as outlined in the FASB’s Accounting Standards Codification (ASC) 820, 820 three Level 1 Level 2 Level 3 no The Company uses observable market data, when available, in making fair value measurements. Fair value measurements are classified according to the lowest level input that is significant to the valuation. The fair value of the Company’s investment securities was determined based on Level 1 Inventories Inventories are stated at the lower of cost and net realizable value, with cost determined on a first first June 30, 2018 December 31, 2017 Finished goods $ 31,782 $ 62,932 Raw materials 168,735 141,028 Work-In-Process 44,143 61,085 Total $ 244,660 $ 265,045 Property and Equipment Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the respective assets. Estimated useful asset life by classification is as follows: Years Computers and office equipment 3 - 7 Leasehold improvements 3 Manufacturing tooling 3 - 7 Demo equipment 3 The Company’s fixed assets consist of the following: June 30, 2018 December 31, 2017 Computers and office equipment $ 201,123 $ 183,528 Leasehold improvements 122,188 25,635 Manufacturing tooling 108,955 108,955 Demo equipment 59,210 43,368 Total 491,476 361,486 Less: Accumulated depreciation 307,091 273,770 Total Fixed Assets, Net $ 184,385 $ 87,716 Upon retirement or sale, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred. Depreciation expense was $18,825 $33,321 three six June 30, 2018 $14,519 $30,204 three six June 30, 2017. Intangible Assets Intangible assets consist of trademarks and patent costs. Amortization expense was $4,070 $7,741 three six June 30, 2018 $2,902 $5,790 three six June 30, 2017. Income Taxes The Company accounts for income taxes in accordance with ASC 740 Income Taxes 740” 740, There is no 100% The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not no Tax years subsequent to 2014 Offering Costs Costs incurred which are direct and incremental to an offering of the Company’s securities are deferred and charged against the proceeds of the offering, unless such costs are deemed to be insignificant in which case they are expensed as incurred. Patents and Intellectual Property On January 25, 2014, No. PCT/US2014/013081 61756763 one January 25, 2013. 148 The Company’s PCT patent application is for the new model of the surgical fluid waste management system. The Company obtained a favorable International Search Report from the PCT searching authority indicating that the claims in its PCT application are patentable (i.e., novel and non-obvious) over the cited prior art. A feature claimed in the PCT application is the ability to maintain continuous suction to the surgical field while measuring, recording and evacuating fluid to the facility’s sewer drainage system. This provides for continuous operation of the STREAMWAY System unit in suctioning waste fluids, which means that suction is not The Company holds the following granted patents in the United States and a pending application in the United States on its earlier models: US7469727, US8123731 No. US20090216205 August 8, 2023. In July 2015, The United States Patent Office has assigned application #14/763,459 As of November 22, 2017, #14743665.3 1651 Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high credit quality financial institutions and, by policy, generally limits the amount of credit exposure to any one $794,125 Segments The Company operates in two three six June 30, 2018 2017 $3,178 $0 three 2018 2017, $5,866 $26,662 first six 2018 2017, Risks and Uncertainties The Company is subject to risks common to companies in the medical device industry, including, but not | NOTE 1 Nature of Operations and Continuance of Operations The Company was originally incorporated on April 23, 2002 August 6, 2013, December 16, 2013, August 31, 2015, February 1, 2018, February 1, 2018. February 2, 2018. As of December 31, 2017, 6,943,283 $.01 1 25 October 27, 2016. April 2009, 510 The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company has suffered recurring losses from operations and had a stockholders’ deficit until August 31, 2015 not Since inception to December 31, 2017, $29,065,934 $2,055,000 $13,555,003 $1,739,770 $3,937,500 $358,312 $1,300,000 $5,685,000 Recent Accounting Developments In May 2014, 2014 09, Revenue from Contracts with Customers 606, 2015 14, “Revenue from Contracts with Customers: Deferral of the Effective Date,” 2016 08, “Revenue from Contracts with Customers: Principal versus Agent Considerations (Reporting Revenue Gross versus Net),” 2016 10, “Revenue from Contracts with Customers: Identifying Performance Obligations and Licensing,” 2016 12, “Revenue from Contracts with Customers: Narrow-Scope Improvements and Practical Expedients.” 2017 13. December 15, 2017, not two 606. January 1, 2018 January 1, 2018, not In August 2014, 2014 15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern December 15, 2016, first 2017. In July 2015, No. 2015 11 , Inventory (Topic 330 December 15, 2016, first 2017. In November 2015, 2015 17, “Income Taxes (Topic 740 December 15, 2016 first 2017. In January 2016, No. 2016 01, Financial Instruments-Overall (Subtopic 825 10 2016 01” not not December 15, 2017, not In February 2016, No. 2016 02, (Topic 842” 2016 02” December 15, 2018. In March 2016, No. 2016 09, “Compensation (Topic 718 “ASU2016 09” 2016 09 December 15, 2016. first 2017. In August 2016, No. 2016 15, Statement of Cash Flows (Topic 230 December 15, 2017, not 2016 15 On December 22, 2017, 2017 34% 21%. We reviewed all other significant newly issued accounting pronouncements and determined they are either not no Valuation of Intangible Assets We review identifiable intangible assets for impairment in accordance with ASC 350 may not may not not Accounting Policies and Estimate The presentation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Presentation of Taxes Collected from Customers Sales taxes are imposed on the Company’s sales to nonexempt customers. The Company collects the taxes from customers and remits the entire amounts to the governmental authorities. The Company’s accounting policy is to exclude the taxes collected and remitted from revenues and expenses. Shipping and Handling Shipping and handling charges billed to customers are recorded as revenue. Shipping and handling costs are recorded within cost of goods sold on the statement of operations. Advertising Advertising costs are expensed as incurred. Advertising expenses were $37,060 2017, $71,212 2016. Research and Development Research and development costs are charged to operations as incurred. Research and development costs were approximately $289,000 $406,000 2017 2016, Revenue Recognition The Company recognizes revenue in accordance with the SEC’s Staff Accounting Bulletin Revenue Recognition and ASC 606 We recognize revenue when the following criteria are met: persuasive evidence of an arrangement exists – we receive both a signed purchase order and contract of terms and conditions confirming the sale from the customer; delivery has occurred – the goods are shipped from our warehouse and delivered and accepted by the customer; the selling price is fixed or determinable – confirmed on the customer purchase order and then invoiced immediately upon shipment of the goods; and collectability is reasonably assured – our customers are long standing hospitals, ambulatory surgical centers and others that pass credit checks. The terms of our agreements with our customers are specified in written agreements. These written agreements, the purchase order and the matching invoice, constitute the persuasive evidence of the arrangements with our customers that are a precondition to the recognition of revenue. We undertake an evaluation of the creditworthiness of both new and, on a periodic basis, existing customers. Based on these reviews we determine whether collection of our prospective revenue is probable. We have adopted the provisions of Accounting Standards Update, or “ASU” 2014 09, 606 606 January 1, 2018 While we continue to assess all potential impacts of the standard, it is currently anticipated that the standard will not Cash Equivalents The Company considers all highly liquid debt instruments with a maturity of three Certificates of Deposit Short-term interest-bearing investments are those with maturities of less than one three one Investment Securities Readily marketable investments in debt and equity services are classified as available-for-sale and are reported at fair value with unrealized gains losses recorded in other comprehensive income. Unrealized gains are charged to earnings when an incline in fair value above the cost basis is determined to be other-than-temporary. Realized gains and losses on dispositions are based on the net proceeds and the adjusted book value of the securities sold, using the specific identification method. Fair Value Measurements Under generally accepted accounting principles as outlined in the Financial Accounting Standards Board’s Accounting Standards Certification 820, 820 three Level 1 Level 2 Level 3 no The Company uses observable market data, when available, in making fair value measurements. Fair value measurements are classified according to the lowest level input that is significant to the valuation. The fair value of the Company’s investment securities were determined based on Level 1 Receivables Receivables are reported at the amount the Company expects to collect on balances outstanding. The Company provides for probable uncollectible amounts through charges to earnings and credits to the valuation based on management’s assessment of the current status of individual accounts, changes to the valuation allowance have not Inventories Inventories are stated at the lower of cost or market, with cost determined on a first first December 31, 2017 December 31, 2016 Finished goods $ 62,932 $ 38,201 Raw materials 141,028 165,812 Work-In-Process 61,085 68,195 Total $ 265,045 $ 272,208 Property and Equipment Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the respective assets. Estimated useful asset life by classification is as follows: Years Computers and office equipment 3 - 7 Leasehold improvements 5 Manufacturing Tooling 3 - 7 Demo Equipment 3 The Company’s investment in Fixed Assets consists of the following: December 31, 2017 December 31, 2016 Computers and office equipment $ 183,528 $ 164,318 Leasehold Improvements 25,635 25,635 Manufacturing Tooling 108,955 103,204 Demo Equipment 43,368 23,236 Total 361,486 316,393 Less: Accumulated Depreciation 273,770 214,897 Total Fixed Assets, Net $ 87,716 $ 101,496 Upon retirement or sale, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred. Depreciation expense was $58,872 2017 $73,249 2016. Intangible Assets Intangible assets consist of trademarks and patent costs. Amortization expense was $12,689 2017 $9,107 2016. Income Taxes The Company accounts for income taxes in accordance with ASC 740 Income Taxes (“ASC 740” 740, The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not no Tax years subsequent to 2014 Patents and Intellectual Property On January 25th, 2014, No. PCT/US2014/013081 61756763 one January 25th, 2013. 148 Our PCT patent application is for the new model of the surgical fluid waste management system. We obtained a favorable International Search Report from the PCT searching authority indicating that the claims in our PCT application are patentable (i.e., novel and non-obvious) over the cited prior art. A feature claimed in the PCT application is the ability to maintain continuous suction to the surgical field while measuring, recording and evacuating fluid to the facilities sewer drainage system. This provides for continuous operation of the STREAMWAY System unit in suctioning waste fluids, which means that suction is not The Company holds the following granted patents in the United States and a pending application in the United States on its earlier models: US7469727, US8123731 No. US20090216205 August 8, 2023. In July 2015, The United States Patent Office has assigned application #14/763,459 As of November 22, 2017, #14743665.3 1651, Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high credit quality financial institutions and, by policy, generally limits the amount of credit exposure to any one $563,000 Product Warranty Costs In 2017 2016, $6,209 $34,665 Segments The Company operates in two 2017 2016 $26,662 2017. Risks and Uncertainties The Company is subject to risks common to companies in the medical device industry, including, but not |
Note 2 - Development Stage Oper
Note 2 - Development Stage Operations | 6 Months Ended |
Jun. 30, 2018 | |
Notes to Financial Statements | |
Development Stage Enterprise Disclosures [Text Block] | NOTE 2 The Company was formed April 23, 2002. December 31, 2017, 6,943,283 $3,131.25. |
Note 3 - Stockholders' Equity (
Note 3 - Stockholders' Equity (Deficit), Stock Options and Warrants | 6 Months Ended | 12 Months Ended |
Jun. 30, 2018 | Dec. 31, 2017 | |
Notes to Financial Statements | ||
Stockholders' Equity Note Disclosure [Text Block] | NOTE 4 2018 In January 2018, 2,900,000 $0.95 one 0.3 one $1.00 $2,755,000, 45 290,000 87,000 $0.001 February 21, 2018, 215,247 $0.01, $0.9497 $188,066 $16,354 8% Share Exchange Agreement With Helomics On January 11, 2018, 2,500,000 1,100,000 March 2018 $500,000 5% 25% $500,000 1,100,000 12 $8,000,000. 20% may Merger Agreement with Helomics On October 26, 2018, not 4.0 3.5 1.1 20% 860,000 18 $8.8 23.7 $1.00 5.0 $1.00 75% $8.8 0.6 $1.00 23.7 14.2 $1.00 995,000 $0.01 597,000 $0.01 Completion of the Merger is subject to customary closing conditions including the approval of the Merger by the stockholders of both companies and other conditions. The Merger Agreement likewise contains customary representations, warranties and covenants, including covenants obligating each of the Company and Helomics to continue to conduct their respective businesses in the ordinary course, and to provide reasonable access to each other’s information. Finally, the Merger Agreement contains certain termination rights in favor of each of the Company and Helomics. Increases in Authorized Shares At a special meeting of the stockholders on January 29, 2017, 8,000,000 24,000,000 At the annual meeting on December 28, 2017, 24,000,000 50,000,000 $0.01 January 2, 2018. Equity Incentive Plan The Company has an equity incentive plan, which allows issuance of incentive and non-qualified stock options to employees, directors and consultants of the Company, where permitted under the plan. The exercise price for each stock option is determined by the Board of Directors. Vesting requirements are determined by the Board of Directors when granted and currently range from immediate to three three ten Accounting for share-based payment The Company uses the Black-Scholes option valuation model which requires the input of significant assumptions including an estimate of the average period of time employees will retain vested stock options before exercising them, the estimated volatility of the Company's common stock price over the expected term, the expected dividend rate, the risk-free interest rate, and forfeiture taken at occurrence. Changes in the assumptions can materially affect the estimate of fair value of stock-based compensation and, consequently, the related expense recognized. The assumptions the Company uses in calculating the fair value of stock-based payment awards represent the Company's best estimates, which involve inherent uncertainties and the application of management's judgment. As a result, if factors change and the Company uses different assumptions, the Company's equity-based compensation expense could be materially different in the future. Since the Company's common stock has no no 2 7 15 10 When an option or warrant is granted in place of cash compensation for services, the Company deems the value of the service rendered to be the value of the option or warrant. In most cases, however, an option or warrant is granted in addition to other forms of compensation and its separate value is difficult to determine without utilizing an option pricing model. For that reason the Company also uses the Black-Scholes option-pricing model to value options and warrants granted to non-employees, which requires the input of significant assumptions including an estimate of the average period the investors or consultants will retain vested stock options and warrants before exercising them, the estimated volatility of the Company's common stock price over the expected term, the number of options and warrants that will ultimately be forfeited before completing vesting requirements, the expected dividend rate and the risk-free interest rate. Changes in the assumptions can materially affect the estimate of fair value of stock-based consulting and/or compensation and, consequently, the related expense recognized. Since the Company has limited trading history in its stock and no first Valuation and accounting for options and warrants The Company determines the grant date fair value of options and warrants using a Black-Scholes option valuation model based upon assumptions regarding risk-free interest rate, expected dividend rate, volatility and estimated term. On January 15, 2018, 50,000 $0.01 $0.97 four third fourth On March 12, 2018, 111,112 $0.01 $1.35 four third fourth For grants of stock option and warrants in 2018 2.33% 3.00% 0% 59% 66% 5 10 $0.4816 $1.0044 The following summarizes transactions for stock options and warrants for the periods indicated: Stock Options Warrants Number of Average Number of Average Exercise Outstanding at December 31, 2016 165,643 $ 11.22 871,101 $ 52.22 Issued 2,612,070 1.45 1,082,946 1.49 Expired (12,730 ) 10.39 (2,790 ) 281.46 Exercised - - - - Outstanding at December 31, 2017 2,764,983 $ 2.00 1,951,257 $ 23.74 Issued 482,402 1.11 957,000 1.00 Expired (127,130 ) 2.22 (10,706 ) 199.55 Exercised - - (341,169 ) 1.00 Outstanding at June 30, 2018 3,120,255 $ 1.85 2,556,382 $ 5.97 At June 30, 2018, 2,154,442 $2.05 9.40 2,556,382 six June 2018 June 2017 $460,368 18,276 $997,772 16 The following summarizes the status of options and warrants outstanding at June 30, 2018: Range of Prices Shares Weighted Remaining Life Options $ 0.91 10,000 9.80 $ 0.965 3,000 9.88 $ 0.97 191,753 9.52 $ 1.01 124,358 9.51 $ 1.10 22,730 9.76 $ 1.13 143,807 10.00 $ 1.35 111,112 9.71 $ 1.454 17,200 9.26 $ 1.47 2,373,226 8.99 $ 2.10 14,286 8.76 $ 2.25 293 8.16 $ 2.42 20,640 8.14 $ 2.80 57,145 8.51 $ 3.75 3,998 8.01 $ 4.125 3,636 8.26 $ 4.1975 7,147 8.22 $ 4.25 3,529 7.76 $ 5.125 3,902 8.19 $ 65.75 190 7.32 $ 73.50 1,157 7.51 $ 77.50 2,323 7.01 $ 80.25 187 7.26 $ 86.25 232 6.76 $ 131.25 81 4.19 $ 148.125 928 4.72 $ 150.00 1,760 4.13 $ 162.50 123 6.51 $ 206.25 121 6.26 $ 248.4375 121 5.04 $ 262.50 130 5.04 $ 281.25 529 4.55 $ 318.75 3 4.86 $ 346.875 72 5.76 $ 431.25 306 5.69 $ 506.25 188 5.51 $ 596.25 42 5.25 3,120,255 Warrants $ 1.00 1,372,828 4.36 $ 1.07 697,946 4.35 $ 2.25 385,000 3.57 $ 123.75 94,084 2.17 $ 243.75 2,529 1.10 $ 309.375 2,850 1.11 $ 309.50 222 1.36 $ 506.25 59 0.63 $ 609.375 862 0.60 2,556,382 At the annual meeting on December 28, 2017, 2012 5,000,000, December 4, 2017, 2012 2016 July 28, 2016 not 2.5 2016 not 2012 2017 December 28, 2017. $1.9 fourth 2017. Stock Options and Warrants Granted by the Company The following table is the listing of stock options and warrants as of June 30, 2018 Stock Options: Year Shares Price 2011 173 $281.25 2012 1,841 131.25 – 150.00 2013 1,553 148.13 – 596.25 2014 836 162.50 – 431.25 2015 4,088 65.75 – 86.25 2016 100,292 2.25 – 5.13 2017 2,529,070 1.01 - 2.10 2018 482,402 0.91 - 1.35 Total 3,120,255 $0.91 – 596.25 Warrants: Year Shares Price 2014 6,455 $243.75 – $609.38 2015 94,151 0.00 – 243.75 2016 504,666 1.00 2017 1,082,946 1.07 - 2.25 2018 868,164 1.00 Total 2,556,382 $0.00 – $609.38 | NOTE 3 2015 On August 31, 2015 ( 1,666,667 $9.00 $8.28 $0.72 8.00% $13.8 45 250,000 not 1% $70,000. On August 31, 2015, 228,343 1,895,010 75,801 1,895,010 7,580,040 Each Unit consisted of one $0.01 one four February 29, 2016. For a description of the terms of the Series B Convertible Preferred Stock included within the Units, see “Certificate of Designation for Series B Preferred Stock” below. For a description of the terms of the Series A Warrants included within the Units, see “Series A Warrants” below. Series A Warrants August 31, 2020. one $123.75 Holders may Total Shares = (A x Where: ☐ Total Shares is the number of shares of Common Stock to be issued upon a Cashless Exercise. ☐ A is the total number of shares with respect to which the Series A Warrant is then being exercised. ☐ B is the Black Scholes Value (as defined below). ☐ C is the closing bid price of the Common Stock as of two no may $0.43 The Black Scholes Value (as defined above) as of September 30, 2016 $4.319, September 30, 2016, $4.125. .40 6,141,115 September 30, 2016, 2,318,663 35,084 August 31, 2015 two $0.43 $4.319 September 30, 2016), 564 The Series A Warrants will not 4.99% 13 1934, In addition to (but not three 1 2 Unit Purchase Option The Company, in connection with the Offering, entered into a Unit Purchase Option Agreement, dated as of August 31, 2015 ( 5% 83,333 125% $11.25 May 2016 135,995 Series B Preferred Stock Each share of Series B Preferred Stock is convertible into one six not 4.99% no No Unit Exchange On February 4, 2014, $2,055,000 20,550 $0.01, $100 February 4, 2014. August 31, 2015, 228,343 3,391 3 9 August 31, 2015, no Redemption of Convertible Notes In connection with the closing of the Offering, $933,074 40% $1,548,792. 4. $167,031 Registered Exchange Offer for Warrants On March 25, 2016, $0.01 3,157,186 March 31, 2016, 10.05 may one 10.2 one April 21, 2016. 1,770,556 18,059,671 March 31, 2016 July 6, 2016 1,251,510 20,122 2016 On November 29, 2016, $1,983,337. 756,999 $2.62 five 756,999 six $4.46 $1,739,770. 2017 On January 19, 2017 1,750,000 $2.25 one 0.2 one $2.25 $3,937,500. 175,000 35,000 $0.01 $358,312. 2017 On November 30, 2017, 1,213,819 $1.071 606,910 $1.26 five one six $1,300,000 1.167 1,250,269 142,466 $189,285. Equity Incentive Plan The Company has an equity incentive plan, which allows issuance of incentive and non-qualified stock options to employees, directors and consultants of the Company, where permitted under the plan. The exercise price for each stock option is determined by the Board of Directors. Vesting requirements are determined by the Board of Directors when granted and currently range from immediate to three three ten Accounting for share-based payment The Company has adopted ASC 718 Compensation-Stock Compensation 718" 718 January 1, 2006 January 1, 2006. January 1, 2006, not ASC 718 Since the Company's common stock has no no 2 7 15 10 When an option or warrant is granted in place of cash compensation for services, the Company deems the value of the service rendered to be the value of the option or warrant. In most cases, however, an option or warrant is granted in addition to other forms of compensation and its separate value is difficult to determine without utilizing an option pricing model. For that reason the Company also uses the Black-Scholes option-pricing model to value options and warrants granted to non-employees, which requires the input of significant assumptions including an estimate of the average period the investors or consultants will retain vested stock options and warrants before exercising them, the estimated volatility of the Company's common stock price over the expected term, the number of options and warrants that will ultimately be forfeited before completing vesting requirements, the expected dividend rate and the risk-free interest rate. Changes in the assumptions can materially affect the estimate of fair value of stock-based consulting and/or compensation and, consequently, the related expense recognized. Since the Company has limited trading history in its stock and no first Valuation and accounting for options and warrants The Company determines the grant date fair value of options and warrants using a Black-Scholes option valuation model based upon assumptions regarding risk-free interest rate, expected dividend rate, volatility and estimated term. On July 1, 2016, 40,000 $0.01 $3.75 six fifth sixth On October 4, 2016, 400,000 $0.01, For grants of stock options and warrants in 2016 1.46% 2.45% 0% 59% 66% 5 10 $1.6329 $3.7195 On April 19, 2017, 400,000 $0.01, For grants of stock options and warrants in 2017 1.92% 2.40% 0% 59% 66% 5 10 $0.6541 $1.5489 The following summarizes transactions for stock options and warrants for the periods indicated: Stock Options Warrants Number of Average Number of Average Outstanding at December 31, 2015 31,350 $ 133.23 323,099 $ 128.40 Issued 157,982 3.14 1,487,881 0.71 Expired (22,377 ) 122.13 - - Exercised (1,312 ) 65.75 (939,879 ) - Outstanding at December 31, 2016 165,643 $ 11.22 871,101 $ 52.22 Issued 2,612,070 1.45 1,082,946 1.49 Expired (12,730 ) 10.39 (2,790 ) 281.46 Exercised - - - - Outstanding at December 31, 2017 2,764,983 $ 2.00 1,951,257 $ 23.74 At December 31, 2017, 1,728,264 $2.29 9.45 1,253,311 2017 2016 $1,892,159 $165,271, $1,139,172 24 The following summarizes the status of options and warrants outstanding at December 31, 2017: Range of Exercise Prices Shares Weighted Options: $ 1.01 124,358 10.00 $ 1.454 17,200 9.75 $ 1.47 2,456,226 9.48 $ 2.10 14,286 9.25 $ 2.25 293 8.65 $ 2.42 24,768 8.38 $ 2.80 57,145 9.01 $ 3.75 44,000 8.50 $ 4.125 3,636 8.75 $ 4.1975 7,147 8.72 $ 4.25 3,529 8.25 $ 5.125 3,902 8.69 $ 65.75 190 7.40 $ 73.50 1,157 8.01 $ 77.50 2,323 7.50 $ 80.25 187 7.75 $ 86.25 232 7.25 $ 131.25 81 4.69 $ 148.125 928 5.21 $ 150.00 1,760 4.63 $ 162.50 123 7.01 $ 206.25 121 6.75 $ 248.4375 121 5.54 $ 262.50 130 5.54 $ 281.25 529 5.04 $ 318.75 3 5.35 $ 346.875 72 6.25 $ 431.25 306 6.19 $ 506.25 188 6.00 $ 596.25 42 5.75 Total 2,764,983 Warrants $ 1.07 697,946 4.85 $ 2.25 385,000 4.06 $ 4.46 756,999 3.92 $ 93.75 2,255 0.19 $ 123.75 94,084 2.67 $ 150.00 4,114 0.20 $ 225.00 107 0.07 $ 243.75 2,529 1.59 $ 281.25 3,107 0.14 $ 309.375 2,850 1.61 $ 309.50 222 1.85 $ 337.50 178 0.46 $ 371.25 944 0.41 $ 506.25 59 1.12 $ 609.375 862 1.09 Total 1,951,257 Stock options and warrants expire on various dates from January 2018 December 2027. At a special meeting of stockholders held on September 15, 2016, 100,000,000 200,000,000 September 16, 2016, October 26, 2016, one twenty-five 1:25 200,000,000 8,000,000 5:00 October 27, 2016, October 28, 2016. may January 29, 2017. 8,000,000 24,000,000 December 28, 2017, January 2, 2018, 24,000,000 50,000,000 $0.01 2012 5,000,000, December 4, 2017, 2012 2016 not 2.5 2016 not 2012 2017 December 28, 2017. $1.9 fourth 2017. Stock Options and Warrants Granted by the Company The following table is the listing of stock options and warrants as of December 31, 2017 Stock Options: Year Shares Price 2011 173 281.25 2012 1,841 131.25 – 150.00 2013 1,553 148.13 – 596.25 2014 835 162.50 – 431.25 2015 4,088 65.75 – 86.25 2016 144,423 2.25 – 5.13 2017 2,612,070 1.01 – 2.10 Total 2,764,983 $ 1.01 – 596.25 Warrants: Year Shares Price 2013 10,705 93.75 – 371.25 2014 6,455 243.75 – 609.38 2015 94,152 0.00 – 243.75 2016 756,999 4.46 2017 1,082,946 1.07 – 2.25 Total 1,951,257 $ 0.00 – 609.38 |
Note 4 - Notes Receivable
Note 4 - Notes Receivable | 6 Months Ended | 12 Months Ended |
Jun. 30, 2018 | Dec. 31, 2017 | |
Notes to Financial Statements | ||
Financing Receivables [Text Block] | NOTE 5 In July 2017, 8% December 31, 2017. $1,070,000 December 31, 2017. March 2018, $1,112,524, 8% two February 28, 2020. In October 2017, $600,000 December 2017, $67,512 fifty 50% March 2018, $500,000 833,333 5% 25%. $167,512 | NOTE 4– In July 2017, 8% December 31, 2017. $1,070,000 December 31, 2017. March 2018, $1,112,524, eight 8% two February 28, 2020. The Company advanced $600,000 8% April 30, 2018. December 2017, $67,512.10 fifty 50% March 2018, $500,000 833,333 5% 25%. $167,512.10 |
Note 5 - Loss Per Share
Note 5 - Loss Per Share | 6 Months Ended | 12 Months Ended |
Jun. 30, 2018 | Dec. 31, 2017 | |
Notes to Financial Statements | ||
Earnings Per Share [Text Block] | NOTE 6 The following table presents the shares used in the basic and diluted loss per common share computations: Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Numerator Net loss available in basic and diluted calculation $ (2,373,410 ) $ (2,543,670 ) $ (4,133,432 ) $ (3,885,517 ) Comprehensive loss (2,373,410 ) (2,543,670 ) (4,133,432 ) (3,885,517 ) Denominator: Weighted average common shares outstanding-basic 11,878,490 6,167,689 11,632,221 6,308,554 Effect of diluted stock options, warrants and preferred stock (1) - - - - Weighted average common shares outstanding-basic 11,878,490 6,167,689 11,632,221 6,308,554 Loss per common share-basic and diluted $ (0.20 ) $ (0.41 ) $ (0.36 ) $ (0.62 ) ( 1 June 30, 2018 June 30, 2017 5,676,637 3,850,878, June 30, 2018 79,246. | NOTE 5 The following table presents the shares used in the basic and diluted loss per common share computations: Year Ended December 31, 2017 2016 Numerator: Net loss available in basic and diluted calculation $ (7,746,593 ) $ (6,526,014 ) Other comprehensive income: Unrealized gain (loss) from marketable securities - 1,501 Comprehensive (loss) (7,746,593 ) (6,524,513 ) Denominator: Weighted average common shares outstanding-basic 6,362,989 2,823,345 Effect of dilutive stock options, warrants and preferred stock (1) - - Weighted average common shares outstanding-basic 6,362,989 2,823,345 Loss per common share-basic and diluted $ (1.22 ) $ (2.31 ) ( 1 December 31, 2017 December 31, 2016 4,716,240 1,036,744, December 31, 2017 79,246 647,819 |
Note 6 - Income Taxes
Note 6 - Income Taxes | 12 Months Ended |
Dec. 31, 2017 | |
Notes to Financial Statements | |
Income Tax Disclosure [Text Block] | NOTE 6– The provision for income taxes consists of an amount for taxes currently payable and a provision for tax consequences deferred to future periods. Deferred income taxes are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. Deferred income tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The Tax Reform Act was enacted December 22, 2017. January 1, 2018 34% 21%. There was no 100% no 100% During September 2013, 382 may September 2013, not At December 31, 2016, $30.9 2017, 382 2022 $13.0 December 31, 2016, 2022 2037 December 31, 2016, $10.7 $0.2 At December 31, 2017, $34.5 2018, 382 2022 $12.2 December 31, 2017, 2022 2037 December 31, 2017, $7.4 $0.2 The valuation allowance has been recorded due to the uncertainty of realization of the benefits associated with the net operating losses. Future events and changes in circumstances could cause this valuation allowance to change. The components of deferred income taxes at December 31, 2017 December 31, 2016 December 31, 2017 December 31, 2016 Deferred Tax Asset: Net Operating Loss $ 7,393,100 $ 10,755,000 Other 215,843 189,000 Total Deferred Tax Asset 7,608,943 10,944,000 Less Valuation Allowance 7,608,943 10,944,000 Net Deferred Income Taxes $ — $ — |
Note 7 - Rent Obligation
Note 7 - Rent Obligation | 12 Months Ended |
Dec. 31, 2017 | |
Notes to Financial Statements | |
Leases of Lessee Disclosure [Text Block] | NOTE 7 Our corporate offices are located at 2915 900, 55121. November 22, 2017, second January 28, 2013. three February 1, 2018 January 31, 2021. 5,773 2,945 2,828 January 31, 2021. $66,122 $66,239 2017 2016, The Company’s rent obligation for the next four 2018 $ 39,000 2019 $ 40,000 2020 $ 42,000 2021 $ 3,000 |
Note 8 - Related Party Transact
Note 8 - Related Party Transactions | 6 Months Ended | 12 Months Ended |
Jun. 30, 2018 | Dec. 31, 2017 | |
Notes to Financial Statements | ||
Related Party Transactions Disclosure [Text Block] | NOTE 7 The Audit Committee has the responsibility to review and approve all transactions to which a related party and the Company may In April 2018, one six $12,000 240,000 2012 | NOTE 8 The Audit Committee has the responsibility to review and approve all transactions to which a related party and the Company may One of the Company’s directors, Richard L. Gabriel, is the Chief Operating Officer and serves as a director of GLG Pharma (“GLG”). Another Company director, Tim Krochuk, is on the supervisory board for GLG. In September 20, 2016, 400,000 four 100,000 November 1, 2016, November 2, 2016, April 2017, |
Note 9 - Retirement Savings Pla
Note 9 - Retirement Savings Plans | 12 Months Ended |
Dec. 31, 2017 | |
Notes to Financial Statements | |
Pension and Other Postretirement Benefits Disclosure [Text Block] | NOTE 9 We have a pre-tax salary reduction/profit-sharing plan under the provisions of Section 401 2016, 2017, 100% 4.0% $29,952 $33,143 2017 2016. no 2017 2016. |
Note 10 - Supplemental Cash Flo
Note 10 - Supplemental Cash Flow Data | 12 Months Ended |
Dec. 31, 2017 | |
Notes to Financial Statements | |
Cash Flow, Supplemental Disclosures [Text Block] | NOTE 10 Cash payments for interest were $0 $3 December 31, 2017 December 31, 2016, |
Note 11 - Subsequent Events
Note 11 - Subsequent Events | 6 Months Ended | 12 Months Ended |
Jun. 30, 2018 | Dec. 31, 2017 | |
Notes to Financial Statements | ||
Subsequent Events [Text Block] | NOTE 8 On July 13, 2017, 2012 2016 July 28, 2016, not December 2017, July 2018, no | NOTE 11 In January 2018, 2,900,000 $0.95 one 0.3 one $1.00 $2,755,000, 45 290,000 87,000 $0.001 February 21, 2018, 215,247 $0.01, $0.9497 $188,066 $16,354 8% On January 11, 2018, 2,500,000 1,100,000 $500,000 5% 25% $500,000 12 $8,000,000. 20% may On February 22, 2018, $667,512.50. $500,000 833,333 2,500,000 10,000,000 3,333,333 25% 13,333,333 $167,512.50 On February 27, 2018, may 25% 48Hour |
Note 12 - Investment Securities
Note 12 - Investment Securities and Other Comprehensive Income (Loss) | 12 Months Ended |
Dec. 31, 2017 | |
Notes to Financial Statements | |
Investment Securities and Other Comprehensive Income/(Loss) [Text Block] | NOTE 12 The cost and fair values of investment securities available-for-sale at December 31, 2016 December 31, 2016 Note Description Cost Gross Unrealized Gross Fair Value Mutual Funds $ 282,828 $ 1,501 $ - $ 284,329 |
Significant Accounting Policies
Significant Accounting Policies (Policies) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2018 | Dec. 31, 2017 | |
Accounting Policies [Abstract] | ||
Basis of Accounting, Policy [Policy Text Block] | Nature of Operations and Continuance of Operations Precision Therapeutics Inc., (the “Company”) was originally incorporated on April 23, 2002 August 6, 2013, December 16, 2013, August 31, 2015, February 1, 2018, February 1, 2018. February 2, 2018. As of June 30, 2018, 12,089,446 $.01 two 1 2 April 2009, 510 The Company acquired 25% first 2018, April 2018 June 2018, 4. 149,000 first The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company has incurred recurring losses from operations and has an accumulated deficit of $58,898,476. not $1,004,269 June 30, 2018 one not Since inception to June 30, 2018, $35,840,380 1 $2,055,000 2 $13,555,003 3 $1,739,770 4 $3,937,500 $358,312 5 $1,300,000 6 $2,755,000 7 $5,685,000 | Nature of Operations and Continuance of Operations The Company was originally incorporated on April 23, 2002 August 6, 2013, December 16, 2013, August 31, 2015, February 1, 2018, February 1, 2018. February 2, 2018. As of December 31, 2017, 6,943,283 $.01 1 25 October 27, 2016. April 2009, 510 The accompanying financial statements have been prepared assuming the Company will continue as a going concern. The Company has suffered recurring losses from operations and had a stockholders’ deficit until August 31, 2015 not Since inception to December 31, 2017, $29,065,934 $2,055,000 $13,555,003 $1,739,770 $3,937,500 $358,312 $1,300,000 $5,685,000 |
Interim Financial Statements, Policy [Policy Text Block] | Interim Financial Statements The Company has prepared the unaudited interim financial statements and related unaudited financial information in the footnotes in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”) for interim financial statements. These interim financial statements reflect all adjustments consisting of normal recurring accruals, which in the opinion of management, are necessary to present fairly the Company’s position, the results of its operations and its cash flows for the interim periods. These interim financial statements reflect all intercompany eliminations. These interim financial statements should be read in conjunction with the annual financial statements and the notes thereto contained in the Form 10 April 2, 2018. may not | |
New Accounting Pronouncements, Policy [Policy Text Block] | Recent Accounting Developments In May 2014, No. 2014 09, Revenue from Contracts with Customers (Topic 606 January 1, 2018 not December 31, 2017. January 1, 2018 606, not 605, Revenue Recognition not December 31, 2017, not January 1, 2018, no 3 In January 2016, No. 2016 01, Financial Instruments-Overall (Subtopic 825 10 2016 01” not not January 1, 2018. June 30, 2018, no In February 2016, No. 2016 02, Leases (Topic 842 2016 02” December 15, 2018. | Recent Accounting Developments In May 2014, 2014 09, Revenue from Contracts with Customers 606, 2015 14, “Revenue from Contracts with Customers: Deferral of the Effective Date,” 2016 08, “Revenue from Contracts with Customers: Principal versus Agent Considerations (Reporting Revenue Gross versus Net),” 2016 10, “Revenue from Contracts with Customers: Identifying Performance Obligations and Licensing,” 2016 12, “Revenue from Contracts with Customers: Narrow-Scope Improvements and Practical Expedients.” 2017 13. December 15, 2017, not two 606. January 1, 2018 January 1, 2018, not In August 2014, 2014 15, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern December 15, 2016, first 2017. In July 2015, No. 2015 11 , Inventory (Topic 330 December 15, 2016, first 2017. In November 2015, 2015 17, “Income Taxes (Topic 740 December 15, 2016 first 2017. In January 2016, No. 2016 01, Financial Instruments-Overall (Subtopic 825 10 2016 01” not not December 15, 2017, not In February 2016, No. 2016 02, (Topic 842” 2016 02” December 15, 2018. In March 2016, No. 2016 09, “Compensation (Topic 718 “ASU2016 09” 2016 09 December 15, 2016. first 2017. In August 2016, No. 2016 15, Statement of Cash Flows (Topic 230 December 15, 2017, not 2016 15 On December 22, 2017, 2017 34% 21%. We reviewed all other significant newly issued accounting pronouncements and determined they are either not no |
Goodwill and Intangible Assets, Intangible Assets, Indefinite-Lived, Policy [Policy Text Block] | Valuation of Intangible Assets The Company reviews identifiable intangible assets for impairment annually, or whenever events or changes in circumstances indicate the carrying amount may not may not not | Valuation of Intangible Assets We review identifiable intangible assets for impairment in accordance with ASC 350 may not may not not |
Use of Estimates, Policy [Policy Text Block] | Accounting Policies and Estimates The presentation of financial statements is in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. | Accounting Policies and Estimate The presentation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. |
Cash and Cash Equivalents, Policy [Policy Text Block] | Cash Equivalents The Company considers all highly liquid debt instruments with a maturity of three | Cash Equivalents The Company considers all highly liquid debt instruments with a maturity of three |
Certificates of Deposit Policy [Policy Text Block] | Certificates of Deposit Short-term interest-bearing investments are those with maturities of less than one three one | Certificates of Deposit Short-term interest-bearing investments are those with maturities of less than one three one |
Fair Value Measurement, Policy [Policy Text Block] | Fair Value Measurements Under generally accepted accounting principles as outlined in the FASB’s Accounting Standards Codification (ASC) 820, 820 three Level 1 Level 2 Level 3 no The Company uses observable market data, when available, in making fair value measurements. Fair value measurements are classified according to the lowest level input that is significant to the valuation. The fair value of the Company’s investment securities was determined based on Level 1 | Fair Value Measurements Under generally accepted accounting principles as outlined in the Financial Accounting Standards Board’s Accounting Standards Certification 820, 820 three Level 1 Level 2 Level 3 no The Company uses observable market data, when available, in making fair value measurements. Fair value measurements are classified according to the lowest level input that is significant to the valuation. The fair value of the Company’s investment securities were determined based on Level 1 |
Inventory, Policy [Policy Text Block] | Inventories Inventories are stated at the lower of cost and net realizable value, with cost determined on a first first June 30, 2018 December 31, 2017 Finished goods $ 31,782 $ 62,932 Raw materials 168,735 141,028 Work-In-Process 44,143 61,085 Total $ 244,660 $ 265,045 | Inventories Inventories are stated at the lower of cost or market, with cost determined on a first first December 31, 2017 December 31, 2016 Finished goods $ 62,932 $ 38,201 Raw materials 141,028 165,812 Work-In-Process 61,085 68,195 Total $ 265,045 $ 272,208 |
Property, Plant and Equipment, Policy [Policy Text Block] | Property and Equipment Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the respective assets. Estimated useful asset life by classification is as follows: Years Computers and office equipment 3 - 7 Leasehold improvements 3 Manufacturing tooling 3 - 7 Demo equipment 3 The Company’s fixed assets consist of the following: June 30, 2018 December 31, 2017 Computers and office equipment $ 201,123 $ 183,528 Leasehold improvements 122,188 25,635 Manufacturing tooling 108,955 108,955 Demo equipment 59,210 43,368 Total 491,476 361,486 Less: Accumulated depreciation 307,091 273,770 Total Fixed Assets, Net $ 184,385 $ 87,716 Upon retirement or sale, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred. Depreciation expense was $18,825 $33,321 three six June 30, 2018 $14,519 $30,204 three six June 30, 2017. | Property and Equipment Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation of property and equipment is computed using the straight-line method over the estimated useful lives of the respective assets. Estimated useful asset life by classification is as follows: Years Computers and office equipment 3 - 7 Leasehold improvements 5 Manufacturing Tooling 3 - 7 Demo Equipment 3 The Company’s investment in Fixed Assets consists of the following: December 31, 2017 December 31, 2016 Computers and office equipment $ 183,528 $ 164,318 Leasehold Improvements 25,635 25,635 Manufacturing Tooling 108,955 103,204 Demo Equipment 43,368 23,236 Total 361,486 316,393 Less: Accumulated Depreciation 273,770 214,897 Total Fixed Assets, Net $ 87,716 $ 101,496 Upon retirement or sale, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is reflected in operations. Maintenance and repairs are charged to operations as incurred. Depreciation expense was $58,872 2017 $73,249 2016. |
Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block] | Intangible Assets Intangible assets consist of trademarks and patent costs. Amortization expense was $4,070 $7,741 three six June 30, 2018 $2,902 $5,790 three six June 30, 2017. | Intangible Assets Intangible assets consist of trademarks and patent costs. Amortization expense was $12,689 2017 $9,107 2016. |
Income Tax, Policy [Policy Text Block] | Income Taxes The Company accounts for income taxes in accordance with ASC 740 Income Taxes 740” 740, There is no 100% The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not no Tax years subsequent to 2014 | Income Taxes The Company accounts for income taxes in accordance with ASC 740 Income Taxes (“ASC 740” 740, The Company reviews income tax positions expected to be taken in income tax returns to determine if there are any income tax uncertainties. The Company recognizes tax benefits from uncertain tax positions only if it is more likely than not no Tax years subsequent to 2014 |
Offering Costs [Policy Text Block] | Offering Costs Costs incurred which are direct and incremental to an offering of the Company’s securities are deferred and charged against the proceeds of the offering, unless such costs are deemed to be insignificant in which case they are expensed as incurred. | |
Intangible Assets, Finite-Lived, Policy [Policy Text Block] | Patents and Intellectual Property On January 25, 2014, No. PCT/US2014/013081 61756763 one January 25, 2013. 148 The Company’s PCT patent application is for the new model of the surgical fluid waste management system. The Company obtained a favorable International Search Report from the PCT searching authority indicating that the claims in its PCT application are patentable (i.e., novel and non-obvious) over the cited prior art. A feature claimed in the PCT application is the ability to maintain continuous suction to the surgical field while measuring, recording and evacuating fluid to the facility’s sewer drainage system. This provides for continuous operation of the STREAMWAY System unit in suctioning waste fluids, which means that suction is not The Company holds the following granted patents in the United States and a pending application in the United States on its earlier models: US7469727, US8123731 No. US20090216205 August 8, 2023. In July 2015, The United States Patent Office has assigned application #14/763,459 As of November 22, 2017, #14743665.3 1651 | Patents and Intellectual Property On January 25th, 2014, No. PCT/US2014/013081 61756763 one January 25th, 2013. 148 Our PCT patent application is for the new model of the surgical fluid waste management system. We obtained a favorable International Search Report from the PCT searching authority indicating that the claims in our PCT application are patentable (i.e., novel and non-obvious) over the cited prior art. A feature claimed in the PCT application is the ability to maintain continuous suction to the surgical field while measuring, recording and evacuating fluid to the facilities sewer drainage system. This provides for continuous operation of the STREAMWAY System unit in suctioning waste fluids, which means that suction is not The Company holds the following granted patents in the United States and a pending application in the United States on its earlier models: US7469727, US8123731 No. US20090216205 August 8, 2023. In July 2015, The United States Patent Office has assigned application #14/763,459 As of November 22, 2017, #14743665.3 1651, |
Concentration Risk, Credit Risk, Policy [Policy Text Block] | Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high credit quality financial institutions and, by policy, generally limits the amount of credit exposure to any one $794,125 | Credit Risk Financial instruments which potentially subject the Company to concentrations of credit risk consist principally of cash. The Company places its cash with high credit quality financial institutions and, by policy, generally limits the amount of credit exposure to any one $563,000 |
Segment Reporting, Policy [Policy Text Block] | Segments The Company operates in two three six June 30, 2018 2017 $3,178 $0 three 2018 2017, $5,866 $26,662 first six 2018 2017, | Segments The Company operates in two 2017 2016 $26,662 2017. |
Risks and Uncertainties Policy [Policy Text Block] | Risks and Uncertainties The Company is subject to risks common to companies in the medical device industry, including, but not | Risks and Uncertainties The Company is subject to risks common to companies in the medical device industry, including, but not |
Presentation of Taxes Collected From Customers, Policy [Policy Text Block] | Presentation of Taxes Collected from Customers Sales taxes are imposed on the Company’s sales to nonexempt customers. The Company collects the taxes from customers and remits the entire amounts to the governmental authorities. The Company’s accounting policy is to exclude the taxes collected and remitted from revenues and expenses. | |
Shipping and Handling Cost, Policy [Policy Text Block] | Shipping and Handling Shipping and handling charges billed to customers are recorded as revenue. Shipping and handling costs are recorded within cost of goods sold on the statement of operations. | |
Advertising Costs, Policy [Policy Text Block] | Advertising Advertising costs are expensed as incurred. Advertising expenses were $37,060 2017, $71,212 2016. | |
Research and Development Expense, Policy [Policy Text Block] | Research and Development Research and development costs are charged to operations as incurred. Research and development costs were approximately $289,000 $406,000 2017 2016, | |
Revenue Recognition, Policy [Policy Text Block] | Revenue Recognition The Company recognizes revenue in accordance with the SEC’s Staff Accounting Bulletin Revenue Recognition and ASC 606 We recognize revenue when the following criteria are met: persuasive evidence of an arrangement exists – we receive both a signed purchase order and contract of terms and conditions confirming the sale from the customer; delivery has occurred – the goods are shipped from our warehouse and delivered and accepted by the customer; the selling price is fixed or determinable – confirmed on the customer purchase order and then invoiced immediately upon shipment of the goods; and collectability is reasonably assured – our customers are long standing hospitals, ambulatory surgical centers and others that pass credit checks. The terms of our agreements with our customers are specified in written agreements. These written agreements, the purchase order and the matching invoice, constitute the persuasive evidence of the arrangements with our customers that are a precondition to the recognition of revenue. We undertake an evaluation of the creditworthiness of both new and, on a periodic basis, existing customers. Based on these reviews we determine whether collection of our prospective revenue is probable. We have adopted the provisions of Accounting Standards Update, or “ASU” 2014 09, 606 606 January 1, 2018 While we continue to assess all potential impacts of the standard, it is currently anticipated that the standard will not | |
Marketable Securities, Policy [Policy Text Block] | Investment Securities Readily marketable investments in debt and equity services are classified as available-for-sale and are reported at fair value with unrealized gains losses recorded in other comprehensive income. Unrealized gains are charged to earnings when an incline in fair value above the cost basis is determined to be other-than-temporary. Realized gains and losses on dispositions are based on the net proceeds and the adjusted book value of the securities sold, using the specific identification method. | |
Receivables, Policy [Policy Text Block] | Receivables Receivables are reported at the amount the Company expects to collect on balances outstanding. The Company provides for probable uncollectible amounts through charges to earnings and credits to the valuation based on management’s assessment of the current status of individual accounts, changes to the valuation allowance have not | |
Standard Product Warranty, Policy [Policy Text Block] | Product Warranty Costs In 2017 2016, $6,209 $34,665 |
Note 1 - Summary of Significa_3
Note 1 - Summary of Significant Accounting Policies (Tables) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2018 | Dec. 31, 2017 | |
Notes Tables | ||
Schedule of Inventory, Current [Table Text Block] | June 30, 2018 December 31, 2017 Finished goods $ 31,782 $ 62,932 Raw materials 168,735 141,028 Work-In-Process 44,143 61,085 Total $ 244,660 $ 265,045 | December 31, 2017 December 31, 2016 Finished goods $ 62,932 $ 38,201 Raw materials 141,028 165,812 Work-In-Process 61,085 68,195 Total $ 265,045 $ 272,208 |
Property Plant and Equipment Useful Life [Table Text Block] | Years Computers and office equipment 3 - 7 Leasehold improvements 3 Manufacturing tooling 3 - 7 Demo equipment 3 | Years Computers and office equipment 3 - 7 Leasehold improvements 5 Manufacturing Tooling 3 - 7 Demo Equipment 3 |
Property, Plant and Equipment [Table Text Block] | June 30, 2018 December 31, 2017 Computers and office equipment $ 201,123 $ 183,528 Leasehold improvements 122,188 25,635 Manufacturing tooling 108,955 108,955 Demo equipment 59,210 43,368 Total 491,476 361,486 Less: Accumulated depreciation 307,091 273,770 Total Fixed Assets, Net $ 184,385 $ 87,716 | December 31, 2017 December 31, 2016 Computers and office equipment $ 183,528 $ 164,318 Leasehold Improvements 25,635 25,635 Manufacturing Tooling 108,955 103,204 Demo Equipment 43,368 23,236 Total 361,486 316,393 Less: Accumulated Depreciation 273,770 214,897 Total Fixed Assets, Net $ 87,716 $ 101,496 |
Note 2 - Equity Method Invest_2
Note 2 - Equity Method Investment (Tables) | 6 Months Ended |
Jun. 30, 2018 | |
Notes Tables | |
Equity Method Investments [Table Text Block] | Helomics Holdings Corporation For the Six Months Ended June 30, 2018 Revenue $ 215,055 Gross margin $ (71,625 ) Net loss from continuing operations $ (4,529,380 ) Net loss to investee $ (4,331,380 )1 |
Note 4 - Stockholders' Equity_2
Note 4 - Stockholders' Equity, Stock Options and Warrants (Tables) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2018 | Dec. 31, 2017 | |
Notes Tables | ||
Share-based Compensation, Activity [Table Text Block] | Stock Options Warrants Number of Average Number of Average Exercise Outstanding at December 31, 2016 165,643 $ 11.22 871,101 $ 52.22 Issued 2,612,070 1.45 1,082,946 1.49 Expired (12,730 ) 10.39 (2,790 ) 281.46 Exercised - - - - Outstanding at December 31, 2017 2,764,983 $ 2.00 1,951,257 $ 23.74 Issued 482,402 1.11 957,000 1.00 Expired (127,130 ) 2.22 (10,706 ) 199.55 Exercised - - (341,169 ) 1.00 Outstanding at June 30, 2018 3,120,255 $ 1.85 2,556,382 $ 5.97 | Stock Options Warrants Number of Average Number of Average Outstanding at December 31, 2015 31,350 $ 133.23 323,099 $ 128.40 Issued 157,982 3.14 1,487,881 0.71 Expired (22,377 ) 122.13 - - Exercised (1,312 ) 65.75 (939,879 ) - Outstanding at December 31, 2016 165,643 $ 11.22 871,101 $ 52.22 Issued 2,612,070 1.45 1,082,946 1.49 Expired (12,730 ) 10.39 (2,790 ) 281.46 Exercised - - - - Outstanding at December 31, 2017 2,764,983 $ 2.00 1,951,257 $ 23.74 |
Schedule of Share-based Compensation Shares Authorized Under Stock Option and Warrant Plans by Exercise Price Range [Table Text Block] | Range of Prices Shares Weighted Remaining Life Options $ 0.91 10,000 9.80 $ 0.965 3,000 9.88 $ 0.97 191,753 9.52 $ 1.01 124,358 9.51 $ 1.10 22,730 9.76 $ 1.13 143,807 10.00 $ 1.35 111,112 9.71 $ 1.454 17,200 9.26 $ 1.47 2,373,226 8.99 $ 2.10 14,286 8.76 $ 2.25 293 8.16 $ 2.42 20,640 8.14 $ 2.80 57,145 8.51 $ 3.75 3,998 8.01 $ 4.125 3,636 8.26 $ 4.1975 7,147 8.22 $ 4.25 3,529 7.76 $ 5.125 3,902 8.19 $ 65.75 190 7.32 $ 73.50 1,157 7.51 $ 77.50 2,323 7.01 $ 80.25 187 7.26 $ 86.25 232 6.76 $ 131.25 81 4.19 $ 148.125 928 4.72 $ 150.00 1,760 4.13 $ 162.50 123 6.51 $ 206.25 121 6.26 $ 248.4375 121 5.04 $ 262.50 130 5.04 $ 281.25 529 4.55 $ 318.75 3 4.86 $ 346.875 72 5.76 $ 431.25 306 5.69 $ 506.25 188 5.51 $ 596.25 42 5.25 3,120,255 Warrants $ 1.00 1,372,828 4.36 $ 1.07 697,946 4.35 $ 2.25 385,000 3.57 $ 123.75 94,084 2.17 $ 243.75 2,529 1.10 $ 309.375 2,850 1.11 $ 309.50 222 1.36 $ 506.25 59 0.63 $ 609.375 862 0.60 2,556,382 | Range of Exercise Prices Shares Weighted Options: $ 1.01 124,358 10.00 $ 1.454 17,200 9.75 $ 1.47 2,456,226 9.48 $ 2.10 14,286 9.25 $ 2.25 293 8.65 $ 2.42 24,768 8.38 $ 2.80 57,145 9.01 $ 3.75 44,000 8.50 $ 4.125 3,636 8.75 $ 4.1975 7,147 8.72 $ 4.25 3,529 8.25 $ 5.125 3,902 8.69 $ 65.75 190 7.40 $ 73.50 1,157 8.01 $ 77.50 2,323 7.50 $ 80.25 187 7.75 $ 86.25 232 7.25 $ 131.25 81 4.69 $ 148.125 928 5.21 $ 150.00 1,760 4.63 $ 162.50 123 7.01 $ 206.25 121 6.75 $ 248.4375 121 5.54 $ 262.50 130 5.54 $ 281.25 529 5.04 $ 318.75 3 5.35 $ 346.875 72 6.25 $ 431.25 306 6.19 $ 506.25 188 6.00 $ 596.25 42 5.75 Total 2,764,983 Warrants $ 1.07 697,946 4.85 $ 2.25 385,000 4.06 $ 4.46 756,999 3.92 $ 93.75 2,255 0.19 $ 123.75 94,084 2.67 $ 150.00 4,114 0.20 $ 225.00 107 0.07 $ 243.75 2,529 1.59 $ 281.25 3,107 0.14 $ 309.375 2,850 1.61 $ 309.50 222 1.85 $ 337.50 178 0.46 $ 371.25 944 0.41 $ 506.25 59 1.12 $ 609.375 862 1.09 Total 1,951,257 |
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block] | Stock Options: Year Shares Price 2011 173 $281.25 2012 1,841 131.25 – 150.00 2013 1,553 148.13 – 596.25 2014 836 162.50 – 431.25 2015 4,088 65.75 – 86.25 2016 100,292 2.25 – 5.13 2017 2,529,070 1.01 - 2.10 2018 482,402 0.91 - 1.35 Total 3,120,255 $0.91 – 596.25 Warrants: Year Shares Price 2014 6,455 $243.75 – $609.38 2015 94,151 0.00 – 243.75 2016 504,666 1.00 2017 1,082,946 1.07 - 2.25 2018 868,164 1.00 Total 2,556,382 $0.00 – $609.38 | Stock Options: Year Shares Price 2011 173 281.25 2012 1,841 131.25 – 150.00 2013 1,553 148.13 – 596.25 2014 835 162.50 – 431.25 2015 4,088 65.75 – 86.25 2016 144,423 2.25 – 5.13 2017 2,612,070 1.01 – 2.10 Total 2,764,983 $ 1.01 – 596.25 Warrants: Year Shares Price 2013 10,705 93.75 – 371.25 2014 6,455 243.75 – 609.38 2015 94,152 0.00 – 243.75 2016 756,999 4.46 2017 1,082,946 1.07 – 2.25 Total 1,951,257 $ 0.00 – 609.38 |
Note 6 - Loss Per Share (Tables
Note 6 - Loss Per Share (Tables) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2018 | Dec. 31, 2017 | |
Notes Tables | ||
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] | Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Numerator Net loss available in basic and diluted calculation $ (2,373,410 ) $ (2,543,670 ) $ (4,133,432 ) $ (3,885,517 ) Comprehensive loss (2,373,410 ) (2,543,670 ) (4,133,432 ) (3,885,517 ) Denominator: Weighted average common shares outstanding-basic 11,878,490 6,167,689 11,632,221 6,308,554 Effect of diluted stock options, warrants and preferred stock (1) - - - - Weighted average common shares outstanding-basic 11,878,490 6,167,689 11,632,221 6,308,554 Loss per common share-basic and diluted $ (0.20 ) $ (0.41 ) $ (0.36 ) $ (0.62 ) | Year Ended December 31, 2017 2016 Numerator: Net loss available in basic and diluted calculation $ (7,746,593 ) $ (6,526,014 ) Other comprehensive income: Unrealized gain (loss) from marketable securities - 1,501 Comprehensive (loss) (7,746,593 ) (6,524,513 ) Denominator: Weighted average common shares outstanding-basic 6,362,989 2,823,345 Effect of dilutive stock options, warrants and preferred stock (1) - - Weighted average common shares outstanding-basic 6,362,989 2,823,345 Loss per common share-basic and diluted $ (1.22 ) $ (2.31 ) |
Note 1 - Summary of Significa_4
Note 1 - Summary of Significant Accounting Policies -2 (Tables) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2018 | Dec. 31, 2017 | |
Notes Tables | ||
Schedule of Inventory, Current [Table Text Block] | June 30, 2018 December 31, 2017 Finished goods $ 31,782 $ 62,932 Raw materials 168,735 141,028 Work-In-Process 44,143 61,085 Total $ 244,660 $ 265,045 | December 31, 2017 December 31, 2016 Finished goods $ 62,932 $ 38,201 Raw materials 141,028 165,812 Work-In-Process 61,085 68,195 Total $ 265,045 $ 272,208 |
Property Plant and Equipment Useful Life [Table Text Block] | Years Computers and office equipment 3 - 7 Leasehold improvements 3 Manufacturing tooling 3 - 7 Demo equipment 3 | Years Computers and office equipment 3 - 7 Leasehold improvements 5 Manufacturing Tooling 3 - 7 Demo Equipment 3 |
Property, Plant and Equipment [Table Text Block] | June 30, 2018 December 31, 2017 Computers and office equipment $ 201,123 $ 183,528 Leasehold improvements 122,188 25,635 Manufacturing tooling 108,955 108,955 Demo equipment 59,210 43,368 Total 491,476 361,486 Less: Accumulated depreciation 307,091 273,770 Total Fixed Assets, Net $ 184,385 $ 87,716 | December 31, 2017 December 31, 2016 Computers and office equipment $ 183,528 $ 164,318 Leasehold Improvements 25,635 25,635 Manufacturing Tooling 108,955 103,204 Demo Equipment 43,368 23,236 Total 361,486 316,393 Less: Accumulated Depreciation 273,770 214,897 Total Fixed Assets, Net $ 87,716 $ 101,496 |
Note 3 - Stockholders' Equity_2
Note 3 - Stockholders' Equity (Deficit), Stock Options and Warrants (Tables) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2018 | Dec. 31, 2017 | |
Notes Tables | ||
Share-based Compensation, Activity [Table Text Block] | Stock Options Warrants Number of Average Number of Average Exercise Outstanding at December 31, 2016 165,643 $ 11.22 871,101 $ 52.22 Issued 2,612,070 1.45 1,082,946 1.49 Expired (12,730 ) 10.39 (2,790 ) 281.46 Exercised - - - - Outstanding at December 31, 2017 2,764,983 $ 2.00 1,951,257 $ 23.74 Issued 482,402 1.11 957,000 1.00 Expired (127,130 ) 2.22 (10,706 ) 199.55 Exercised - - (341,169 ) 1.00 Outstanding at June 30, 2018 3,120,255 $ 1.85 2,556,382 $ 5.97 | Stock Options Warrants Number of Average Number of Average Outstanding at December 31, 2015 31,350 $ 133.23 323,099 $ 128.40 Issued 157,982 3.14 1,487,881 0.71 Expired (22,377 ) 122.13 - - Exercised (1,312 ) 65.75 (939,879 ) - Outstanding at December 31, 2016 165,643 $ 11.22 871,101 $ 52.22 Issued 2,612,070 1.45 1,082,946 1.49 Expired (12,730 ) 10.39 (2,790 ) 281.46 Exercised - - - - Outstanding at December 31, 2017 2,764,983 $ 2.00 1,951,257 $ 23.74 |
Schedule of Share-based Compensation Shares Authorized Under Stock Option and Warrant Plans by Exercise Price Range [Table Text Block] | Range of Prices Shares Weighted Remaining Life Options $ 0.91 10,000 9.80 $ 0.965 3,000 9.88 $ 0.97 191,753 9.52 $ 1.01 124,358 9.51 $ 1.10 22,730 9.76 $ 1.13 143,807 10.00 $ 1.35 111,112 9.71 $ 1.454 17,200 9.26 $ 1.47 2,373,226 8.99 $ 2.10 14,286 8.76 $ 2.25 293 8.16 $ 2.42 20,640 8.14 $ 2.80 57,145 8.51 $ 3.75 3,998 8.01 $ 4.125 3,636 8.26 $ 4.1975 7,147 8.22 $ 4.25 3,529 7.76 $ 5.125 3,902 8.19 $ 65.75 190 7.32 $ 73.50 1,157 7.51 $ 77.50 2,323 7.01 $ 80.25 187 7.26 $ 86.25 232 6.76 $ 131.25 81 4.19 $ 148.125 928 4.72 $ 150.00 1,760 4.13 $ 162.50 123 6.51 $ 206.25 121 6.26 $ 248.4375 121 5.04 $ 262.50 130 5.04 $ 281.25 529 4.55 $ 318.75 3 4.86 $ 346.875 72 5.76 $ 431.25 306 5.69 $ 506.25 188 5.51 $ 596.25 42 5.25 3,120,255 Warrants $ 1.00 1,372,828 4.36 $ 1.07 697,946 4.35 $ 2.25 385,000 3.57 $ 123.75 94,084 2.17 $ 243.75 2,529 1.10 $ 309.375 2,850 1.11 $ 309.50 222 1.36 $ 506.25 59 0.63 $ 609.375 862 0.60 2,556,382 | Range of Exercise Prices Shares Weighted Options: $ 1.01 124,358 10.00 $ 1.454 17,200 9.75 $ 1.47 2,456,226 9.48 $ 2.10 14,286 9.25 $ 2.25 293 8.65 $ 2.42 24,768 8.38 $ 2.80 57,145 9.01 $ 3.75 44,000 8.50 $ 4.125 3,636 8.75 $ 4.1975 7,147 8.72 $ 4.25 3,529 8.25 $ 5.125 3,902 8.69 $ 65.75 190 7.40 $ 73.50 1,157 8.01 $ 77.50 2,323 7.50 $ 80.25 187 7.75 $ 86.25 232 7.25 $ 131.25 81 4.69 $ 148.125 928 5.21 $ 150.00 1,760 4.63 $ 162.50 123 7.01 $ 206.25 121 6.75 $ 248.4375 121 5.54 $ 262.50 130 5.54 $ 281.25 529 5.04 $ 318.75 3 5.35 $ 346.875 72 6.25 $ 431.25 306 6.19 $ 506.25 188 6.00 $ 596.25 42 5.75 Total 2,764,983 Warrants $ 1.07 697,946 4.85 $ 2.25 385,000 4.06 $ 4.46 756,999 3.92 $ 93.75 2,255 0.19 $ 123.75 94,084 2.67 $ 150.00 4,114 0.20 $ 225.00 107 0.07 $ 243.75 2,529 1.59 $ 281.25 3,107 0.14 $ 309.375 2,850 1.61 $ 309.50 222 1.85 $ 337.50 178 0.46 $ 371.25 944 0.41 $ 506.25 59 1.12 $ 609.375 862 1.09 Total 1,951,257 |
Disclosure of Share-based Compensation Arrangements by Share-based Payment Award [Table Text Block] | Stock Options: Year Shares Price 2011 173 $281.25 2012 1,841 131.25 – 150.00 2013 1,553 148.13 – 596.25 2014 836 162.50 – 431.25 2015 4,088 65.75 – 86.25 2016 100,292 2.25 – 5.13 2017 2,529,070 1.01 - 2.10 2018 482,402 0.91 - 1.35 Total 3,120,255 $0.91 – 596.25 Warrants: Year Shares Price 2014 6,455 $243.75 – $609.38 2015 94,151 0.00 – 243.75 2016 504,666 1.00 2017 1,082,946 1.07 - 2.25 2018 868,164 1.00 Total 2,556,382 $0.00 – $609.38 | Stock Options: Year Shares Price 2011 173 281.25 2012 1,841 131.25 – 150.00 2013 1,553 148.13 – 596.25 2014 835 162.50 – 431.25 2015 4,088 65.75 – 86.25 2016 144,423 2.25 – 5.13 2017 2,612,070 1.01 – 2.10 Total 2,764,983 $ 1.01 – 596.25 Warrants: Year Shares Price 2013 10,705 93.75 – 371.25 2014 6,455 243.75 – 609.38 2015 94,152 0.00 – 243.75 2016 756,999 4.46 2017 1,082,946 1.07 – 2.25 Total 1,951,257 $ 0.00 – 609.38 |
Note 5 - Loss Per Share (Tables
Note 5 - Loss Per Share (Tables) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2018 | Dec. 31, 2017 | |
Notes Tables | ||
Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] | Three Months Ended June 30, Six Months Ended June 30, 2018 2017 2018 2017 Numerator Net loss available in basic and diluted calculation $ (2,373,410 ) $ (2,543,670 ) $ (4,133,432 ) $ (3,885,517 ) Comprehensive loss (2,373,410 ) (2,543,670 ) (4,133,432 ) (3,885,517 ) Denominator: Weighted average common shares outstanding-basic 11,878,490 6,167,689 11,632,221 6,308,554 Effect of diluted stock options, warrants and preferred stock (1) - - - - Weighted average common shares outstanding-basic 11,878,490 6,167,689 11,632,221 6,308,554 Loss per common share-basic and diluted $ (0.20 ) $ (0.41 ) $ (0.36 ) $ (0.62 ) | Year Ended December 31, 2017 2016 Numerator: Net loss available in basic and diluted calculation $ (7,746,593 ) $ (6,526,014 ) Other comprehensive income: Unrealized gain (loss) from marketable securities - 1,501 Comprehensive (loss) (7,746,593 ) (6,524,513 ) Denominator: Weighted average common shares outstanding-basic 6,362,989 2,823,345 Effect of dilutive stock options, warrants and preferred stock (1) - - Weighted average common shares outstanding-basic 6,362,989 2,823,345 Loss per common share-basic and diluted $ (1.22 ) $ (2.31 ) |
Note 6 - Income Taxes (Tables)
Note 6 - Income Taxes (Tables) | 12 Months Ended |
Dec. 31, 2017 | |
Notes Tables | |
Schedule of Deferred Tax Assets and Liabilities [Table Text Block] | December 31, 2017 December 31, 2016 Deferred Tax Asset: Net Operating Loss $ 7,393,100 $ 10,755,000 Other 215,843 189,000 Total Deferred Tax Asset 7,608,943 10,944,000 Less Valuation Allowance 7,608,943 10,944,000 Net Deferred Income Taxes $ — $ — |
Note 7 - Rent Obligation (Table
Note 7 - Rent Obligation (Tables) | 12 Months Ended |
Dec. 31, 2017 | |
Notes Tables | |
Schedule of Rent Expense [Table Text Block] | 2018 $ 39,000 2019 $ 40,000 2020 $ 42,000 2021 $ 3,000 |
Note 12 - Investment Securiti_2
Note 12 - Investment Securities and Other Comprehensive Income (Loss) (Tables) | 6 Months Ended |
Jun. 30, 2018 | |
Notes Tables | |
Schedule of Available-for-sale Securities Reconciliation [Table Text Block] | December 31, 2016 Note Description Cost Gross Unrealized Gross Fair Value Mutual Funds $ 282,828 $ 1,501 $ - $ 284,329 |
Note 1 - Summary of Significa_5
Note 1 - Summary of Significant Accounting Policies (Details Textual) | Feb. 22, 2017USD ($) | Nov. 29, 2016USD ($) | Aug. 31, 2015USD ($) | Jan. 31, 2018USD ($) | Jun. 30, 2018USD ($)$ / sharesshares | Jun. 30, 2017USD ($) | Jun. 30, 2018USD ($)$ / sharesshares | Jun. 30, 2017USD ($) | Dec. 31, 2017USD ($)$ / sharesshares | Dec. 31, 2016USD ($)$ / sharesshares | Dec. 31, 2017USD ($)$ / sharesshares | Jun. 30, 2018USD ($)$ / sharesshares | Mar. 31, 2018 | Feb. 21, 2018$ / shares | Dec. 28, 2017$ / shares | Apr. 19, 2017$ / shares | Oct. 04, 2016$ / shares | Dec. 31, 2015USD ($) |
Common Stock, Shares, Outstanding, Ending Balance | shares | 12,089,446 | 12,089,446 | 6,943,283 | 4,564,428 | 6,943,283 | 12,089,446 | ||||||||||||
Common Stock, Par or Stated Value Per Share | $ / shares | $ 0.01 | $ 0.01 | $ 0.01 | $ 0.01 | $ 0.01 | $ 0.01 | $ 0.01 | $ 0.01 | $ 0.01 | $ 0.01 | ||||||||
Retained Earnings (Accumulated Deficit), Ending Balance | $ (58,898,476) | $ (58,898,476) | $ (54,765,045) | $ (47,018,451) | $ (54,765,045) | $ (58,898,476) | ||||||||||||
Cash and Cash Equivalents, at Carrying Value, Ending Balance | 1,004,269 | $ 1,159,849 | 1,004,269 | $ 1,159,849 | 766,189 | 1,764,090 | 766,189 | 1,004,269 | $ 4,856,232 | |||||||||
Stockholders' Equity, Period Increase (Decrease), Total | 29,065,934 | 35,840,380 | ||||||||||||||||
Stock Issued During Period, Value, New Issues | 2,755,087 | 3,421,188 | 3,421,188 | |||||||||||||||
Proceeds from Issuance or Sale of Equity, Total | $ 13,800,000 | |||||||||||||||||
Debt Instrument, Increase (Decrease), Net, Total | $ 5,685,000 | $ 5,685,000 | ||||||||||||||||
Depreciation, Total | 18,825 | 14,519 | 33,321 | 30,204 | 58,872 | 73,249 | ||||||||||||
Amortization of Intangible Assets, Total | 4,070 | 2,902 | 7,741 | 5,790 | 12,689 | 9,107 | ||||||||||||
Income Tax Expense (Benefit), Total | $ 0 | 0 | $ 0 | 0 | $ 0 | |||||||||||||
Valuation Allowance Percentage | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | |||||||||||||
Unrecognized Tax Benefits, Ending Balance | $ 0 | $ 0 | $ 0 | $ 0 | $ 0 | |||||||||||||
Cash, Uninsured Amount | 794,125 | $ 794,125 | $ 563,000 | 563,000 | 794,125 | |||||||||||||
Number of Operating Segments | 2 | 2 | ||||||||||||||||
Non-US [Member] | ||||||||||||||||||
Revenues, Total | $ 3,178 | $ 0 | $ 5,866 | 26,662 | $ 26,662 | |||||||||||||
Earliest Tax Year [Member] | ||||||||||||||||||
Open Tax Year | 2,014 | |||||||||||||||||
Private Placement [Member] | ||||||||||||||||||
Stock Issued During Period, Value, New Issues | 1,213,819 | |||||||||||||||||
IPO [Member] | ||||||||||||||||||
Stock Issued During Period, Value, New Issues | 13,555,003 | 13,555,003 | ||||||||||||||||
Proceeds from Issuance or Sale of Equity, Total | 3,937,500 | 3,937,500 | ||||||||||||||||
The 2016 Registered Direct Offering [Member] | ||||||||||||||||||
Stock Issued During Period, Value, New Issues | $ 1,625,905 | |||||||||||||||||
Proceeds from Issuance or Sale of Equity, Net of Stock Issuance Costs | $ 1,739,770 | 1,739,770 | 1,739,770 | |||||||||||||||
Proceeds from Issuance or Sale of Equity, Total | $ 1,983,337 | |||||||||||||||||
Over-Allotment Option [Member] | ||||||||||||||||||
Stock Issued During Period, Value, New Issues | $ 204,422 | $ 393,750 | $ 393,750 | |||||||||||||||
Proceeds from Issuance or Sale of Equity, Total | $ 358,312 | 358,312 | 358,312 | |||||||||||||||
The 2018 Public Offering [Member] | ||||||||||||||||||
Proceeds from Issuance or Sale of Equity, Total | $ 2,755,000 | 2,755,000 | ||||||||||||||||
Series A Convertible Preferred Stock [Member] | Private Placement [Member] | ||||||||||||||||||
Stock Issued During Period, Value, New Issues | 2,055,000 | 2,055,000 | ||||||||||||||||
Series C Convertible Preferred Stock [Member] | Private Placement [Member] | ||||||||||||||||||
Stock Issued During Period, Value, New Issues | $ 1,300,000 | $ 1,300,000 | ||||||||||||||||
Helomics Holding Corp. [Member] | ||||||||||||||||||
Share Exchange Agreement, Potential Interest | 25.00% |
Note 1 - Summary of Significa_6
Note 1 - Summary of Significant Accounting Policies - Schedule of Inventory (Details) - USD ($) | Jun. 30, 2018 | Dec. 31, 2017 | Dec. 31, 2016 |
Finished goods | $ 31,782 | $ 62,932 | $ 38,201 |
Raw materials | 168,735 | 141,028 | 165,812 |
Work-In-Process | 44,143 | 61,085 | 68,195 |
Total | $ 244,660 | $ 265,045 | $ 272,208 |
Note 1 - Summary of Significa_7
Note 1 - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment, Useful Life (Details) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2018 | Dec. 31, 2017 | |
Leasehold Improvements [Member] | ||
Property, plant, and equipment, useful life (Year) | 3 years | 5 years |
Demo Equipment [Member] | ||
Property, plant, and equipment, useful life (Year) | 3 years | 3 years |
Minimum [Member] | Office Equipment [Member] | ||
Property, plant, and equipment, useful life (Year) | 3 years | 3 years |
Minimum [Member] | Manufacturing Tooling [Member] | ||
Property, plant, and equipment, useful life (Year) | 3 years | 3 years |
Maximum [Member] | Office Equipment [Member] | ||
Property, plant, and equipment, useful life (Year) | 7 years | 7 years |
Maximum [Member] | Manufacturing Tooling [Member] | ||
Property, plant, and equipment, useful life (Year) | 7 years | 7 years |
Note 1 - Summary of Significa_8
Note 1 - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment (Details) - USD ($) | Jun. 30, 2018 | Dec. 31, 2017 | Dec. 31, 2016 |
Property, Plant, and Equipment Gross | $ 491,476 | $ 361,486 | $ 316,393 |
Less: Accumulated depreciation | 307,091 | 273,770 | 214,897 |
Total Fixed Assets, Net | 184,385 | 87,716 | 101,496 |
Office Equipment [Member] | |||
Property, Plant, and Equipment Gross | 201,123 | 183,528 | 164,318 |
Leasehold Improvements [Member] | |||
Property, Plant, and Equipment Gross | 122,188 | 25,635 | 25,635 |
Manufacturing Tooling [Member] | |||
Property, Plant, and Equipment Gross | 108,955 | 108,955 | 103,204 |
Demo Equipment [Member] | |||
Property, Plant, and Equipment Gross | $ 59,210 | $ 43,368 | $ 23,236 |
Note 2 - Equity Method Invest_3
Note 2 - Equity Method Investment (Details Textual) | Jun. 30, 2018 | Feb. 27, 2018 |
Helomics Holding Corp. [Member] | ||
Equity Method Investment, Ownership Percentage | 75.00% | 80.00% |
Note 2 - Equity Method Invest_4
Note 2 - Equity Method Investment - Summary of Equity Method Investments (Details) - Helomics Holding Corp. [Member] | 6 Months Ended | |
Jun. 30, 2018USD ($) | ||
Revenue | $ 215,055 | |
Gross margin | (71,625) | |
Net loss from continuing operations | (4,529,380) | |
Net loss to investee | $ (4,331,380) | [1] |
[1] | The loss to investee was calculated at 80% for the initial period of ownership, January 11, 2018 - February 27, 2018, and then at 75% for the remainder of the six-month period at the current equity investment percentage owned by the Company. |
Note 3 - Revenue Recognition (D
Note 3 - Revenue Recognition (Details Textual) - USD ($) | 6 Months Ended | ||
Jun. 30, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Maintenance Plan, Service Requirement, Period Subsequent to One Year Anniversary of Invoice | 1 year | ||
Standard Product Warranty, Term | 1 year | ||
Accounts Receivable, Net, Current, Total | $ 315,327 | $ 137,499 | $ 38,919 |
Contract with Customer, Liability, Current | $ 18,342 | $ 6,663 | $ 7,998 |
Minimum [Member] | |||
Standard Payment Term for Customers | 30 days | ||
Maximum [Member] | |||
Standard Payment Term for Customers | 60 days |
Note 4 - Stockholders' Equity_3
Note 4 - Stockholders' Equity, Stock Options and Warrants (Details Textual) | Jun. 28, 2018USD ($)$ / sharesshares | Mar. 12, 2018$ / sharesshares | Feb. 21, 2018USD ($)$ / sharesshares | Jan. 15, 2018$ / sharesshares | Jan. 11, 2018USD ($)shares | Feb. 22, 2017USD ($) | Jan. 19, 2017$ / sharesshares | Oct. 04, 2016$ / sharesshares | Jul. 01, 2016$ / sharesshares | Aug. 31, 2015USD ($)$ / shares | Jan. 31, 2018USD ($)$ / sharesshares | Dec. 31, 2017USD ($)$ / sharesshares | Jun. 30, 2018USD ($)$ / sharesshares | Jun. 30, 2017USD ($) | Dec. 31, 2017USD ($)$ / sharesshares | Dec. 31, 2016USD ($)$ / sharesshares | Dec. 31, 2017USD ($)$ / sharesshares | Jun. 30, 2018USD ($)$ / sharesshares | Mar. 31, 2018USD ($)shares | Jan. 02, 2018shares | Dec. 28, 2017$ / sharesshares | Apr. 19, 2017$ / shares | Jan. 29, 2017shares | Oct. 27, 2016shares | Sep. 30, 2016$ / shares | Sep. 15, 2016shares | Sep. 14, 2016shares |
Stock Issued During Period, Shares, New Issues | 400,000 | ||||||||||||||||||||||||||
Share Price | $ / shares | $ 4.125 | ||||||||||||||||||||||||||
Proceeds from Issuance or Sale of Equity, Total | $ | $ 13,800,000 | ||||||||||||||||||||||||||
Common Stock, Par or Stated Value Per Share | $ / shares | $ 0.01 | $ 0.01 | $ 0.01 | $ 0.01 | $ 0.01 | $ 0.01 | $ 0.01 | $ 0.01 | $ 0.01 | $ 0.01 | |||||||||||||||||
Shares Issued, Price Per Share | $ / shares | $ 9 | ||||||||||||||||||||||||||
Common Stock, Shares Authorized | 50,000,000 | 50,000,000 | 50,000,000 | 50,000,000 | 50,000,000 | 50,000,000 | 50,000,000 | 24,000,000 | 8,000,000 | 200,000,000 | 100,000,000 | ||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate | 0.00% | 0.00% | 0.00% | ||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number | 1,728,264 | 2,154,442 | 1,728,264 | 1,728,264 | 2,154,442 | ||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price | $ / shares | $ 2.29 | $ 2.05 | $ 2.29 | $ 2.29 | $ 2.05 | ||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term | 9 years 146 days | 9 years 164 days | |||||||||||||||||||||||||
Class of Warrant or Right Number of Warrants Vested and Exercisable | 1,253,311 | 2,556,382 | 1,253,311 | 1,253,311 | 2,556,382 | ||||||||||||||||||||||
Allocated Share-based Compensation Expense, Total | $ | $ 460,368 | $ 18,276 | $ 1,892,159 | $ 165,271 | |||||||||||||||||||||||
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options | $ | $ 1,139,172 | $ 997,772 | $ 1,139,172 | $ 1,139,172 | $ 997,772 | ||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Incremental Compensation Cost | $ | $ 1,900,000 | ||||||||||||||||||||||||||
Employee Stock Option [Member] | |||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 482,402 | 2,612,070 | 157,982 | ||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | $ / shares | $ 1.11 | $ 1.45 | $ 3.14 | ||||||||||||||||||||||||
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition | 1 year 120 days | 2 years | |||||||||||||||||||||||||
Vice President of Sales [Member] | |||||||||||||||||||||||||||
Common Stock, Par or Stated Value Per Share | $ / shares | $ 0.01 | $ 0.01 | |||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 50,000 | 40,000 | |||||||||||||||||||||||||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares | $ 0.97 | $ 3.75 | |||||||||||||||||||||||||
Number of Equal Installments Options are Expected to Vest | 4 | 6 | |||||||||||||||||||||||||
Vice President of Sales and Marketing [Member] | |||||||||||||||||||||||||||
Common Stock, Par or Stated Value Per Share | $ / shares | $ 0.01 | ||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 111,112 | ||||||||||||||||||||||||||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares | $ 1.35 | ||||||||||||||||||||||||||
Number of Equal Installments Options are Expected to Vest | 4 | ||||||||||||||||||||||||||
Maximum [Member] | |||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 609.38 | $ 609.38 | $ 609.38 | $ 609.38 | $ 609.38 | ||||||||||||||||||||||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares | $ 596.25 | $ 596.25 | |||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate | 3.00% | 2.40% | 2.45% | ||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate | 66.00% | ||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term | 10 years | 10 years | 10 years | ||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | $ / shares | $ 1.0044 | $ 1.5489 | $ 3.7195 | ||||||||||||||||||||||||
Minimum [Member] | |||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 0 | 0 | 0 | $ 0 | $ 0 | ||||||||||||||||||||||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares | $ 0.91 | $ 1.01 | |||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate | 2.33% | 1.92% | 1.46% | ||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate | 59.00% | ||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term | 5 years | 5 years | 5 years | ||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | $ / shares | $ 0.4816 | $ 0.6541 | $ 1.6329 | ||||||||||||||||||||||||
Equity Incentive Plan [Member] | Maximum [Member] | |||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period | 3 years | 3 years | |||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period | 10 years | 10 years | |||||||||||||||||||||||||
Equity Incentive Plan [Member] | Minimum [Member] | |||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period | 3 years | 3 years | |||||||||||||||||||||||||
Stock Incentive Plan 2012 [Member] | |||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 2,500,000 | ||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized | 5,000,000 | ||||||||||||||||||||||||||
Helomics Holding Corp. [Member] | |||||||||||||||||||||||||||
Notes Payable, Total | $ | $ 8,800,000 | ||||||||||||||||||||||||||
Helomics Holding Corp. [Member] | |||||||||||||||||||||||||||
Convertible Preferred Stock Held, Conversion Feature, Percent | 20.00% | ||||||||||||||||||||||||||
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares | 1,100,000 | ||||||||||||||||||||||||||
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Held in Escrow | 860,000 | ||||||||||||||||||||||||||
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares Held in Escrow, Period | 1 year 180 days | ||||||||||||||||||||||||||
Percentage of Holders of Acquiree's Promissory Note Agreeing to Merger | 75.00% | ||||||||||||||||||||||||||
Business Acquisition, Warrant Exchange Ratio | 0.6 | ||||||||||||||||||||||||||
Helomics Holding Corp. [Member] | Common Stock [Member] | |||||||||||||||||||||||||||
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares | 4,000,000 | ||||||||||||||||||||||||||
Helomics Holding Corp. [Member] | Convertible Preferred Stock [Member] | |||||||||||||||||||||||||||
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares | 3,500,000 | ||||||||||||||||||||||||||
Helomics Holding Corp. [Member] | |||||||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 1,100,000 | ||||||||||||||||||||||||||
Share Exchange Agreement, Shares Received | 2,500,000 | ||||||||||||||||||||||||||
Share Exchange Agreement, Convertible Notes Receivable | $ | $ 500,000 | ||||||||||||||||||||||||||
Share Exchange Agreement, Convertible Notes, Percent of Stock | 5.00% | ||||||||||||||||||||||||||
Share Exchange Agreement, Potential Interest | 25.00% | ||||||||||||||||||||||||||
Share Exchange Agreement, Number of Shares Held in Escrow | 1,100,000 | ||||||||||||||||||||||||||
Share Exchange Agreement, Contingent Revenue, Minimum | $ | $ 8,000,000 | ||||||||||||||||||||||||||
Convertible Preferred Stock Held, Conversion Feature, Percent | 20.00% | ||||||||||||||||||||||||||
Helomics Warrants Held by Investors [Member] | Helomics Holding Corp. [Member] | |||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 1 | ||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 23,700,000 | ||||||||||||||||||||||||||
Helomics Warrants Held by Investors [Member] | Helomics Holding Corp. [Member] | |||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 1 | ||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 5,000,000 | ||||||||||||||||||||||||||
Precision Warrants [Member] | Helomics Holding Corp. [Member] | |||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 1 | ||||||||||||||||||||||||||
Business Acquisition, Warrant Issued or Issuable, Exercise Price | $ / shares | $ 1 | ||||||||||||||||||||||||||
Business Acquisition, Equity Interest Issued or Issuable from Exchange of Warrants | 23,700,000 | ||||||||||||||||||||||||||
Class of Warrant or Right, Additional Number of Securities Called by Warrants or Rights | 14,200,000 | ||||||||||||||||||||||||||
Helomics Warrants Held by Other Parties [Member] | |||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 0.01 | ||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 597,000 | ||||||||||||||||||||||||||
Helomics Warrants Held by Other Parties [Member] | Helomics Holding Corp. [Member] | |||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 0.01 | ||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 995,000 | ||||||||||||||||||||||||||
The 2018 Public Offering [Member] | |||||||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 2,900,000 | ||||||||||||||||||||||||||
Share Price | $ / shares | $ 0.95 | ||||||||||||||||||||||||||
Proceeds from Issuance or Sale of Equity, Total | $ | $ 2,755,000 | $ 2,755,000 | |||||||||||||||||||||||||
The 2018 Public Offering [Member] | Series E Warrants [Member] | |||||||||||||||||||||||||||
Class of Warrant or Right, Issued per Unit | 0.3 | ||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right | 1 | ||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 1 | ||||||||||||||||||||||||||
Over-Allotment Option [Member] | |||||||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 215,247 | ||||||||||||||||||||||||||
Proceeds from Issuance or Sale of Equity, Total | $ | $ 358,312 | $ 358,312 | $ 358,312 | ||||||||||||||||||||||||
Sale of Stock, Underwriter Option Term | 45 days | ||||||||||||||||||||||||||
Sale of Stock, Underwriter Option, Maximum Additional Shares of Common Stock Available for Purchase | 175,000 | 290,000 | |||||||||||||||||||||||||
Sale of Stock, Underwriter Option, Number of Securities Called by Maximum Additional Warrants Available for Purchase | 35,000 | 87,000 | |||||||||||||||||||||||||
Sale of Stock, Underwriter Option, Exercise Price of Additional Warrants Available for Purchase | $ / shares | $ 0.01 | $ 0.001 | |||||||||||||||||||||||||
Shares Issued, Price Per Share | $ / shares | $ 0.9497 | ||||||||||||||||||||||||||
Proceeds from Underwriter Shares Exercised, Net | $ | $ 188,066 | ||||||||||||||||||||||||||
Stock Issued During Period, Underwriter Discount | $ | $ 16,354 | ||||||||||||||||||||||||||
Underwriter Discount Percentage | 8.00% |
Note 4 - Stockholders' Equity_4
Note 4 - Stockholders' Equity, Stock Options and Warrants - Summary of Transactions for Stock Options and Warrants (Details) - $ / shares | 6 Months Ended | 12 Months Ended | |
Jun. 30, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Number of Shares Outstanding (in shares) | 2,764,983 | ||
Average Exercise Price Exercised (in dollars per share) | $ 65.75 | ||
Number of Shares Outstanding (in shares) | 3,120,255 | 2,764,983 | |
Warrant [Member] | |||
Number of Shares Outstanding (in shares) | 1,951,257 | 871,101 | 323,099 |
Average Exercise Price Outstanding (in dollars per share) | $ 23.74 | $ 52.22 | $ 128.40 |
Number of Shares Issued (in shares) | 957,000 | 1,082,946 | 1,487,881 |
Average Exercise Price Issued (in dollars per share) | $ 1 | $ 1.49 | $ 0.71 |
Number of Shares Expired (in shares) | (10,706) | (2,790) | |
Average Exercise Price Expired (in dollars per share) | $ 199.55 | $ 281.46 | |
Number of Shares Exercised (in shares) | (341,169) | (939,879) | |
Average Exercise Price Exercised (in dollars per share) | $ 1 | ||
Number of Shares Outstanding (in shares) | 2,556,382 | 1,951,257 | 871,101 |
Average Exercise Price Outstanding (in dollars per share) | $ 5.97 | $ 23.74 | $ 52.22 |
Employee Stock Option [Member] | |||
Number of Shares Outstanding (in shares) | 2,764,983 | 165,643 | 31,350 |
Average Exercise Price Outstanding (in dollars per share) | $ 2 | $ 11.22 | $ 133.23 |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 482,402 | 2,612,070 | 157,982 |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | $ 1.11 | $ 1.45 | $ 3.14 |
Number of Shares Expired (in shares) | (127,130) | (12,730) | (22,377) |
Average Exercise Price Expired (in dollars per share) | $ 2.22 | $ 10.39 | $ 122.13 |
Number of Shares Exercised (in shares) | (1,312) | ||
Average Exercise Price Exercised (in dollars per share) | $ 65.75 | ||
Number of Shares Outstanding (in shares) | 3,120,255 | 2,764,983 | 165,643 |
Average Exercise Price Outstanding (in dollars per share) | $ 1.85 | $ 2 | $ 11.22 |
Note 4 - Stockholders' Equity_5
Note 4 - Stockholders' Equity, Stock Options and Warrants - Summary of Status of Options and Warrants Outstanding (Details) - $ / shares | 6 Months Ended | 12 Months Ended |
Jun. 30, 2018 | Dec. 31, 2017 | |
Shares, options (in shares) | 3,120,255 | 2,764,983 |
Shares, warrants (in shares) | 2,556,382 | 1,951,257 |
Warrant One [Member] | ||
Warrant exercises, exercise price per share (in dollars per share) | $ 1 | $ 1.07 |
Shares, warrants (in shares) | 1,372,828 | 697,946 |
Weighted average remaining life, warrants (Year) | 4 years 131 days | 4 years 310 days |
Warrant Two [Member] | ||
Warrant exercises, exercise price per share (in dollars per share) | $ 1.07 | $ 2.25 |
Shares, warrants (in shares) | 697,946 | 385,000 |
Weighted average remaining life, warrants (Year) | 4 years 127 days | 4 years 21 days |
Warrant Three [Member] | ||
Warrant exercises, exercise price per share (in dollars per share) | $ 2.25 | $ 4.46 |
Shares, warrants (in shares) | 385,000 | 756,999 |
Weighted average remaining life, warrants (Year) | 3 years 208 days | 3 years 335 days |
Warrant Four [Member] | ||
Warrant exercises, exercise price per share (in dollars per share) | $ 123.75 | $ 93.75 |
Shares, warrants (in shares) | 94,084 | 2,255 |
Weighted average remaining life, warrants (Year) | 2 years 62 days | 69 days |
Warrant Five [Member] | ||
Warrant exercises, exercise price per share (in dollars per share) | $ 243.75 | $ 123.75 |
Shares, warrants (in shares) | 2,529 | 94,084 |
Weighted average remaining life, warrants (Year) | 1 year 36 days | 2 years 244 days |
Warrant Six [Member] | ||
Warrant exercises, exercise price per share (in dollars per share) | $ 309.375 | $ 150 |
Shares, warrants (in shares) | 2,850 | 4,114 |
Weighted average remaining life, warrants (Year) | 1 year 40 days | 73 days |
Warrant Seven [Member] | ||
Warrant exercises, exercise price per share (in dollars per share) | $ 309.50 | $ 225 |
Shares, warrants (in shares) | 222 | 107 |
Weighted average remaining life, warrants (Year) | 1 year 131 days | 25 days |
Warrant Eight [Member] | ||
Warrant exercises, exercise price per share (in dollars per share) | $ 506.25 | $ 243.75 |
Shares, warrants (in shares) | 59 | 2,529 |
Weighted average remaining life, warrants (Year) | 229 days | 1 year 215 days |
Warrant Nine [Member] | ||
Warrant exercises, exercise price per share (in dollars per share) | $ 609.375 | $ 281.25 |
Shares, warrants (in shares) | 862 | 3,107 |
Weighted average remaining life, warrants (Year) | 219 days | 51 days |
Stock Options One [Member] | ||
Range of exercise prices, options (in dollars per share) | $ 0.91 | $ 1.01 |
Shares, options (in shares) | 10,000 | 124,358 |
Weighted average remaining life, options (Year) | 9 years 292 days | 10 years |
Stock Options Twenty Seven [Member] | ||
Range of exercise prices, options (in dollars per share) | $ 162.50 | $ 346.875 |
Shares, options (in shares) | 123 | 72 |
Weighted average remaining life, options (Year) | 6 years 186 days | 6 years 91 days |
Stock Options Two [Member] | ||
Range of exercise prices, options (in dollars per share) | $ 0.965 | $ 1.454 |
Shares, options (in shares) | 3,000 | 17,200 |
Weighted average remaining life, options (Year) | 9 years 321 days | 9 years 273 days |
Stock Options Twenty Eight [Member] | ||
Range of exercise prices, options (in dollars per share) | $ 206.25 | $ 431.25 |
Shares, options (in shares) | 121 | 306 |
Weighted average remaining life, options (Year) | 6 years 94 days | 6 years 69 days |
Stock Options Three [Member] | ||
Range of exercise prices, options (in dollars per share) | $ 0.97 | $ 1.47 |
Shares, options (in shares) | 191,753 | 2,456,226 |
Weighted average remaining life, options (Year) | 9 years 189 days | 9 years 175 days |
Stock Options Twenty Nine [Member] | ||
Range of exercise prices, options (in dollars per share) | $ 248.4375 | $ 506.25 |
Shares, options (in shares) | 121 | 188 |
Weighted average remaining life, options (Year) | 5 years 14 days | 6 years |
Stock Options Four [Member] | ||
Range of exercise prices, options (in dollars per share) | $ 1.01 | $ 2.10 |
Shares, options (in shares) | 124,358 | 14,286 |
Weighted average remaining life, options (Year) | 9 years 186 days | 9 years 91 days |
Stock Options Thirty [Member] | ||
Range of exercise prices, options (in dollars per share) | $ 262.50 | $ 596.25 |
Shares, options (in shares) | 130 | 42 |
Weighted average remaining life, options (Year) | 5 years 14 days | 5 years 273 days |
Stock Options Five [Member] | ||
Range of exercise prices, options (in dollars per share) | $ 1.10 | $ 2.25 |
Shares, options (in shares) | 22,730 | 293 |
Weighted average remaining life, options (Year) | 9 years 277 days | 8 years 237 days |
Stock Options Thirty-One [Member] | ||
Range of exercise prices, options (in dollars per share) | $ 281.25 | |
Shares, options (in shares) | 529 | |
Weighted average remaining life, options (Year) | 4 years 200 days | |
Stock Options Six [Member] | ||
Range of exercise prices, options (in dollars per share) | $ 1.13 | $ 2.42 |
Shares, options (in shares) | 143,807 | 24,768 |
Weighted average remaining life, options (Year) | 10 years | 8 years 138 days |
Stock Options Thirty-Two [Member] | ||
Range of exercise prices, options (in dollars per share) | $ 318.75 | |
Shares, options (in shares) | 3 | |
Weighted average remaining life, options (Year) | 4 years 313 days | |
Stock Options Seven [Member] | ||
Range of exercise prices, options (in dollars per share) | $ 1.35 | $ 2.80 |
Shares, options (in shares) | 111,112 | 57,145 |
Weighted average remaining life, options (Year) | 9 years 259 days | 9 years 3 days |
Stock Options Thirty-Three [Member] | ||
Range of exercise prices, options (in dollars per share) | $ 346.875 | |
Shares, options (in shares) | 72 | |
Weighted average remaining life, options (Year) | 5 years 277 days | |
Stock Options Eight [Member] | ||
Range of exercise prices, options (in dollars per share) | $ 1.454 | $ 3.75 |
Shares, options (in shares) | 17,200 | 44,000 |
Weighted average remaining life, options (Year) | 9 years 94 days | 8 years 182 days |
Stock Options Thirty-Four [Member] | ||
Range of exercise prices, options (in dollars per share) | $ 431.25 | |
Shares, options (in shares) | 306 | |
Weighted average remaining life, options (Year) | 5 years 251 days | |
Stock Options Nine [Member] | ||
Range of exercise prices, options (in dollars per share) | $ 1.47 | $ 4.125 |
Shares, options (in shares) | 2,373,226 | 3,636 |
Weighted average remaining life, options (Year) | 8 years 361 days | 8 years 273 days |
Stock Options Thirty-Five [Member] | ||
Range of exercise prices, options (in dollars per share) | $ 506.25 | |
Shares, options (in shares) | 188 | |
Weighted average remaining life, options (Year) | 5 years 186 days | |
Stock Options Ten [Member] | ||
Range of exercise prices, options (in dollars per share) | $ 2.10 | $ 4.1975 |
Shares, options (in shares) | 14,286 | 7,147 |
Weighted average remaining life, options (Year) | 8 years 277 days | 8 years 262 days |
Stock Options Thirty-Six [Member] | ||
Range of exercise prices, options (in dollars per share) | $ 596.25 | |
Shares, options (in shares) | 42 | |
Weighted average remaining life, options (Year) | 5 years 91 days | |
Stock Options Eleven [Member] | ||
Range of exercise prices, options (in dollars per share) | $ 2.25 | $ 4.25 |
Shares, options (in shares) | 293 | 3,529 |
Weighted average remaining life, options (Year) | 8 years 58 days | 8 years 91 days |
Stock Options Twelve [Member] | ||
Range of exercise prices, options (in dollars per share) | $ 2.42 | $ 5.125 |
Shares, options (in shares) | 20,640 | 3,902 |
Weighted average remaining life, options (Year) | 8 years 51 days | 8 years 251 days |
Stock Options Thirteen [Member] | ||
Range of exercise prices, options (in dollars per share) | $ 2.80 | $ 65.75 |
Shares, options (in shares) | 57,145 | 190 |
Weighted average remaining life, options (Year) | 8 years 186 days | 7 years 146 days |
Stock Options Fourteen [Member] | ||
Range of exercise prices, options (in dollars per share) | $ 3.75 | $ 73.50 |
Shares, options (in shares) | 3,998 | 1,157 |
Weighted average remaining life, options (Year) | 8 years 3 days | 8 years 3 days |
Stock Options Fifteen [Member] | ||
Range of exercise prices, options (in dollars per share) | $ 4.125 | $ 77.50 |
Shares, options (in shares) | 3,636 | 2,323 |
Weighted average remaining life, options (Year) | 8 years 94 days | 7 years 182 days |
Stock Options Sixteen [Member] | ||
Range of exercise prices, options (in dollars per share) | $ 4.1975 | $ 80.25 |
Shares, options (in shares) | 7,147 | 187 |
Weighted average remaining life, options (Year) | 8 years 80 days | 7 years 273 days |
Stock Options Seventeen [Member] | ||
Range of exercise prices, options (in dollars per share) | $ 4.25 | $ 86.25 |
Shares, options (in shares) | 3,529 | 232 |
Weighted average remaining life, options (Year) | 7 years 277 days | 7 years 91 days |
Stock Options Eighteen [Member] | ||
Range of exercise prices, options (in dollars per share) | $ 5.125 | $ 131.25 |
Shares, options (in shares) | 3,902 | 81 |
Weighted average remaining life, options (Year) | 8 years 69 days | 4 years 251 days |
Stock Options Nineteen [Member] | ||
Range of exercise prices, options (in dollars per share) | $ 65.75 | $ 148.125 |
Shares, options (in shares) | 190 | 928 |
Weighted average remaining life, options (Year) | 7 years 116 days | 5 years 76 days |
Stock Options Twenty [Member] | ||
Range of exercise prices, options (in dollars per share) | $ 73.50 | $ 150 |
Shares, options (in shares) | 1,157 | 1,760 |
Weighted average remaining life, options (Year) | 7 years 186 days | 4 years 229 days |
Stock Options Twenty One [Member] | ||
Range of exercise prices, options (in dollars per share) | $ 77.50 | $ 162.50 |
Shares, options (in shares) | 2,323 | 123 |
Weighted average remaining life, options (Year) | 7 years 3 days | 7 years 3 days |
Stock Options Twenty Two [Member] | ||
Range of exercise prices, options (in dollars per share) | $ 80.25 | $ 206.25 |
Shares, options (in shares) | 187 | 121 |
Weighted average remaining life, options (Year) | 7 years 94 days | 6 years 273 days |
Stock Options Twenty Three [Member] | ||
Range of exercise prices, options (in dollars per share) | $ 86.25 | $ 248.4375 |
Shares, options (in shares) | 232 | 121 |
Weighted average remaining life, options (Year) | 6 years 277 days | 5 years 197 days |
Stock Options Twenty Four [Member] | ||
Range of exercise prices, options (in dollars per share) | $ 131.25 | $ 262.50 |
Shares, options (in shares) | 81 | 130 |
Weighted average remaining life, options (Year) | 4 years 69 days | 5 years 197 days |
Stock Options Twenty Five [Member] | ||
Range of exercise prices, options (in dollars per share) | $ 148.125 | $ 281.25 |
Shares, options (in shares) | 928 | 529 |
Weighted average remaining life, options (Year) | 4 years 262 days | 5 years 14 days |
Stock Options Twenty Six [Member] | ||
Range of exercise prices, options (in dollars per share) | $ 150 | $ 318.75 |
Shares, options (in shares) | 1,760 | 3 |
Weighted average remaining life, options (Year) | 4 years 47 days | 5 years 127 days |
Note 4 - Stockholders' Equity_6
Note 4 - Stockholders' Equity, Stock Options and Warrants - Schedule of Listing of Stock Options and Warrants (Details) - $ / shares | 6 Months Ended | 12 Months Ended |
Jun. 30, 2018 | Dec. 31, 2017 | |
Shares, options (in shares) | 3,120,255 | 2,764,983 |
Shares, warrants (in shares) | 2,556,382 | 1,951,257 |
Minimum [Member] | ||
Price, options (in dollars per share) | $ 0.91 | $ 1.01 |
Warrant exercises, exercise price per share (in dollars per share) | 0 | 0 |
Maximum [Member] | ||
Price, options (in dollars per share) | 596.25 | 596.25 |
Warrant exercises, exercise price per share (in dollars per share) | $ 609.38 | $ 609.38 |
Warrants 2014 [Member] | ||
Shares, warrants (in shares) | 6,455 | 6,455 |
Warrants 2014 [Member] | Minimum [Member] | ||
Warrant exercises, exercise price per share (in dollars per share) | $ 243.75 | $ 243.75 |
Warrants 2014 [Member] | Maximum [Member] | ||
Warrant exercises, exercise price per share (in dollars per share) | $ 609.38 | $ 609.38 |
Warrants 2015 [Member] | ||
Shares, warrants (in shares) | 94,151 | 94,152 |
Warrants 2015 [Member] | Minimum [Member] | ||
Warrant exercises, exercise price per share (in dollars per share) | $ 0 | $ 0 |
Warrants 2015 [Member] | Maximum [Member] | ||
Warrant exercises, exercise price per share (in dollars per share) | $ 243.75 | $ 243.75 |
Warrants 2016 [Member] | ||
Shares, warrants (in shares) | 504,666 | 756,999 |
Warrant exercises, exercise price per share (in dollars per share) | $ 1 | $ 4.46 |
Warrants 2017 [Member] | ||
Shares, warrants (in shares) | 1,082,946 | 1,082,946 |
Warrants 2017 [Member] | Minimum [Member] | ||
Warrant exercises, exercise price per share (in dollars per share) | $ 1.07 | $ 1.07 |
Warrants 2017 [Member] | Maximum [Member] | ||
Warrant exercises, exercise price per share (in dollars per share) | $ 2.25 | $ 2.25 |
Warrants 2018 [Member] | ||
Shares, warrants (in shares) | 868,164 | |
Warrant exercises, exercise price per share (in dollars per share) | $ 1 | |
Stock Options 2011 [Member] | ||
Shares, options (in shares) | 173 | 173 |
Price, options (in dollars per share) | $ 281.25 | $ 281.25 |
Stock Options 2012 [Member] | ||
Shares, options (in shares) | 1,841 | 1,841 |
Stock Options 2012 [Member] | Minimum [Member] | ||
Price, options (in dollars per share) | $ 131.25 | $ 131.25 |
Stock Options 2012 [Member] | Maximum [Member] | ||
Price, options (in dollars per share) | $ 150 | $ 150 |
Stock Options 2013 [Member] | ||
Shares, options (in shares) | 1,553 | 1,553 |
Stock Options 2013 [Member] | Minimum [Member] | ||
Price, options (in dollars per share) | $ 148.13 | $ 148.13 |
Stock Options 2013 [Member] | Maximum [Member] | ||
Price, options (in dollars per share) | $ 596.25 | $ 596.25 |
Stock Options 2014 [Member] | ||
Shares, options (in shares) | 836 | 835 |
Stock Options 2014 [Member] | Minimum [Member] | ||
Price, options (in dollars per share) | $ 162.50 | $ 162.50 |
Stock Options 2014 [Member] | Maximum [Member] | ||
Price, options (in dollars per share) | $ 431.25 | $ 431.25 |
Stock Options 2015 [Member] | ||
Shares, options (in shares) | 4,088 | 4,088 |
Stock Options 2015 [Member] | Minimum [Member] | ||
Price, options (in dollars per share) | $ 65.75 | $ 65.75 |
Stock Options 2015 [Member] | Maximum [Member] | ||
Price, options (in dollars per share) | $ 86.25 | $ 86.25 |
Stock Options 2016 [Member] | ||
Shares, options (in shares) | 100,292 | 144,423 |
Stock Options 2016 [Member] | Minimum [Member] | ||
Price, options (in dollars per share) | $ 2.25 | $ 2.25 |
Stock Options 2016 [Member] | Maximum [Member] | ||
Price, options (in dollars per share) | $ 5.13 | $ 5.13 |
Stock Options 2017 [Member] | ||
Shares, options (in shares) | 2,529,070 | 2,612,070 |
Stock Options 2017 [Member] | Minimum [Member] | ||
Price, options (in dollars per share) | $ 1.01 | $ 1.01 |
Stock Options 2017 [Member] | Maximum [Member] | ||
Price, options (in dollars per share) | $ 2.10 | $ 2.10 |
Stock Options 2018 [Member] | ||
Shares, options (in shares) | 482,402 | |
Stock Options 2018 [Member] | Minimum [Member] | ||
Price, options (in dollars per share) | $ 0.91 | |
Stock Options 2018 [Member] | Maximum [Member] | ||
Price, options (in dollars per share) | $ 1.35 |
Note 5 - Notes Receivable (Deta
Note 5 - Notes Receivable (Details Textual) - USD ($) | 1 Months Ended | ||||
Mar. 31, 2018 | Dec. 31, 2017 | Nov. 30, 2017 | Oct. 31, 2017 | Jul. 31, 2017 | |
Advance to Helomics [Member] | |||||
Notes Receivable, Interest Rate, Stated Percentage | 8.00% | ||||
Payments to Acquire Notes Receivable | $ 600,000 | $ 600,000 | |||
Advances to De Lage Landen [Member] | |||||
Payments to Acquire Notes Receivable | $ 67,512.10 | ||||
Lease to Purchase Equipment, Down Payment, Percentage | 50.00% | ||||
CytoBioscience [Member] | Promissory Notes Receivable [Member] | |||||
Notes Receivable, Interest Rate, Stated Percentage | 8.00% | 8.00% | |||
Financing Receivable, Net, Total | $ 1,112,524 | $ 1,070,000 | |||
Notes Receivable, Term | 2 years | ||||
Helomics Holding Corp. [Member] | |||||
Financing Receivable, Net, Total | $ 167,512 | ||||
Share Exchange Agreement, Outstanding Receivables, Amount Converted | $ 500,000 | ||||
Share Exchange Agreement, Shares Received Upon Conversion of Receivables | 833,333 | ||||
Share Exchange Agreement, Convertible Notes, Percent of Stock | 5.00% | ||||
Investment, Ownership Percent | 25.00% |
Note 6 - Loss Per Share (Detail
Note 6 - Loss Per Share (Details Textual) - shares | 6 Months Ended | 12 Months Ended | ||
Jun. 30, 2018 | Jun. 30, 2017 | Dec. 31, 2017 | Dec. 31, 2016 | |
Options and Warrants [Member] | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 5,676,637 | 3,850,878 | 4,716,240 | 1,036,744 |
Preferred Stock 1 [Member] | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 79,246 |
Note 6 - Loss Per Share - Share
Note 6 - Loss Per Share - Shares Used in Basic and Diluted Loss Per Common Share Computations (Details) - USD ($) | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||||||||
Jun. 30, 2018 | Jun. 30, 2017 | Jun. 30, 2018 | Jun. 30, 2017 | Dec. 31, 2017 | Dec. 31, 2016 | |||||||
Net loss available in basic and diluted calculation | $ (2,373,410) | $ (2,543,670) | $ (4,133,432) | $ (3,885,517) | $ (7,746,593) | $ (6,526,014) | ||||||
Comprehensive loss | $ (2,373,410) | $ (2,543,670) | $ (4,133,432) | $ (3,885,517) | $ (7,746,593) | $ (6,524,513) | ||||||
Weighted average common shares outstanding-basic (in shares) | 11,878,490 | 6,167,689 | 11,632,221 | 6,308,554 | 6,362,989 | 2,823,345 | ||||||
Effect of diluted stock options, warrants and preferred stock (1) (in shares) | [1] | [1] | [1] | [1] | [2] | [2] | ||||||
Loss per common share - basic and diluted (in dollars per share) | $ (0.20) | $ (0.41) | $ (0.36) | $ (0.62) | $ (1.22) | $ (2.31) | ||||||
[1] | The number of shares underlying options and warrants outstanding as of June 30, 2018 and June 30, 2017 are 5,676,637 and 3,850,878, respectively. The number of shares underlying the preferred stock as of June 30, 2018 is 79,246. The effect of the shares that would be issued upon exercise of such options, warrants and preferred stock has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive. | |||||||||||
[2] | The number of shares underlying options and warrants outstanding as of December 31, 2017 and December 31, 2016 are 4,716,240 and 1,036,744, respectively. The number of shares underlying the preferred stock as of December 31, 2017 is 79,246 for Series B Convertible and 647,819 for Series C Convertible. The effect of the shares that would be issued upon exercise of such options, warrants and preferred stock has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive. |
Note 7 - Related Party Transa_2
Note 7 - Related Party Transactions (Details Textual) - Director [Member] | 1 Months Ended |
Apr. 30, 2018USD ($)shares | |
Related Party Transaction, Monthly Cash Payment | $ | $ 12,000 |
Restricted Stock Units (RSUs) [Member] | Stock Incentive Plan 2012 [Member] | |
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period | shares | 240,000 |
Note 1 - Summary of Significa_9
Note 1 - Summary of Significant Accounting Policies -2 (Details Textual) | Feb. 22, 2017USD ($) | Nov. 29, 2016USD ($) | Oct. 27, 2016 | Aug. 31, 2015USD ($) | Jun. 30, 2018USD ($)$ / sharesshares | Jun. 30, 2017USD ($) | Jun. 30, 2018USD ($)$ / sharesshares | Jun. 30, 2017USD ($) | Dec. 31, 2018 | Dec. 31, 2017USD ($)$ / sharesshares | Dec. 31, 2016USD ($)$ / sharesshares | Dec. 31, 2017USD ($)$ / sharesshares | Jun. 30, 2018USD ($)$ / sharesshares | Feb. 21, 2018$ / shares | Dec. 28, 2017$ / shares | Apr. 19, 2017$ / shares | Oct. 04, 2016$ / shares |
Common Stock, Shares, Outstanding, Ending Balance | shares | 12,089,446 | 12,089,446 | 6,943,283 | 4,564,428 | 6,943,283 | 12,089,446 | |||||||||||
Common Stock, Par or Stated Value Per Share | $ / shares | $ 0.01 | $ 0.01 | $ 0.01 | $ 0.01 | $ 0.01 | $ 0.01 | $ 0.01 | $ 0.01 | $ 0.01 | $ 0.01 | |||||||
Stockholders' Equity, Period Increase (Decrease), Total | $ 29,065,934 | $ 35,840,380 | |||||||||||||||
Stock Issued During Period, Value, New Issues | $ 2,755,087 | $ 3,421,188 | $ 3,421,188 | ||||||||||||||
Proceeds from Issuance or Sale of Equity, Total | $ 13,800,000 | ||||||||||||||||
Debt Instrument, Increase (Decrease), Net, Total | 5,685,000 | 5,685,000 | |||||||||||||||
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent | 34.00% | ||||||||||||||||
Advertising Expense | $ 37,060 | $ 71,212 | |||||||||||||||
Research and Development Expense, Total | 289,000 | 406,000 | |||||||||||||||
Depreciation, Total | $ 18,825 | $ 14,519 | 33,321 | 30,204 | 58,872 | 73,249 | |||||||||||
Amortization of Intangible Assets, Total | 4,070 | 2,902 | 7,741 | 5,790 | 12,689 | 9,107 | |||||||||||
Unrecognized Tax Benefits, Ending Balance | 0 | 0 | 0 | 0 | 0 | ||||||||||||
Cash, Uninsured Amount | 794,125 | $ 794,125 | 563,000 | 563,000 | 794,125 | ||||||||||||
Product Warranty Expense | $ 6,209 | 34,665 | |||||||||||||||
Number of Operating Segments | 2 | 2 | |||||||||||||||
Non-US [Member] | |||||||||||||||||
Revenues, Total | $ 3,178 | $ 0 | $ 5,866 | 26,662 | $ 26,662 | ||||||||||||
Scenario, Forecast [Member] | |||||||||||||||||
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent | 21.00% | ||||||||||||||||
Private Placement [Member] | |||||||||||||||||
Stock Issued During Period, Value, New Issues | 1,213,819 | ||||||||||||||||
IPO [Member] | |||||||||||||||||
Stock Issued During Period, Value, New Issues | 13,555,003 | 13,555,003 | |||||||||||||||
Proceeds from Issuance or Sale of Equity, Total | 3,937,500 | 3,937,500 | |||||||||||||||
The 2016 Registered Direct Offering [Member] | |||||||||||||||||
Stock Issued During Period, Value, New Issues | $ 1,625,905 | ||||||||||||||||
Proceeds from Issuance or Sale of Equity, Net of Stock Issuance Costs | $ 1,739,770 | 1,739,770 | 1,739,770 | ||||||||||||||
Proceeds from Issuance or Sale of Equity, Total | $ 1,983,337 | ||||||||||||||||
Over-Allotment Option [Member] | |||||||||||||||||
Stock Issued During Period, Value, New Issues | $ 204,422 | $ 393,750 | $ 393,750 | ||||||||||||||
Proceeds from Issuance or Sale of Equity, Total | $ 358,312 | 358,312 | 358,312 | ||||||||||||||
Series A Convertible Preferred Stock [Member] | Private Placement [Member] | |||||||||||||||||
Stock Issued During Period, Value, New Issues | 2,055,000 | 2,055,000 | |||||||||||||||
Series C Convertible Preferred Stock [Member] | Private Placement [Member] | |||||||||||||||||
Stock Issued During Period, Value, New Issues | $ 1,300,000 | $ 1,300,000 | |||||||||||||||
Reverse Stock Split [Member] | |||||||||||||||||
Stockholders' Equity Note, Stock Split, Conversion Ratio | 25 |
Note 1 - Summary of Signific_10
Note 1 - Summary of Significant Accounting Policies - Schedule of Inventories (Details) - USD ($) | Jun. 30, 2018 | Dec. 31, 2017 | Dec. 31, 2016 |
Finished goods | $ 31,782 | $ 62,932 | $ 38,201 |
Raw materials | 168,735 | 141,028 | 165,812 |
Work-In-Process | 44,143 | 61,085 | 68,195 |
Total | $ 244,660 | $ 265,045 | $ 272,208 |
Note 1 - Summary of Signific_11
Note 1 - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment, Useful Lives (Details) | 6 Months Ended | 12 Months Ended |
Jun. 30, 2018 | Dec. 31, 2017 | |
Leasehold Improvements [Member] | ||
Property, plant, and equipment, useful life (Year) | 3 years | 5 years |
Demo Equipment [Member] | ||
Property, plant, and equipment, useful life (Year) | 3 years | 3 years |
Minimum [Member] | Office Equipment [Member] | ||
Property, plant, and equipment, useful life (Year) | 3 years | 3 years |
Minimum [Member] | Manufacturing Tooling [Member] | ||
Property, plant, and equipment, useful life (Year) | 3 years | 3 years |
Maximum [Member] | Office Equipment [Member] | ||
Property, plant, and equipment, useful life (Year) | 7 years | 7 years |
Maximum [Member] | Manufacturing Tooling [Member] | ||
Property, plant, and equipment, useful life (Year) | 7 years | 7 years |
Note 1 - Summary of Signific_12
Note 1 - Summary of Significant Accounting Policies - Schedule of Property, Plant and Equipment, Net (Details) - USD ($) | Jun. 30, 2018 | Dec. 31, 2017 | Dec. 31, 2016 |
Property, Plant, and Equipment Gross | $ 491,476 | $ 361,486 | $ 316,393 |
Less: Accumulated depreciation | 307,091 | 273,770 | 214,897 |
Total Fixed Assets, Net | 184,385 | 87,716 | 101,496 |
Office Equipment [Member] | |||
Property, Plant, and Equipment Gross | 201,123 | 183,528 | 164,318 |
Leasehold Improvements [Member] | |||
Property, Plant, and Equipment Gross | 122,188 | 25,635 | 25,635 |
Manufacturing Tooling [Member] | |||
Property, Plant, and Equipment Gross | 108,955 | 108,955 | 103,204 |
Demo Equipment [Member] | |||
Property, Plant, and Equipment Gross | $ 59,210 | $ 43,368 | $ 23,236 |
Note 2 - Development Stage Op_2
Note 2 - Development Stage Operations (Details Textual) - $ / shares | Dec. 31, 2017 | Sep. 30, 2016 |
Common Stock, Shares, Issued, Total | 6,943,283 | |
Share Price | $ 4.125 | |
Common Stock [Member] | Maximum [Member] | ||
Share Price | $ 3,131.25 |
Note 3 - Stockholders' Equity_3
Note 3 - Stockholders' Equity (Deficit), Stock Options and Warrants (Details Textual) | Feb. 21, 2018$ / sharesshares | Jan. 15, 2018$ / sharesshares | Nov. 30, 2017USD ($)$ / sharesshares | Apr. 19, 2017$ / sharesshares | Feb. 22, 2017USD ($) | Jan. 19, 2017USD ($)$ / sharesshares | Nov. 29, 2016USD ($)$ / sharesshares | Oct. 27, 2016shares | Oct. 04, 2016$ / sharesshares | Jul. 01, 2016$ / sharesshares | Mar. 31, 2016shares | Aug. 31, 2015USD ($)$ / sharesshares | Feb. 04, 2014USD ($)$ / sharesshares | Jan. 31, 2018$ / sharesshares | May 31, 2016shares | Dec. 31, 2017USD ($)$ / sharesshares | Jul. 06, 2016shares | Jun. 30, 2018USD ($)$ / sharesshares | Jun. 30, 2017USD ($)shares | Sep. 30, 2016$ / sharesshares | Dec. 31, 2017USD ($)$ / sharesshares | Dec. 31, 2016USD ($)$ / sharesshares | Dec. 31, 2017USD ($)$ / sharesshares | Jun. 30, 2018USD ($)$ / sharesshares | Jan. 02, 2018$ / sharesshares | Dec. 28, 2017$ / sharesshares | Jan. 29, 2017shares | Sep. 15, 2016shares | Sep. 14, 2016shares | Apr. 21, 2016shares | Mar. 25, 2016$ / sharesshares |
Shares Issued, Price Per Share | $ / shares | $ 9 | ||||||||||||||||||||||||||||||
Underwriter Price | $ / shares | 8.28 | ||||||||||||||||||||||||||||||
Underwriting Discount | $ / shares | $ 0.72 | ||||||||||||||||||||||||||||||
Underwriting Commission | 8.00% | ||||||||||||||||||||||||||||||
Proceeds from Issuance or Sale of Equity, Total | $ | $ 13,800,000 | ||||||||||||||||||||||||||||||
Option Granted to Underwriter to Purchase Additional Units Period | 45 days | ||||||||||||||||||||||||||||||
Option Granted to Underwriter to Purchase Additional Units Number of Units Granted | 250,000 | ||||||||||||||||||||||||||||||
Underwriting Agreement Non-accountable Expense Allowance Percentage | 1.00% | ||||||||||||||||||||||||||||||
Common Stock, Par or Stated Value Per Share | $ / shares | $ 0.01 | $ 0.01 | $ 0.01 | $ 0.01 | $ 0.01 | $ 0.01 | $ 0.01 | $ 0.01 | $ 0.01 | $ 0.01 | |||||||||||||||||||||
Share Price | $ / shares | $ 4.125 | ||||||||||||||||||||||||||||||
Class of Warrant or Right, Outstanding | 1,951,257 | 2,556,382 | 1,951,257 | 1,951,257 | 2,556,382 | ||||||||||||||||||||||||||
Stock Issued During Period, Value, New Issues | $ | $ 2,755,087 | $ 3,421,188 | $ 3,421,188 | ||||||||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 400,000 | ||||||||||||||||||||||||||||||
Proceeds from Issuance of Convertible Preferred Stock | $ | $ 1,300,001 | ||||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate | 0.00% | 0.00% | 0.00% | ||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum | 59.00% | 59.00% | |||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum | 66.00% | 66.00% | |||||||||||||||||||||||||||||
Reverse Shares Issued for Escrow Pursuant to Termination of Agreement, Shares | 400,000 | ||||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number | 1,728,264 | 2,154,442 | 1,728,264 | 1,728,264 | 2,154,442 | ||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price | $ / shares | $ 2.29 | $ 2.05 | $ 2.29 | $ 2.29 | $ 2.05 | ||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term | 9 years 146 days | 9 years 164 days | |||||||||||||||||||||||||||||
Class of Warrant or Right Number of Warrants Vested and Exercisable | 1,253,311 | 2,556,382 | 1,253,311 | 1,253,311 | 2,556,382 | ||||||||||||||||||||||||||
Allocated Share-based Compensation Expense, Total | $ | $ 460,368 | 18,276 | $ 1,892,159 | $ 165,271 | |||||||||||||||||||||||||||
Employee Service Share-based Compensation, Nonvested Awards, Compensation Not yet Recognized, Stock Options | $ | $ 1,139,172 | $ 997,772 | $ 1,139,172 | $ 1,139,172 | $ 997,772 | ||||||||||||||||||||||||||
Common Stock, Shares Authorized | 8,000,000 | 50,000,000 | 50,000,000 | 50,000,000 | 50,000,000 | 50,000,000 | 50,000,000 | 50,000,000 | 24,000,000 | 200,000,000 | 100,000,000 | ||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Incremental Compensation Cost | $ | $ 1,900,000 | ||||||||||||||||||||||||||||||
Reverse Stock Split [Member] | |||||||||||||||||||||||||||||||
Stockholders' Equity Note, Stock Split, Conversion Ratio | 25 | ||||||||||||||||||||||||||||||
Vice President of Sales [Member] | |||||||||||||||||||||||||||||||
Common Stock, Par or Stated Value Per Share | $ / shares | $ 0.01 | $ 0.01 | |||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 50,000 | 40,000 | |||||||||||||||||||||||||||||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares | $ 0.97 | $ 3.75 | |||||||||||||||||||||||||||||
Number of Equal Installments Options are Expected to Vest | 4 | 6 | |||||||||||||||||||||||||||||
Stock Incentive Plan 2012 [Member] | |||||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 2,500,000 | ||||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized | 5,000,000 | ||||||||||||||||||||||||||||||
Subsequent Event [Member] | |||||||||||||||||||||||||||||||
Common Stock, Par or Stated Value Per Share | $ / shares | 0.01 | $ 0.01 | |||||||||||||||||||||||||||||
Common Stock, Shares Authorized | 50,000,000 | ||||||||||||||||||||||||||||||
Subsequent Event [Member] | Stock Incentive Plan 2012 [Member] | |||||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized | 5,000,000 | ||||||||||||||||||||||||||||||
The 2016 Registered Direct Offering [Member] | |||||||||||||||||||||||||||||||
Proceeds from Issuance or Sale of Equity, Total | $ | $ 1,983,337 | ||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 4.46 | ||||||||||||||||||||||||||||||
Share Price | $ / shares | $ 2.62 | ||||||||||||||||||||||||||||||
Stock Issued During Period, Value, New Issues | $ | $ 1,625,905 | ||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 756,999 | ||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 756,999 | ||||||||||||||||||||||||||||||
Class of Warrant or Right Term | 5 years | ||||||||||||||||||||||||||||||
Class of Warrant or Right, Vesting Period | 180 days | ||||||||||||||||||||||||||||||
Proceeds from Issuance or Sale of Equity, Net of Stock Issuance Costs | $ | $ 1,739,770 | $ 1,739,770 | $ 1,739,770 | ||||||||||||||||||||||||||||
The 2017 Public Offering [Member] | |||||||||||||||||||||||||||||||
Proceeds from Issuance or Sale of Equity, Total | $ | $ 3,937,500 | ||||||||||||||||||||||||||||||
Share Price | $ / shares | $ 2.25 | ||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 1,750,000 | ||||||||||||||||||||||||||||||
Share Per Each Unit | 1 | ||||||||||||||||||||||||||||||
Over-Allotment Option [Member] | |||||||||||||||||||||||||||||||
Shares Issued, Price Per Share | $ / shares | $ 0.9497 | ||||||||||||||||||||||||||||||
Proceeds from Issuance or Sale of Equity, Total | $ | $ 358,312 | $ 358,312 | $ 358,312 | ||||||||||||||||||||||||||||
Stock Issued During Period, Value, New Issues | $ | $ 204,422 | 393,750 | $ 393,750 | ||||||||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 215,247 | ||||||||||||||||||||||||||||||
Sale of Stock, Underwriter Option, Maximum Additional Shares of Common Stock Available for Purchase | 175,000 | 290,000 | |||||||||||||||||||||||||||||
Sale of Stock, Underwriter Option, Number of Securities Called by Maximum Additional Warrants Available for Purchase | 35,000 | 87,000 | |||||||||||||||||||||||||||||
Sale of Stock, Underwriter Option, Exercise Price of Additional Warrants Available for Purchase | $ / shares | $ 0.01 | $ 0.001 | |||||||||||||||||||||||||||||
Over-Allotment Option [Member] | Subsequent Event [Member] | |||||||||||||||||||||||||||||||
Share Price | $ / shares | $ 0.9497 | ||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 215,247 | ||||||||||||||||||||||||||||||
Sale of Stock, Underwriter Option, Maximum Additional Shares of Common Stock Available for Purchase | 290,000 | ||||||||||||||||||||||||||||||
Sale of Stock, Underwriter Option, Number of Securities Called by Maximum Additional Warrants Available for Purchase | 87,000 | ||||||||||||||||||||||||||||||
Sale of Stock, Underwriter Option, Exercise Price of Additional Warrants Available for Purchase | $ / shares | $ 0.001 | ||||||||||||||||||||||||||||||
Private Placement [Member] | |||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 1.26 | ||||||||||||||||||||||||||||||
Stock Issued During Period, Value, New Issues | $ | $ 1,213,819 | ||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 606,910 | ||||||||||||||||||||||||||||||
Class of Warrant or Right Term | 5 years 182 days | ||||||||||||||||||||||||||||||
Class of Warrant or Right, Vesting Period | 180 days | ||||||||||||||||||||||||||||||
Proceeds from Issuance of Convertible Preferred Stock | $ | $ 1,300,000 | ||||||||||||||||||||||||||||||
Conversion from Series C Convertible Preferred Stock to Common Stock [Member] | Subsequent Event [Member] | |||||||||||||||||||||||||||||||
Convertible Preferred Stock, Shares Issued upon Conversion | 1.167 | 1.167 | |||||||||||||||||||||||||||||
Conversion of Stock, Shares Issued | 1,250,269 | ||||||||||||||||||||||||||||||
The Convertible Notes [Member] | |||||||||||||||||||||||||||||||
Debt Instrument Redemption Principal Amount | $ | $ 933,074 | ||||||||||||||||||||||||||||||
Debt Instrument Redemption Premium Percentage | 40.00% | ||||||||||||||||||||||||||||||
Debt Instrument Redemption Price | $ | $ 1,548,792 | ||||||||||||||||||||||||||||||
Debt Instrument Redemption Amount Paid to Affiliates | $ | $ 167,031 | ||||||||||||||||||||||||||||||
Series B Convertible Preferred Stock [Member] | |||||||||||||||||||||||||||||||
Beneficial Ownership Limitation Percentage | 4.99% | ||||||||||||||||||||||||||||||
Stock Issued During Period, Value, New Issues | $ | $ 2,055,000 | ||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 20,550 | ||||||||||||||||||||||||||||||
Preferred Stock Par Value | $ / shares | $ 0.01 | ||||||||||||||||||||||||||||||
Preferred Stock Stated Value | $ / shares | $ 100 | ||||||||||||||||||||||||||||||
Preferred Stock, Shares Outstanding, Ending Balance | 79,246 | 79,246 | 79,246 | 79,246 | 79,246 | 79,246 | |||||||||||||||||||||||||
Series A Convertible Preferred Stock [Member] | |||||||||||||||||||||||||||||||
Preferred Stock, Shares Outstanding, Ending Balance | 0 | ||||||||||||||||||||||||||||||
Series C Convertible Preferred Stock [Member] | |||||||||||||||||||||||||||||||
Preferred Stock, Shares Outstanding, Ending Balance | 647,819 | 0 | 647,819 | 0 | 647,819 | 0 | |||||||||||||||||||||||||
Series A Warrants [Member] | Exchange Offer [Member] | |||||||||||||||||||||||||||||||
Stock to be Issued for Exchange Offer, Shares, Maximum | 3,157,186 | ||||||||||||||||||||||||||||||
Cashless Exercise of Common Stock Warrants, Total | 10.05 | ||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 1,770,556 | ||||||||||||||||||||||||||||||
Exchange from Series B Warrants to Warrant Shares [Member] | Exchange Offer [Member] | |||||||||||||||||||||||||||||||
Common Stock, Par or Stated Value Per Share | $ / shares | $ 0.01 | ||||||||||||||||||||||||||||||
Series B Warrants [Member] | Exchange Offer [Member] | |||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right | 1 | ||||||||||||||||||||||||||||||
Class of Warrant or Right Exercised During Period | 1,251,510 | ||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, Warrants Exercised | 20,122 | ||||||||||||||||||||||||||||||
Cashless Exercise of Common Stock Warrants, Total | 10.2 | ||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Warrants or Rights | 18,059,671 | ||||||||||||||||||||||||||||||
Series D Warrants [Member] | The 2017 Public Offering [Member] | |||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 2.25 | ||||||||||||||||||||||||||||||
Class of Warrant or Right, Issued per Unit | 0.2 | ||||||||||||||||||||||||||||||
Common Stock [Member] | |||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, Conversion of Convertible Securities | 589,747 | 660,522 | |||||||||||||||||||||||||||||
Stock Issued During Period, Value, New Issues | $ | $ 29,000 | $ 17,500 | $ 17,500 | ||||||||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 2,900,000 | 1,750,000 | 1,750,000 | ||||||||||||||||||||||||||||
Reverse Shares Issued for Escrow Pursuant to Termination of Agreement, Shares | 400,000 | 400,000 | |||||||||||||||||||||||||||||
Common Stock [Member] | The 2016 Registered Direct Offering [Member] | |||||||||||||||||||||||||||||||
Stock Issued During Period, Value, New Issues | $ | $ 7,570 | ||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 756,999 | ||||||||||||||||||||||||||||||
Common Stock [Member] | Over-Allotment Option [Member] | |||||||||||||||||||||||||||||||
Shares Issued, Price Per Share | $ / shares | $ 0.9497 | $ 0.9497 | |||||||||||||||||||||||||||||
Stock Issued During Period, Value, New Issues | $ | $ 2,153 | $ 1,750 | $ 1,750 | ||||||||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 215,247 | 175,000 | 175,000 | ||||||||||||||||||||||||||||
Common Stock [Member] | Series A Warrants [Member] | |||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, Warrants Exercised | 2,318,663 | ||||||||||||||||||||||||||||||
Common Stock [Member] | Series B Warrants [Member] | |||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, Warrants Exercised | 628,237 | ||||||||||||||||||||||||||||||
Preferred Stock [Member] | |||||||||||||||||||||||||||||||
Stock Issued During Period, Value, New Issues | $ | |||||||||||||||||||||||||||||||
Preferred Stock [Member] | Over-Allotment Option [Member] | |||||||||||||||||||||||||||||||
Stock Issued During Period, Value, New Issues | $ | |||||||||||||||||||||||||||||||
Preferred Stock [Member] | Private Placement [Member] | |||||||||||||||||||||||||||||||
Stock Issued During Period, Value, New Issues | $ | $ 12,138 | ||||||||||||||||||||||||||||||
Preferred Stock [Member] | Series C Convertible Preferred Stock [Member] | Subsequent Event [Member] | |||||||||||||||||||||||||||||||
Stock Redeemed or Called During Period, Shares | 142,466 | ||||||||||||||||||||||||||||||
Payments for Repurchase of Convertible Preferred Stock | $ | $ 189,285 | ||||||||||||||||||||||||||||||
Preferred Stock [Member] | Series C Convertible Preferred Stock [Member] | Private Placement [Member] | |||||||||||||||||||||||||||||||
Shares Issued, Price Per Share | $ / shares | $ 1.071 | ||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, New Issues | 1,213,819 | ||||||||||||||||||||||||||||||
Corporate Stock Transfer Inc. [Member] | |||||||||||||||||||||||||||||||
Unit Agreement Number of Shares of Common Stock Included in Each Unit | 1 | ||||||||||||||||||||||||||||||
Common Stock, Par or Stated Value Per Share | $ / shares | $ 0.01 | ||||||||||||||||||||||||||||||
Corporate Stock Transfer Inc. [Member] | Series A Warrants [Member] | |||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right | 0.4 | ||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 123.75 | $ 123.75 | $ 123.75 | ||||||||||||||||||||||||||||
Cash Less Exercise Formula Definition of Letter C in the Formula Closing Bid Price Number of Trading Days Prior to the Time of Exercise | 2 days | ||||||||||||||||||||||||||||||
Cash Less Exercise Formula Closing Bid Price Per Share Minimum to Be Used in the Formula | $ / shares | $ 0.43 | $ 0.43 | $ 0.43 | ||||||||||||||||||||||||||||
Warrants Option to Settle in Cash Fair Value Disclosure | $ / shares | $ 4.319 | ||||||||||||||||||||||||||||||
Class of Warrant or Right Exercised During Period | 6,141,115 | ||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, Warrants Exercised | 2,318,663 | ||||||||||||||||||||||||||||||
Class of Warrant or Right, Outstanding | 35,084 | 35,084 | 35,084 | ||||||||||||||||||||||||||||
Class of Warrant or Right Cash less Exercise Common Stock Price That Would Result in a Dilutive Exercise | $ / shares | $ 0.43 | $ 0.43 | $ 0.43 | ||||||||||||||||||||||||||||
Beneficial Ownership Limitation Percentage | 4.99% | ||||||||||||||||||||||||||||||
Corporate Stock Transfer Inc. [Member] | Series A Warrants [Member] | Scenario, All Outstanding Warrants Exercised at Minimum Bid Price [Member] | |||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, Warrants Exercised | 564 | ||||||||||||||||||||||||||||||
Corporate Stock Transfer Inc. [Member] | Series B Convertible Preferred Stock [Member] | |||||||||||||||||||||||||||||||
Unit Agreement Number of Shares of Common Stock Included in Each Unit | 1 | ||||||||||||||||||||||||||||||
Corporate Stock Transfer Inc. [Member] | Series A Convertible Preferred Stock [Member] | |||||||||||||||||||||||||||||||
Unit Agreement Number of Shares of Common Stock Included in Each Unit | 4 | ||||||||||||||||||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right | 1 | ||||||||||||||||||||||||||||||
Maximum [Member] | |||||||||||||||||||||||||||||||
Underwriting Agreement Expenses Agreed to Reimburse the Underwriter | $ | $ 70,000 | ||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | 609.38 | $ 609.38 | $ 609.38 | 609.38 | 609.38 | ||||||||||||||||||||||||||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares | $ 596.25 | $ 596.25 | |||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate | 3.00% | 2.40% | 2.45% | ||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term | 10 years | 10 years | 10 years | ||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | $ / shares | $ 1.0044 | $ 1.5489 | $ 3.7195 | ||||||||||||||||||||||||||||
Maximum [Member] | Equity Incentive Plan [Member] | |||||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period | 3 years | 3 years | |||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period | 10 years | 10 years | |||||||||||||||||||||||||||||
Maximum [Member] | Common Stock [Member] | |||||||||||||||||||||||||||||||
Share Price | $ / shares | 3,131.25 | $ 3,131.25 | 3,131.25 | ||||||||||||||||||||||||||||
Minimum [Member] | |||||||||||||||||||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ / shares | $ 0 | $ 0 | 0 | $ 0 | $ 0 | ||||||||||||||||||||||||||
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price | $ / shares | $ 0.91 | $ 1.01 | |||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate | 2.33% | 1.92% | 1.46% | ||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term | 5 years | 5 years | 5 years | ||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | $ / shares | $ 0.4816 | $ 0.6541 | $ 1.6329 | ||||||||||||||||||||||||||||
Minimum [Member] | Equity Incentive Plan [Member] | |||||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period | 3 years | 3 years | |||||||||||||||||||||||||||||
Exchange Units [Member] | |||||||||||||||||||||||||||||||
Unit Purchase Option Units Sold | 1,666,667 | ||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, Conversion of Convertible Securities | 1,895,010 | ||||||||||||||||||||||||||||||
Exchange Units [Member] | Series A Convertible Preferred Stock [Member] | |||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, Conversion of Convertible Securities | 3,391 | ||||||||||||||||||||||||||||||
Exchange Units [Member] | Series A Warrants [Member] | |||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, Conversion of Convertible Securities | 7,580,040 | ||||||||||||||||||||||||||||||
Exchange Units [Member] | Common Stock [Member] | |||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, Conversion of Convertible Securities | 75,801 | ||||||||||||||||||||||||||||||
Exchange Units [Member] | Series B Convertible Preferred Stock [Member] | |||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, Conversion of Convertible Securities | 1,895,010 | ||||||||||||||||||||||||||||||
Exchange Units [Member] | Corporate Stock Transfer Inc. [Member] | |||||||||||||||||||||||||||||||
Unit Purchase Option Units Issued | 228,343 | ||||||||||||||||||||||||||||||
Stock Issued During Period, Shares, Conversion of Convertible Securities | 135,995 | ||||||||||||||||||||||||||||||
Unit Purchase Option Number of Units Available for Underwriter to Purchase, Percentage | 5.00% | ||||||||||||||||||||||||||||||
Unit Purchase Option Number of Units Available For Underwriter to Purchase | 83,333 | ||||||||||||||||||||||||||||||
Unit Purchase Option Exercise Price, Percentage | 125.00% | ||||||||||||||||||||||||||||||
Unit Purchase Option Exercise Price | $ / shares | $ 11.25 | ||||||||||||||||||||||||||||||
Employee Stock Option [Member] | |||||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 482,402 | 2,612,070 | 157,982 | ||||||||||||||||||||||||||||
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | $ / shares | $ 1.11 | $ 1.45 | $ 3.14 | ||||||||||||||||||||||||||||
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition | 1 year 120 days | 2 years |
Note 3 - Stockholders' Equity_4
Note 3 - Stockholders' Equity (Deficit), Stock Options and Warrants - Summary of Transactions for Stock Options and Warrants (Details) - $ / shares | 6 Months Ended | 12 Months Ended | |
Jun. 30, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Number of Shares Outstanding (in shares) | 2,764,983 | ||
Options exercise price (in dollars per share) | $ 65.75 | ||
Number of Shares Outstanding (in shares) | 3,120,255 | 2,764,983 | |
Warrant [Member] | |||
Number of Shares Outstanding (in shares) | 1,951,257 | 871,101 | 323,099 |
Average Exercise Price Outstanding (in dollars per share) | $ 23.74 | $ 52.22 | $ 128.40 |
Number of Shares Issued (in shares) | 957,000 | 1,082,946 | 1,487,881 |
Average Exercise Price Issued (in dollars per share) | $ 1 | $ 1.49 | $ 0.71 |
Number of Shares Expired (in shares) | (10,706) | (2,790) | |
Average Exercise Price Expired (in dollars per share) | $ 199.55 | $ 281.46 | |
Number of Shares Exercised (in shares) | (341,169) | (939,879) | |
Average Exercise Price Exercised (in dollars per share) | $ 1 | ||
Number of Shares Outstanding (in shares) | 2,556,382 | 1,951,257 | 871,101 |
Average Exercise Price Outstanding (in dollars per share) | $ 5.97 | $ 23.74 | $ 52.22 |
Employee Stock Option [Member] | |||
Number of Shares Outstanding (in shares) | 2,764,983 | 165,643 | 31,350 |
Average Exercise Price Outstanding (in dollars per share) | $ 2 | $ 11.22 | $ 133.23 |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross | 482,402 | 2,612,070 | 157,982 |
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | $ 1.11 | $ 1.45 | $ 3.14 |
Number of Shares Expired (in shares) | (127,130) | (12,730) | (22,377) |
Average Exercise Price Expired (in dollars per share) | $ 2.22 | $ 10.39 | $ 122.13 |
Number of Shares Exercised (in shares) | (1,312) | ||
Options exercise price (in dollars per share) | $ 65.75 | ||
Number of Shares Outstanding (in shares) | 3,120,255 | 2,764,983 | 165,643 |
Average Exercise Price Outstanding (in dollars per share) | $ 1.85 | $ 2 | $ 11.22 |
Note 3 - Stockholders' Equity_5
Note 3 - Stockholders' Equity (Deficit), Stock Options and Warrants - Summary of Status of Options and Warrants Outstanding (Details) - $ / shares | 6 Months Ended | 12 Months Ended |
Jun. 30, 2018 | Dec. 31, 2017 | |
Shares, options (in shares) | 3,120,255 | 2,764,983 |
Shares, warrants (in shares) | 2,556,382 | 1,951,257 |
Warrant One [Member] | ||
Warrant exercises, exercise price per share (in dollars per share) | $ 1 | $ 1.07 |
Shares, warrants (in shares) | 1,372,828 | 697,946 |
Weighted average remaining life, warrants (Year) | 4 years 131 days | 4 years 310 days |
Warrant Two [Member] | ||
Warrant exercises, exercise price per share (in dollars per share) | $ 1.07 | $ 2.25 |
Shares, warrants (in shares) | 697,946 | 385,000 |
Weighted average remaining life, warrants (Year) | 4 years 127 days | 4 years 21 days |
Warrant Three [Member] | ||
Warrant exercises, exercise price per share (in dollars per share) | $ 2.25 | $ 4.46 |
Shares, warrants (in shares) | 385,000 | 756,999 |
Weighted average remaining life, warrants (Year) | 3 years 208 days | 3 years 335 days |
Warrant Four [Member] | ||
Warrant exercises, exercise price per share (in dollars per share) | $ 123.75 | $ 93.75 |
Shares, warrants (in shares) | 94,084 | 2,255 |
Weighted average remaining life, warrants (Year) | 2 years 62 days | 69 days |
Warrant Five [Member] | ||
Warrant exercises, exercise price per share (in dollars per share) | $ 243.75 | $ 123.75 |
Shares, warrants (in shares) | 2,529 | 94,084 |
Weighted average remaining life, warrants (Year) | 1 year 36 days | 2 years 244 days |
Warrant Six [Member] | ||
Warrant exercises, exercise price per share (in dollars per share) | $ 309.375 | $ 150 |
Shares, warrants (in shares) | 2,850 | 4,114 |
Weighted average remaining life, warrants (Year) | 1 year 40 days | 73 days |
Warrant Seven [Member] | ||
Warrant exercises, exercise price per share (in dollars per share) | $ 309.50 | $ 225 |
Shares, warrants (in shares) | 222 | 107 |
Weighted average remaining life, warrants (Year) | 1 year 131 days | 25 days |
Warrant Eight [Member] | ||
Warrant exercises, exercise price per share (in dollars per share) | $ 506.25 | $ 243.75 |
Shares, warrants (in shares) | 59 | 2,529 |
Weighted average remaining life, warrants (Year) | 229 days | 1 year 215 days |
Warrant Nine [Member] | ||
Warrant exercises, exercise price per share (in dollars per share) | $ 609.375 | $ 281.25 |
Shares, warrants (in shares) | 862 | 3,107 |
Weighted average remaining life, warrants (Year) | 219 days | 51 days |
Warrant Ten [Member] | ||
Warrant exercises, exercise price per share (in dollars per share) | $ 309.375 | |
Shares, warrants (in shares) | 2,850 | |
Weighted average remaining life, warrants (Year) | 1 year 222 days | |
Warrant Eleven [Member] | ||
Warrant exercises, exercise price per share (in dollars per share) | $ 309.50 | |
Shares, warrants (in shares) | 222 | |
Weighted average remaining life, warrants (Year) | 1 year 310 days | |
Warrant Twelve [Member] | ||
Warrant exercises, exercise price per share (in dollars per share) | $ 337.50 | |
Shares, warrants (in shares) | 178 | |
Weighted average remaining life, warrants (Year) | 167 days | |
Warrant Thirteen [Member] | ||
Warrant exercises, exercise price per share (in dollars per share) | $ 371.25 | |
Shares, warrants (in shares) | 944 | |
Weighted average remaining life, warrants (Year) | 149 days | |
Warrant Fourteen [Member] | ||
Warrant exercises, exercise price per share (in dollars per share) | $ 506.25 | |
Shares, warrants (in shares) | 59 | |
Weighted average remaining life, warrants (Year) | 1 year 43 days | |
Warrant Fifteen [Member] | ||
Warrant exercises, exercise price per share (in dollars per share) | $ 609.375 | |
Shares, warrants (in shares) | 862 | |
Weighted average remaining life, warrants (Year) | 1 year 32 days | |
Stock Options One [Member] | ||
Range of exercise prices, options (in dollars per share) | $ 0.91 | $ 1.01 |
Shares, options (in shares) | 10,000 | 124,358 |
Weighted average remaining life, options (Year) | 9 years 292 days | 10 years |
Stock Options Two [Member] | ||
Range of exercise prices, options (in dollars per share) | $ 0.965 | $ 1.454 |
Shares, options (in shares) | 3,000 | 17,200 |
Weighted average remaining life, options (Year) | 9 years 321 days | 9 years 273 days |
Stock Options Three [Member] | ||
Range of exercise prices, options (in dollars per share) | $ 0.97 | $ 1.47 |
Shares, options (in shares) | 191,753 | 2,456,226 |
Weighted average remaining life, options (Year) | 9 years 189 days | 9 years 175 days |
Stock Options Four [Member] | ||
Range of exercise prices, options (in dollars per share) | $ 1.01 | $ 2.10 |
Shares, options (in shares) | 124,358 | 14,286 |
Weighted average remaining life, options (Year) | 9 years 186 days | 9 years 91 days |
Stock Options Five [Member] | ||
Range of exercise prices, options (in dollars per share) | $ 1.10 | $ 2.25 |
Shares, options (in shares) | 22,730 | 293 |
Weighted average remaining life, options (Year) | 9 years 277 days | 8 years 237 days |
Stock Options Six [Member] | ||
Range of exercise prices, options (in dollars per share) | $ 1.13 | $ 2.42 |
Shares, options (in shares) | 143,807 | 24,768 |
Weighted average remaining life, options (Year) | 10 years | 8 years 138 days |
Stock Options Seven [Member] | ||
Range of exercise prices, options (in dollars per share) | $ 1.35 | $ 2.80 |
Shares, options (in shares) | 111,112 | 57,145 |
Weighted average remaining life, options (Year) | 9 years 259 days | 9 years 3 days |
Stock Options Eight [Member] | ||
Range of exercise prices, options (in dollars per share) | $ 1.454 | $ 3.75 |
Shares, options (in shares) | 17,200 | 44,000 |
Weighted average remaining life, options (Year) | 9 years 94 days | 8 years 182 days |
Stock Options Nine [Member] | ||
Range of exercise prices, options (in dollars per share) | $ 1.47 | $ 4.125 |
Shares, options (in shares) | 2,373,226 | 3,636 |
Weighted average remaining life, options (Year) | 8 years 361 days | 8 years 273 days |
Stock Options Ten [Member] | ||
Range of exercise prices, options (in dollars per share) | $ 2.10 | $ 4.1975 |
Shares, options (in shares) | 14,286 | 7,147 |
Weighted average remaining life, options (Year) | 8 years 277 days | 8 years 262 days |
Stock Options Eleven [Member] | ||
Range of exercise prices, options (in dollars per share) | $ 2.25 | $ 4.25 |
Shares, options (in shares) | 293 | 3,529 |
Weighted average remaining life, options (Year) | 8 years 58 days | 8 years 91 days |
Stock Options Twelve [Member] | ||
Range of exercise prices, options (in dollars per share) | $ 2.42 | $ 5.125 |
Shares, options (in shares) | 20,640 | 3,902 |
Weighted average remaining life, options (Year) | 8 years 51 days | 8 years 251 days |
Stock Options Thirteen [Member] | ||
Range of exercise prices, options (in dollars per share) | $ 2.80 | $ 65.75 |
Shares, options (in shares) | 57,145 | 190 |
Weighted average remaining life, options (Year) | 8 years 186 days | 7 years 146 days |
Stock Options Fourteen [Member] | ||
Range of exercise prices, options (in dollars per share) | $ 3.75 | $ 73.50 |
Shares, options (in shares) | 3,998 | 1,157 |
Weighted average remaining life, options (Year) | 8 years 3 days | 8 years 3 days |
Stock Options Fifteen [Member] | ||
Range of exercise prices, options (in dollars per share) | $ 4.125 | $ 77.50 |
Shares, options (in shares) | 3,636 | 2,323 |
Weighted average remaining life, options (Year) | 8 years 94 days | 7 years 182 days |
Stock Options Sixteen [Member] | ||
Range of exercise prices, options (in dollars per share) | $ 4.1975 | $ 80.25 |
Shares, options (in shares) | 7,147 | 187 |
Weighted average remaining life, options (Year) | 8 years 80 days | 7 years 273 days |
Stock Options Seventeen [Member] | ||
Range of exercise prices, options (in dollars per share) | $ 4.25 | $ 86.25 |
Shares, options (in shares) | 3,529 | 232 |
Weighted average remaining life, options (Year) | 7 years 277 days | 7 years 91 days |
Stock Options Eighteen [Member] | ||
Range of exercise prices, options (in dollars per share) | $ 5.125 | $ 131.25 |
Shares, options (in shares) | 3,902 | 81 |
Weighted average remaining life, options (Year) | 8 years 69 days | 4 years 251 days |
Stock Options Nineteen [Member] | ||
Range of exercise prices, options (in dollars per share) | $ 65.75 | $ 148.125 |
Shares, options (in shares) | 190 | 928 |
Weighted average remaining life, options (Year) | 7 years 116 days | 5 years 76 days |
Stock Options Twenty [Member] | ||
Range of exercise prices, options (in dollars per share) | $ 73.50 | $ 150 |
Shares, options (in shares) | 1,157 | 1,760 |
Weighted average remaining life, options (Year) | 7 years 186 days | 4 years 229 days |
Stock Options Twenty One [Member] | ||
Range of exercise prices, options (in dollars per share) | $ 77.50 | $ 162.50 |
Shares, options (in shares) | 2,323 | 123 |
Weighted average remaining life, options (Year) | 7 years 3 days | 7 years 3 days |
Stock Options Twenty Two [Member] | ||
Range of exercise prices, options (in dollars per share) | $ 80.25 | $ 206.25 |
Shares, options (in shares) | 187 | 121 |
Weighted average remaining life, options (Year) | 7 years 94 days | 6 years 273 days |
Stock Options Twenty Three [Member] | ||
Range of exercise prices, options (in dollars per share) | $ 86.25 | $ 248.4375 |
Shares, options (in shares) | 232 | 121 |
Weighted average remaining life, options (Year) | 6 years 277 days | 5 years 197 days |
Stock Options Twenty Four [Member] | ||
Range of exercise prices, options (in dollars per share) | $ 131.25 | $ 262.50 |
Shares, options (in shares) | 81 | 130 |
Weighted average remaining life, options (Year) | 4 years 69 days | 5 years 197 days |
Stock Options Twenty Five [Member] | ||
Range of exercise prices, options (in dollars per share) | $ 148.125 | $ 281.25 |
Shares, options (in shares) | 928 | 529 |
Weighted average remaining life, options (Year) | 4 years 262 days | 5 years 14 days |
Stock Options Twenty Six [Member] | ||
Range of exercise prices, options (in dollars per share) | $ 150 | $ 318.75 |
Shares, options (in shares) | 1,760 | 3 |
Weighted average remaining life, options (Year) | 4 years 47 days | 5 years 127 days |
Stock Options Twenty Seven [Member] | ||
Range of exercise prices, options (in dollars per share) | $ 162.50 | $ 346.875 |
Shares, options (in shares) | 123 | 72 |
Weighted average remaining life, options (Year) | 6 years 186 days | 6 years 91 days |
Stock Options Twenty Eight [Member] | ||
Range of exercise prices, options (in dollars per share) | $ 206.25 | $ 431.25 |
Shares, options (in shares) | 121 | 306 |
Weighted average remaining life, options (Year) | 6 years 94 days | 6 years 69 days |
Stock Options Twenty Nine [Member] | ||
Range of exercise prices, options (in dollars per share) | $ 248.4375 | $ 506.25 |
Shares, options (in shares) | 121 | 188 |
Weighted average remaining life, options (Year) | 5 years 14 days | 6 years |
Stock Options Thirty [Member] | ||
Range of exercise prices, options (in dollars per share) | $ 262.50 | $ 596.25 |
Shares, options (in shares) | 130 | 42 |
Weighted average remaining life, options (Year) | 5 years 14 days | 5 years 273 days |
Note 3 - Stockholders' Equity_6
Note 3 - Stockholders' Equity (Deficit), Stock Options and Warrants - Schedule of Listing of Stock Options and Warrants (Details) - $ / shares | 6 Months Ended | 12 Months Ended |
Jun. 30, 2018 | Dec. 31, 2017 | |
Shares, options (in shares) | 3,120,255 | 2,764,983 |
Shares, warrants (in shares) | 2,556,382 | 1,951,257 |
Minimum [Member] | ||
Price, options (in dollars per share) | $ 0.91 | $ 1.01 |
Warrant exercises, exercise price per share (in dollars per share) | 0 | 0 |
Maximum [Member] | ||
Price, options (in dollars per share) | 596.25 | 596.25 |
Warrant exercises, exercise price per share (in dollars per share) | $ 609.38 | $ 609.38 |
Warrants 2013 [Member] | ||
Shares, warrants (in shares) | 10,705 | |
Warrants 2013 [Member] | Minimum [Member] | ||
Warrant exercises, exercise price per share (in dollars per share) | $ 93.75 | |
Warrants 2013 [Member] | Maximum [Member] | ||
Warrant exercises, exercise price per share (in dollars per share) | $ 371.25 | |
Warrants 2014 [Member] | ||
Shares, warrants (in shares) | 6,455 | 6,455 |
Warrants 2014 [Member] | Minimum [Member] | ||
Warrant exercises, exercise price per share (in dollars per share) | $ 243.75 | $ 243.75 |
Warrants 2014 [Member] | Maximum [Member] | ||
Warrant exercises, exercise price per share (in dollars per share) | $ 609.38 | $ 609.38 |
Warrants 2015 [Member] | ||
Shares, warrants (in shares) | 94,151 | 94,152 |
Warrants 2015 [Member] | Minimum [Member] | ||
Warrant exercises, exercise price per share (in dollars per share) | $ 0 | $ 0 |
Warrants 2015 [Member] | Maximum [Member] | ||
Warrant exercises, exercise price per share (in dollars per share) | $ 243.75 | $ 243.75 |
Warrants 2016 [Member] | ||
Shares, warrants (in shares) | 504,666 | 756,999 |
Warrant exercises, exercise price per share (in dollars per share) | $ 1 | $ 4.46 |
Warrants 2017 [Member] | ||
Shares, warrants (in shares) | 1,082,946 | 1,082,946 |
Warrants 2017 [Member] | Minimum [Member] | ||
Warrant exercises, exercise price per share (in dollars per share) | $ 1.07 | $ 1.07 |
Warrants 2017 [Member] | Maximum [Member] | ||
Warrant exercises, exercise price per share (in dollars per share) | $ 2.25 | $ 2.25 |
Stock Options 2011 [Member] | ||
Shares, options (in shares) | 173 | 173 |
Price, options (in dollars per share) | $ 281.25 | $ 281.25 |
Stock Options 2012 [Member] | ||
Shares, options (in shares) | 1,841 | 1,841 |
Stock Options 2012 [Member] | Minimum [Member] | ||
Price, options (in dollars per share) | $ 131.25 | $ 131.25 |
Stock Options 2012 [Member] | Maximum [Member] | ||
Price, options (in dollars per share) | $ 150 | $ 150 |
Stock Options 2013 [Member] | ||
Shares, options (in shares) | 1,553 | 1,553 |
Stock Options 2013 [Member] | Minimum [Member] | ||
Price, options (in dollars per share) | $ 148.13 | $ 148.13 |
Stock Options 2013 [Member] | Maximum [Member] | ||
Price, options (in dollars per share) | $ 596.25 | $ 596.25 |
Stock Options 2014 [Member] | ||
Shares, options (in shares) | 836 | 835 |
Stock Options 2014 [Member] | Minimum [Member] | ||
Price, options (in dollars per share) | $ 162.50 | $ 162.50 |
Stock Options 2014 [Member] | Maximum [Member] | ||
Price, options (in dollars per share) | $ 431.25 | $ 431.25 |
Stock Options 2015 [Member] | ||
Shares, options (in shares) | 4,088 | 4,088 |
Stock Options 2015 [Member] | Minimum [Member] | ||
Price, options (in dollars per share) | $ 65.75 | $ 65.75 |
Stock Options 2015 [Member] | Maximum [Member] | ||
Price, options (in dollars per share) | $ 86.25 | $ 86.25 |
Stock Options 2016 [Member] | ||
Shares, options (in shares) | 100,292 | 144,423 |
Stock Options 2016 [Member] | Minimum [Member] | ||
Price, options (in dollars per share) | $ 2.25 | $ 2.25 |
Stock Options 2016 [Member] | Maximum [Member] | ||
Price, options (in dollars per share) | $ 5.13 | $ 5.13 |
Stock Options 2017 [Member] | ||
Shares, options (in shares) | 2,529,070 | 2,612,070 |
Stock Options 2017 [Member] | Minimum [Member] | ||
Price, options (in dollars per share) | $ 1.01 | $ 1.01 |
Stock Options 2017 [Member] | Maximum [Member] | ||
Price, options (in dollars per share) | $ 2.10 | $ 2.10 |
Note 4 - Notes Receivable (Deta
Note 4 - Notes Receivable (Details Textual) - USD ($) | Feb. 22, 2018 | Mar. 31, 2018 | Dec. 31, 2017 | Nov. 30, 2017 | Oct. 31, 2017 | Feb. 21, 2018 | Jan. 11, 2018 | Jul. 31, 2017 |
Advance to Helomics [Member] | ||||||||
Notes Receivable, Interest Rate, Stated Percentage | 8.00% | |||||||
Payments to Acquire Notes Receivable | $ 600,000 | $ 600,000 | ||||||
Advances to De Lage Landen [Member] | ||||||||
Payments to Acquire Notes Receivable | $ 67,512.10 | |||||||
Lease to Purchase Equipment, Down Payment, Percentage | 50.00% | |||||||
CytoBioscience [Member] | Promissory Notes Receivable [Member] | ||||||||
Notes Receivable, Interest Rate, Stated Percentage | 8.00% | 8.00% | ||||||
Financing Receivable, Net, Total | $ 1,112,524 | $ 1,070,000 | ||||||
Notes Receivable, Term | 2 years | |||||||
CytoBioscience [Member] | Promissory Notes Receivable [Member] | Subsequent Event [Member] | ||||||||
Notes Receivable, Interest Rate, Stated Percentage | 8.00% | |||||||
Financing Receivable, Net, Total | $ 1,112,524 | |||||||
Notes Receivable, Term | 2 years | |||||||
Helomics Holding Corp. [Member] | ||||||||
Financing Receivable, Net, Total | $ 167,512 | |||||||
Share Exchange Agreement, Outstanding Receivables, Amount Converted | $ 500,000 | |||||||
Share Exchange Agreement, Shares Received Upon Conversion of Receivables | 833,333 | |||||||
Share Exchange Agreement, Convertible Notes, Percent of Stock | 5.00% | |||||||
Investment, Ownership Percent | 25.00% | |||||||
Helomics Holding Corp. [Member] | Subsequent Event [Member] | ||||||||
Financing Receivable, Net, Total | $ 167,512.50 | $ 167,512.10 | $ 667,512.50 | |||||
Share Exchange Agreement, Outstanding Receivables, Amount Converted | $ 500,000 | $ 500,000 | ||||||
Share Exchange Agreement, Shares Received Upon Conversion of Receivables | 833,333 | 833,333 | ||||||
Share Exchange Agreement, Convertible Notes, Percent of Stock | 5.00% | 5.00% | ||||||
Investment, Ownership Percent | 25.00% | 25.00% |
Note 5 - Loss Per Share (Detail
Note 5 - Loss Per Share (Details Textual) - shares | 6 Months Ended | 12 Months Ended | ||
Jun. 30, 2018 | Jun. 30, 2017 | Dec. 31, 2017 | Dec. 31, 2016 | |
Options and Warrants [Member] | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 5,676,637 | 3,850,878 | 4,716,240 | 1,036,744 |
Series B Convertible Preferred Stock [Member] | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 79,246 | |||
Series C Convertible Preferred Stock [Member] | ||||
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount | 647,819 |
Note 5 - Loss Per Share - Share
Note 5 - Loss Per Share - Shares Used in Basic and Diluted Loss Per Common Share Computations (Details) - USD ($) | 3 Months Ended | 6 Months Ended | 12 Months Ended | |||||||||
Jun. 30, 2018 | Jun. 30, 2017 | Jun. 30, 2018 | Jun. 30, 2017 | Dec. 31, 2017 | Dec. 31, 2016 | |||||||
Net loss available in basic and diluted calculation | $ (2,373,410) | $ (2,543,670) | $ (4,133,432) | $ (3,885,517) | $ (7,746,593) | $ (6,526,014) | ||||||
Unrealized gain (loss) from marketable securities | (1,501) | 1,501 | ||||||||||
Comprehensive loss | $ (2,373,410) | $ (2,543,670) | $ (4,133,432) | $ (3,885,517) | $ (7,746,593) | $ (6,524,513) | ||||||
Weighted average common shares outstanding-basic (in shares) | 11,878,490 | 6,167,689 | 11,632,221 | 6,308,554 | 6,362,989 | 2,823,345 | ||||||
Effect of diluted stock options, warrants and preferred stock (1) (in shares) | [1] | [1] | [1] | [1] | [2] | [2] | ||||||
Loss per common share - basic and diluted (in dollars per share) | $ (0.20) | $ (0.41) | $ (0.36) | $ (0.62) | $ (1.22) | $ (2.31) | ||||||
[1] | The number of shares underlying options and warrants outstanding as of June 30, 2018 and June 30, 2017 are 5,676,637 and 3,850,878, respectively. The number of shares underlying the preferred stock as of June 30, 2018 is 79,246. The effect of the shares that would be issued upon exercise of such options, warrants and preferred stock has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive. | |||||||||||
[2] | The number of shares underlying options and warrants outstanding as of December 31, 2017 and December 31, 2016 are 4,716,240 and 1,036,744, respectively. The number of shares underlying the preferred stock as of December 31, 2017 is 79,246 for Series B Convertible and 647,819 for Series C Convertible. The effect of the shares that would be issued upon exercise of such options, warrants and preferred stock has been excluded from the calculation of diluted loss per share because those shares are anti-dilutive. |
Note 6 - Income Taxes (Details
Note 6 - Income Taxes (Details Textual) - USD ($) | 3 Months Ended | 6 Months Ended | 12 Months Ended | ||||
Jun. 30, 2018 | Jun. 30, 2017 | Jun. 30, 2018 | Jun. 30, 2017 | Dec. 31, 2018 | Dec. 31, 2017 | Dec. 31, 2016 | |
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent | 34.00% | ||||||
Income Tax Expense (Benefit), Total | $ 0 | $ 0 | $ 0 | $ 0 | $ 0 | ||
Valuation Allowance Percentage | 100.00% | 100.00% | 100.00% | ||||
State and Local Income Tax Expense (Benefit), Continuing Operations, Total | $ 0 | ||||||
Federal Income Tax Expense (Benefit), Continuing Operations, Total | 0 | ||||||
Domestic Tax Authority [Member] | |||||||
Operating Loss Carryforwards, Total | 34,500,000 | $ 30,900,000 | |||||
Operating Loss Carryforwards, Valuation Allowance, Total | 7,400,000 | 10,700,000 | |||||
State and Local Jurisdiction [Member] | |||||||
Operating Loss Carryforwards, Total | 12,200,000 | 13,000,000 | |||||
Operating Loss Carryforwards, Valuation Allowance, Total | $ 200,000 | $ 200,000 | |||||
Scenario, Forecast [Member] | |||||||
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent | 21.00% |
Note 6 - Income Taxes - Compone
Note 6 - Income Taxes - Components of Deferred Income Taxes (Details) - USD ($) | Dec. 31, 2017 | Dec. 31, 2016 |
Net Operating Loss | $ 7,393,100 | $ 10,755,000 |
Other | 215,843 | 189,000 |
Total Deferred Tax Asset | 7,608,943 | 10,944,000 |
Less Valuation Allowance | 7,608,943 | 10,944,000 |
Net Deferred Income Taxes | $ 0 | $ 0 |
Note 7 - Rent Obligation (Detai
Note 7 - Rent Obligation (Details Textual) | 12 Months Ended | |
Dec. 31, 2017USD ($)ft² | Dec. 31, 2016USD ($) | |
Operating Leases, Rent Expense, Total | $ | $ 66,122 | $ 66,239 |
Corporate Office, Minnesota [Member] | ||
Lessee Leasing Arrangements Operating Leases Terms of Contract Cancellation | 3 years | |
Area of Real Estate Property | 5,773 | |
Corporate Office, Minnesota [Member] | Office Space [Member] | ||
Area of Real Estate Property | 2,945 | |
Corporate Office, Minnesota [Member] | Manufacturing Facility [Member] | ||
Area of Real Estate Property | 2,828 |
Note 7 - Rent Obligation - Rent
Note 7 - Rent Obligation - Rent Obligation (Details) | Dec. 31, 2017USD ($) |
2,018 | $ 39,000 |
2,019 | 40,000 |
2,020 | 42,000 |
2,021 | $ 3,000 |
Note 8 - Related Party Transa_2
Note 8 - Related Party Transactions (Details Textual) - GLG Pharma, LLC. [Member] | Sep. 20, 2016shares |
Stock Expected to be Issued Upon Agreement, Shares | 400,000 |
Stock Expected to be Issued Upon Agreement, Shares, Tranche One | 100,000 |
Stock Expected to be Issued Upon Agreement, Shares, Tranche Two | 100,000 |
Stock Expected to be Issued Upon Agreement, Shares, Tranche Three | 100,000 |
Stock Expected to be Issued Upon Agreement, Shares, Tranche Four | 100,000 |
Note 9 - Retirement Savings P_2
Note 9 - Retirement Savings Plans (Details Textual) - USD ($) | 12 Months Ended | |
Dec. 31, 2017 | Dec. 31, 2016 | |
Defined Contribution Plan, Employer Matching Contribution, Percent of Match | 100.00% | 100.00% |
Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent | 4.00% | 4.00% |
Defined Contribution Plan, Employer Contribution Amount | $ 29,952 | $ 33,143 |
Defined Contribution Plan, Employer Discretionary Contribution Amount | $ 0 | $ 0 |
Note 10 - Supplemental Cash F_2
Note 10 - Supplemental Cash Flow Data (Details Textual) - USD ($) | 12 Months Ended | |
Dec. 31, 2017 | Dec. 31, 2016 | |
Interest Paid, Excluding Capitalized Interest, Operating Activities | $ 0 | $ 3 |
Note 11 - Subsequent Events (De
Note 11 - Subsequent Events (Details Textual) - USD ($) | Feb. 22, 2018 | Feb. 21, 2018 | Jan. 11, 2018 | Feb. 22, 2017 | Jan. 19, 2017 | Oct. 04, 2016 | Aug. 31, 2015 | Mar. 31, 2018 | Jan. 31, 2018 | Dec. 31, 2017 | Jun. 30, 2018 | Jan. 02, 2018 | Dec. 28, 2017 | Apr. 19, 2017 | Dec. 31, 2016 | Sep. 30, 2016 |
Stock Issued During Period, Shares, New Issues | 400,000 | |||||||||||||||
Share Price | $ 4.125 | |||||||||||||||
Proceeds from Issuance or Sale of Equity, Total | $ 13,800,000 | |||||||||||||||
Common Stock, Par or Stated Value Per Share | $ 0.01 | $ 0.01 | $ 0.01 | $ 0.01 | $ 0.01 | $ 0.01 | $ 0.01 | |||||||||
Common Stock, Shares, Outstanding, Ending Balance | 6,943,283 | 12,089,446 | 4,564,428 | |||||||||||||
Helomics Holding Corp. [Member] | ||||||||||||||||
Stock Issued During Period, Shares, New Issues | 1,100,000 | |||||||||||||||
Share Exchange Agreement, Shares Received | 2,500,000 | |||||||||||||||
Share Exchange Agreement, Convertible Notes Receivable | $ 500,000 | |||||||||||||||
Share Exchange Agreement, Convertible Notes, Percent of Stock | 5.00% | |||||||||||||||
Share Exchange Agreement, Potential Interest | 25.00% | |||||||||||||||
Loans Receivable, Net, Total | $ 500,000 | |||||||||||||||
Share Exchange Agreement, Contingent Revenue, Minimum | $ 8,000,000 | |||||||||||||||
Convertible Preferred Stock Held, Conversion Feature, Percent | 20.00% | |||||||||||||||
Financing Receivable, Net, Total | $ 167,512 | |||||||||||||||
Share Exchange Agreement, Outstanding Receivables, Amount Converted | $ 500,000 | |||||||||||||||
Share Exchange Agreement, Shares Received Upon Conversion of Receivables | 833,333 | |||||||||||||||
Investment, Ownership Percent | 25.00% | |||||||||||||||
The 2018 Public Offering [Member] | ||||||||||||||||
Stock Issued During Period, Shares, New Issues | 2,900,000 | |||||||||||||||
Share Price | $ 0.95 | |||||||||||||||
Proceeds from Issuance or Sale of Equity, Total | $ 2,755,000 | $ 2,755,000 | ||||||||||||||
The 2018 Public Offering [Member] | Series E Warrants [Member] | ||||||||||||||||
Class of Warrant or Right, Issued per Unit | 0.3 | |||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right | 1 | |||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 1 | |||||||||||||||
Over-Allotment Option [Member] | ||||||||||||||||
Stock Issued During Period, Shares, New Issues | 215,247 | |||||||||||||||
Proceeds from Issuance or Sale of Equity, Total | $ 358,312 | $ 358,312 | $ 358,312 | |||||||||||||
Sale of Stock, Underwriter Option Term | 45 days | |||||||||||||||
Sale of Stock, Underwriter Option, Maximum Additional Shares of Common Stock Available for Purchase | 175,000 | 290,000 | ||||||||||||||
Sale of Stock, Underwriter Option, Number of Securities Called by Maximum Additional Warrants Available for Purchase | 35,000 | 87,000 | ||||||||||||||
Sale of Stock, Underwriter Option, Exercise Price of Additional Warrants Available for Purchase | $ 0.01 | $ 0.001 | ||||||||||||||
Proceeds from Underwriter Shares Exercised, Net | $ 188,066 | |||||||||||||||
Stock Issued During Period, Underwriter Discount | $ 16,354 | |||||||||||||||
Underwriter Discount Percentage | 8.00% | |||||||||||||||
Subsequent Event [Member] | ||||||||||||||||
Common Stock, Par or Stated Value Per Share | $ 0.01 | $ 0.01 | ||||||||||||||
Subsequent Event [Member] | Helomics Holding Corp. [Member] | ||||||||||||||||
Common Stock, Shares, Outstanding, Ending Balance | 13,333,333 | 10,000,000 | ||||||||||||||
Subsequent Event [Member] | Helomics Holding Corp. [Member] | ||||||||||||||||
Stock Issued During Period, Shares, New Issues | 1,100,000 | |||||||||||||||
Share Exchange Agreement, Shares Received | 2,500,000 | |||||||||||||||
Share Exchange Agreement, Convertible Notes Receivable | $ 500,000 | |||||||||||||||
Share Exchange Agreement, Convertible Notes, Percent of Stock | 5.00% | 5.00% | ||||||||||||||
Share Exchange Agreement, Potential Interest | 25.00% | |||||||||||||||
Share Exchange Agreement, Contingent Revenue, Minimum | $ 8,000,000 | |||||||||||||||
Convertible Preferred Stock Held, Conversion Feature, Percent | 20.00% | |||||||||||||||
Financing Receivable, Net, Total | $ 167,512.50 | $ 667,512.50 | $ 167,512.10 | |||||||||||||
Share Exchange Agreement, Outstanding Receivables, Amount Converted | $ 500,000 | $ 500,000 | ||||||||||||||
Share Exchange Agreement, Shares Received Upon Conversion of Receivables | 833,333 | 833,333 | ||||||||||||||
Holding Interest, Preferred Stock | 2,500,000 | |||||||||||||||
Holding Interest, Common Stock | 3,333,333 | |||||||||||||||
Investment, Ownership Percent | 25.00% | 25.00% | ||||||||||||||
Subsequent Event [Member] | The 2018 Public Offering [Member] | ||||||||||||||||
Stock Issued During Period, Shares, New Issues | 2,900,000 | |||||||||||||||
Share Price | $ 0.95 | |||||||||||||||
Proceeds from Issuance or Sale of Equity, Total | $ 2,755,000 | |||||||||||||||
Subsequent Event [Member] | The 2018 Public Offering [Member] | Series E Warrants [Member] | ||||||||||||||||
Class of Warrant or Right, Issued per Unit | 0.3 | |||||||||||||||
Class of Warrant or Right, Number of Securities Called by Each Warrant or Right | 1 | |||||||||||||||
Class of Warrant or Right, Exercise Price of Warrants or Rights | $ 1 | |||||||||||||||
Subsequent Event [Member] | Over-Allotment Option [Member] | ||||||||||||||||
Stock Issued During Period, Shares, New Issues | 215,247 | |||||||||||||||
Share Price | $ 0.9497 | |||||||||||||||
Sale of Stock, Underwriter Option Term | 45 days | |||||||||||||||
Sale of Stock, Underwriter Option, Maximum Additional Shares of Common Stock Available for Purchase | 290,000 | |||||||||||||||
Sale of Stock, Underwriter Option, Number of Securities Called by Maximum Additional Warrants Available for Purchase | 87,000 | |||||||||||||||
Sale of Stock, Underwriter Option, Exercise Price of Additional Warrants Available for Purchase | $ 0.001 | |||||||||||||||
Proceeds from Underwriter Shares Exercised, Net | $ 188,066 | |||||||||||||||
Stock Issued During Period, Underwriter Discount | $ 16,354 | |||||||||||||||
Underwriter Discount Percentage | 8.00% |
Note 12 - Investment Securiti_3
Note 12 - Investment Securities and Other Comprehensive Income (Loss) - Cost and Fair Values of Investment Securities Available-for-sale (Details) - USD ($) | Dec. 31, 2017 | Dec. 31, 2016 |
Fair Value | $ 284,329 | |
Mutual Fund [Member] | ||
Cost | 282,828 | |
Gross Unrealized Gains | 1,501 | |
Gross Unrealized Losses | ||
Fair Value | $ 284,329 |